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ABSTRACT 
BACKGROUND Objective of this thesis has been the analysis of the sequence 
specific transcription factor p53, a critical tumor suppressor protein, specifically, 
the crosstalk (or functional interactions) with other transcription factors, namely, 
the estrogen receptors, and the modeling in reconstituted assays of the interaction 
of p53 with positive and negative cofactors (e.g. MDM4 and 53BP1) and the 
impact of small molecules, including chemotherapeutic drugs, on such 
interactions. Previous reports have revealed a complex, often negative, crosstalk 
between p53 and estrogen receptors (ERs) related in part to the physical 
interaction between the two proteins.  An example of transcriptional cooperation 
mediated by cognate, non-canonical cis-elements was instead discovered for the 
angiogenesis related VEGFR1, FLT1 promoter.  
MAIN TASK Transcriptional cooperation between p53 and ERs was sought out on 
a global scale using the human breast adenocarcinoma MCF7 cells as a model 
and transcriptome analyses. Cells were subjected to single or combinatorial 
treatments with the chemotherapeutic agent doxorubicin (able to induce p53 
protein stabilization) and the ER ligand 17β-estradiol (E2). 201 differentially 
expressed genes, that showed limited responsiveness to either doxorubicin 
treatment or ER ligand alone, but were up-regulated in a greater than additive 
manner following combined treatment were identified. Among sixteen genes 
chosen for validation using quantitative real-time PCR (qPCR), seven (INPP5D, 
TLR5, KRT15, EPHA2, GDNF, NOTCH1, SOX9) were confirmed to be novel direct 
targets of p53, based on responses in stable MCF7 clone cells silenced for p53, or 
cooperative targets of p53 and ER.  Based on exposure to 5-fuorouracil (another 
genotoxic drug) and nutlin-3a (a non-genotoxic p53-specific activator), the 
combined response identified genes that were consistently regulated, although 
with different kinetics (e.g. INPP5D, CDH26, KRT15), while others (e.g. TLR5, 
SOX9) were treatment selective.  
Promoter pattern searches and chromatin IP experiments for the INPP5D, TLR5, 
KRT15 genes were also performed to interrogate a direct, cis-mediated p53 and 
ERs regulation. While these analyses confirmed the identification of novel direct 
p53 targets, the important contribution of ER in their transcriptional modulation and 
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the role of non-canonical response elements, the correlation between occupancy 
levels and gene expression varied.  
SECONDARY TASK Using a newly developed miniaturized yeast-based assay, 
functional interactions between p53 and its regulators MDM4 and 53BP1 was 
investigated. MDM4 was confirmed as a p53 negative regulator and the impact of 
nutlin-3a or RITA (apoptosis inducer through p53 binding) on the p53-MDM4 
interaction was explored. Instead, no stimulatory effect of the p53 co-activator 
53BP1 was detected. 
CONCLUSIONS Collectively, the results indicate that combinatorial activation of 
p53 and ER can induce novel gene expression programs which have implications 
for cell-cell communications, adhesion, cell differentiation, development and 
inflammatory responses as well as cancer treatments. The yeast-based assay 
represents a versatile tool to study p53 interactions with cofactors. 
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INTRODUCTION 
Mechanisms of transcriptional regulation 
Transcription is one of the first steps that takes place in gene expression and must 
be tightly regulated to be adequately robust, accurate, tailored and responsive to 
temporal, spatial, and physiological signals and changes.   
About the 10% of the encoded genes are thought to be transcription factors 
(TFs) that in eukaryotes can recognize short sequences, called response elements 
(REs) 1. A cis-regulatory region, usually the promoter of a gene, is composed by a 
series of these short DNA sequence motifs, often in multiple copies or partially 
overlapping with each other, that can be bound by general or sequence-specific 
transcription factors 2, 3. Multiple TFs can bind simultaneously this array of REs 
determining the gene expression and its regulation. The number of combinations 
of TFs and REs at the level of a cis-regulatory region can be vast and not easy to 
determine 1. Indeed many factors participate in the process of the recognition of a 
RE by a sequence-specific transcription factor. Cellular condition is extremely 
important because it implies post-transcriptional and post-translational 
modifications, concentration of the TF within the cell and interactions with 
components of the basal transcriptional machinery and its specific cofactors. In 
particular, post-translational modifications play an important role in modulating the 
behavior of a TF, in terms of differential recruitment of partners, nuclear exclusion 
or shuttling, change of binding affinity and site preference as well as change in 
transactivation/transrepression activity. Chromatin state and landscape also 
directly contribute to transcriptional modulation, making DNA more or less 
accessible and increasing or reducing the genomic region that can be recognized 
and bound by a TF. Equally important is also the ‘’quality’’ of the response element 
sequences that determines the selectivity and specificity of TF recognition. The 
activity of a TF can in addition be modulated when it interacts or cooperates with 
other transcription factors present in close proximity 1, 2, 4. 
REs are usually found at the level of the promoter near the transcription start 
site but they might be also present in enhancers or other genomic regions many 
base pairs away from the promoter. TFs are usually active as dimers or tetramers. 
This is thought to increase the binding specificity due to the fact that the total 
sequence length recognized is longer. That could explain why REs are usually 
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composed by two half-sites, where half-site is defined as the minimal sequence 
recognized by a monomer or dimer, in case of a dimeric or a tetrameric TF, 
respectively 1, 2. Indeed, RE sequences are very short and the probability to 
identify one of them in the human genome by chance is extremely high. Taking 
into account that mismatches can be tolerated especially in certain positions of the 
RE, the probability increases considerably. The majority of them are just spurious 
sequences not bound by the specific TF. The factors mentioned above and the 
capacity of a TF to dimerize or tetramerize contribute to discriminate between a 
random sequence and a cis-element 2. Base pair changes can of course affect the 
binding selectivity of a TF although it can still recognize and bind these degenerate 
binding sites expanding the variety of different modulations and regulations that 
can take place on those promoters.   
When two different TFs bind a cis-regulatory region two different scenarios can 
occur, either interaction or synergy. Interaction between two different transcription 
factors is called heterodimerization and it can be preassembled or assembled at 
the level of the promoter itself. Heterosynergy, instead, does not require a direct 
interaction between the two TFs, as shown in Figure 1. Synergy is a mechanism 
that allows a stronger transcriptional response and ensures a better discrimination 
of signal from a background noise due to the presence of similar binding sites in 
the genome. Synergy, as part of cooperation between two TFs, allows the 
integration of information coming from different signal transduction pathways. But 
the mechanisms that control such synergy are still poorly understood. The 
transcriptional machinery (or mediator) is recruited simultaneously and more 
efficiently by two TFs than by only one. Many factors control the simultaneous 
binding of the mediator, including the geometry of the promoter, the shapes of the 
transactivation domains and the ability of the TFs to recruit in concert the 
transcriptional machinery 2. 
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Figure 1. Schematic cartoon showing 
heterosynergy. The mediator complex (basal 
transcriptional machinery) is more efficiently 
recruited at the level of the promoter by two 
or more TFs instead of one. Georges et al., 
2010.  
 
The tumor suppressor p53: Structure, Regulation and Function 
The sequence-specific transcription factors p53 and estrogen receptors are 
considered master regulators because they directly or indirectly control a myriad of 
biological functions.  
p53 is well-known as ‘’the guardian of the genome’’ and it controls several 
responses to stress, mostly related to genome stability, cell cycle and growth 
control, apoptosis, senescence and angiogenesis 5, 6. Nevertheless, p53 can 
regulate many other biological processes including autophagy, energy metabolism, 
mTOR signaling, immune responses, cell motility and migration, cell-cell 
communication, in part through the modulation of several microRNA genes or the 
control of microRNA maturation 5-9 (Figure 2).  
 
 
Figure 2. Chart summarizing the main p53 functions. Vousden and Prives, 2009 
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p53 is mainly a tumor suppressor and it must be maintained at low levels in 
unstressed conditions. The RING-finger ubiquitin E3 ligase MDM2 is its primary 
negative regulator. The short half-life of p53 is in fact due to a continuous 
ubiquitylation and degradation by proteasomes. During stress condition instead its 
ubiquitylation is suppressed in favor of its stability and homotetramers formation. 
p53 tetramers can transactivate target genes through the binding of p53 response 
elements (p53-REs). The tumor suppressor activity can be achieved also outside 
the nucleus. In this case p53 translocates to the mitochondria and triggers 
apoptosis program, interacting directly with anti-apoptotic proteins (Mcl-1, Bcl-xL). 
According to its function, it is not surprising to find p53 mutated in about the 50% 
of the tumors known and its function is probably altered or inactive in the rest of 
the cancer types 5.  
A p53 monomer can be divided in three main functional domains: a 
transactivation domain (N-terminal region), a DNA-binding domain (central core) 
and a tetramerization domain (C-terminal region), although the protein 
organization is more complex. Indeed the N-terminal portion of the protein consists 
of three domains, two transactivation domains (TAD1 and TAD2) required for the 
activation of the transcription of target genes and the interaction with other factors 
(TFs, acetyltransferases and MDM2) 5, 12, 13, and the SH3 domain, a proline-rich 
region (PRD) required for protein-protein interactions, for example with SIN3. SIN3 
is involved in protection of p53 degradation, but also can participate as chromatin 
modifying enzyme in p53-mediated gene repression 14, 15. The p53-RE within 
promoters is recognized by the DNA-binding domain (DBD), located in the central 
portion of the protein. The majority of the mutations occurs at the level of the DBD, 
highlighting the importance for tumor cells of escaping the binding of the targeted 
REs. The C-terminal region carries the tetramerization domain (OD), a nuclear 
localization signal (NLS), a nuclear export signal (NES) and a regulatory domain 
important for the DNA binding (Figure 3) 5, 7.  
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Figure 3. Scheme showing the different p53 domains accordind to references 5,12,13. Numbers 
indicate amino acid residues of the different domains within the protein.  
 
Post-translational modifications play a crucial role in modulating p53 activity. The 
p53 protein is modified by as many as 50 individual post-translational 
modifications. Many of these occur in response to genotoxic or non-genotoxic 
stresses and show interdependence, in a way that one or more modifications can 
nucleate subsequent events. The most common ones reported include 
phosphorylation, acetylation, ubiquitylation, sumoylation, neddylation and some 
evidences of glycosylation and ribosylation as well 5. In the same cellular context 
p53 can be activated but different post-translational modifications can occur 
leading to a different transactivation response. 
As a sequence-specific TF, p53 recognizes a consensus sequence composed 
of two decamers infrequently divided by a spacer. p53 binds as a tetramer the 
consensus sequence 5’-RRRCWWGYYY(N)nRRRCWWGYYY-3’, where N is the 
spacer (0-13 nt), R a purine, Y a pyrimidine and W either adenine or thymine 8-11. 
Each dimer contacts directly six nucleotides within the decamer; one monomer 
binds the ¼-site RRRCW and the other monomer the ¼-site WGYYY. When p53 is 
bound to the target DNA a conformational change occurs in the protein so that the 
orientation of the transactivation domains might be affected, in favor of the 
transcriptional machinery recruitment. The decamers can be oriented either head-
to-head or head-to-tail. The core CWWG sequence of the decamer plays a crucial 
role in determining the level of transactivation, owing the strongest positional 
effect. C and G are essential and required for p53 recognition and CATG is 
thought to be required for the strongest level of transactivation. CAAG and CTTG 
are usually associated with a lower activity and CTAG with an inhibitory function. 
The flanking purines and pyrimidines are also important in modulating the 
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transactivation activity, and in particular the two inner nucleotides with GG/CC as 
the most active and AG/CT the least active. The spacer instead seems to have a 
more transactivation-repressing function; the longer is the spacer (>2) the weaker 
is the transactivation. Non-canonical p53-REs have also been annotated, 
consisting of ½- (a decamer) and ¾-sites (a decamer + ¼-site). The p53 protein is 
able to bind also those REs, most probably as a tetramer where one dimer –in the 
case of ½ sites- or one dimer + a monomer –in the case of ¾ sites- establish 
specific DNA contacts 8-11. In these cases the non-consensus portion of the DNA 
sequence can be bound through non-specific p53 interactions. The role these non-
canonical p53-REs can have in the p53 transcriptional network is still under 
investigation but the contribution on expanding the p53 universe has been 
demonstrated. Specifically, it has been shown that p53 can use those non-
canonical REs to regulate gene expression through the interaction with other 
transcription factors. These interactions might be positive or negative according to 
different cellular conditions 8-11. 
 
Structure, Regulation and Function of Estrogen Receptors 
Estrogen receptors (ERs) belong to the Class I of nuclear receptor transcription 
factors that exert hormonal responses through the activation of many biological 
pathways, mainly stimulating proliferation. ERs are carrying out their roles not only 
in women but also in men, being master regulators essential for development and 
maintenance of normal sexual and reproductive functions, but also playing a role 
in the cardiovascular, musculoskeletal, immune, and central nervous systems. The 
hormone estrogen can be bound by two different ER subtypes, ERα and ERβ, with 
different and non-redundant functions and distinct tissue expression patterns. In 
particular, at the promoter level of proliferative genes, ERα and ERβ seem to have 
opposite actions and the overall balance of both signaling reflects the proliferative 
stimulus due to the hormone. Indeed the ratio between the two proteins, when 
simultaneously expressed within the same cellular context, seems to determine 
the overall estrogen responsiveness. ERα and ERβ are also transcribed from 
different genes located on different chromosomes 16-18.  
The classical mechanism through which ERs transactivate their targets is in a 
ligand-dependent fashion, directly contacting DNA after ER dimerization. Ligand-
bound ERs can also regulate gene expression through protein-protein interaction 
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with other TFs (indirect DNA binding, tethered pathway); in this particular case 
promoters do not require to harbor estrogen receptor response elements (EREs). 
A third mechanism due to ER ligands, occurring within seconds or minutes, 
includes the activation of kinases and phosphatases without involving direct gene 
regulation. This non-genomic pathway with rapid effects requires the binding of the 
hormone to a receptor usually associated with the membrane (either ER or 
another receptor) or a signal activates ERs in the cytoplasm; the final outcome 
involves signaling cascades initiated via second messengers (SM) affecting the ion 
or nitric oxide levels in the cytoplasm (physiological effect). All these mechanisms 
are depicted in Figure 4 together with the so-called ligand-independent pathway 
that includes the activation of ERs through non-canonical signaling, such as 
growth factor signaling. Once kinases are active, ERs can be phosphorylated and 
dimerize in order to directly bind and transactivate the target genes 16-18.  
 
 
Figure 4. Different molecular ER pathways. Heldring et al., 2007 
 
ER activity can also be modulated by post-translational modifications, including 
phosphorylation, acetylation, sumoylation and ubiquitination. Functional ER 
domains are quite well evolutionary conserved and ERα and ERβ share a high 
level of homology (Figure 5). Among the six domains, the most conserved one is 
the central DNA-binding domain, containing two cysteine-cysteine zinc-fingers, 
that shares approximately the 98% of amino acid similarity (C domain). A ligand 
binding domain is also present (E/F domain) and within it the activation function-2 
(AF-2) region drives the ligand-dependent transcriptional activation. At the N-
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terminal portion of the protein (A/B domain with poor homology, 16%) an activation 
function-1 (AF-1) region is involved in the ligand-independent activity, capacity 
considered either absent or negligible for ERβ. The AF regions seem to be 
involved in transcription directly interacting with the transcriptional machinery. AF-2 
is able to recruit coregulators and adaptor proteins that together with the N-
terminal region of the protein regulate gene transcription. Conformation of the 
ligand binding domain is usually altered upon binding to ligand and is involved in 
dimerization together with the C domain. The conformational change allows also 
the recruitment of co-activator proteins. The hinge domain (or D domain) has also 
a role in dimerization and in binding to chaperone heat-shock proteins 19, 20.  
 
 
Figure 5. ER structure, including the functional domains and the degree of homology.  
Abdulkareem and Zurmi, 2012. 
 
ERs are also sequence-specific transcription factors and they bind the estrogen 
response element (ERE) sequence 5’-GGTCANNNTGACC-3’, where N could be 
any nucleotide. When the receptor contacts an ERE the conformation of the ER 
alters. The affinity with which ERα binds an ERE is modulated by extra nucleotides 
flanking the basal ERE (5’-AGGTCANNNTGACCT-3’). The canonical ERE is a 
perfect palindrome, and with the additional nucleotides it forms a 15 bp 
palindromic inverted repeat. Imperfect palindromic EREs differ in one or more 
nucleotides and are less responsive to ERs. Non-palindromic EREs seem to be 
present in the majority of ER responsive genes. The consensus half-site ERE is 
thought to be the minimal target site for ER, and other transcription factors as well 
as cofactors could be required to promote the binding and transcriptional 
modulation 21-22. 
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The intricate p53 and ERs crosstalk 
p53 and ERs appeared to be master regulators that participate in the regulation of 
different biological functions and are activated by different signaling pathways. 
However, there are many evidences that suggest an intricate and not yet well-
understood crosstalk between these two diverse networks. This crosstalk can be 
due for instance to direct interaction between p53 and the ERs, with the more 
frequently described outcome being repression of p53 activity. ERα binds p53 
repressing its transcriptional function. This could be a way used in some abnormal 
cellular growth to suppress anti-proliferative genes, such as genes involved in cell-
cycle arrest and apoptosis, and enhancing the ER responsive proliferative ones. 
That could also explain why the majority of ER-positive breast cancers still express 
wild type p53. Many of ER-negative breast cancers, instead, express mutant p53. 
Experiments performed in breast adenocarcinoma-derived MCF7 cell line (p53 
wild type and positive for ERα) showed that ERα physically binds the promoter-
bound p53 on p53 response elements. The interaction was mapped and seems to 
be due to AF-2 region of ERα and the C-terminal regulatory domain of p53 and 
such interaction can be relieved by stress-dependent post-translational 
modifications of p53, obtained for instance with ionizing radiation 24-27. Some 
observations also link a physical interaction with the inhibition of ERα 
transcriptional activity. p53 interacts ERα in multiple domains repressing its 
function 28, 29. ERα and p53 can therefore be considered respective coregulators.  
However, the p53/ER interaction can also result in mutual positive regulation at 
the level of target gene expression level. For example, estradiol and ERα can act 
through the canonical, estrogen-dependent pathway to positively modulate wild 
type and mutant p53 protein levels. The logical explanation can be attributed to a 
control mechanism that estrogen-dependent cells use to avoid cell death when the 
level of estrogen is low due to the reduction of p53 activity 30, 31. p53 on the other 
side can directly up-regulate ERα gene expression through elements located in the 
promoter 32. This, again, supports the findings of a correlation between the 
presence of wild type p53 and ER-positive breast cancer along with a correlation 
between mutant p53 and ER-negative breast cancer 33, 34. Most of these studies 
addressing p53/ER interaction were performed in breast cancer cell lines, 
underlining the importance of the regulation of the activity and expression of p53 
and ERs in tumors. Many of the studies particularly were performed in MCF7 or 
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MCF7-derived cell lines. The different results obtained can in part be attributed to 
the cellular context on one side and on the other side to the target genes 
considered and to the signaling context created.  
The two transcription factors can also share some coregulators, such as p300 
and MDM2. Some studies, in particular, emphasized the role of the p53 negative 
regulator MDM2 for the ER activity, showing both the inhibition 35 and the positive 
regulation 36 of ERα. In breast cancer cells MDM2 can interact with ERα and p53 
to form a ternary complex promoting ERα turnover through, most probably, its 
ubiquitin-ligase activity; and cellular stress can stabilize ERα and abolish its 
degradation 35. The ternary complex appeared to protect p53 from functional 
deactivation of MDM2 due to the binding of ERα to the p53 N-terminal region 37. 
Other reports in breast cancer cells show instead a positive modulation of ERα-
mediating gene expression and estrogen-responsiveness mediated by a direct 
MDM2-ERα interaction not involving p53 36.     
Recently, a transcriptional cooperation between activated p53 and ligand-bound 
ERs at the promoter of the vascular endothelial growth factor receptor-1 (VEGFR-
1, FLT1 gene) has also been uncovered 38-41. Vascular endothelial growth factor 
(VEGF) participates in angiogenesis and vasculogenesis processes and it can 
bind two principal transmembrane receptors, named VEGFR-1 and VEGFR-2. 
Many cell types in addition to endothelial cells express these two receptors on their 
surface, including also some tumor cells. FLT1 gene can be in fact up-regulated by 
hypoxia; and VEGFB and placental growth factor (PIGF), usually overexpressed in 
pathological conditions, can be its specific ligands. Blood vessels formation is a 
critical step during tumor development and cancer cells must find a way how to 
regulate expression of genes involved in angiogenesis. In this particular case, the 
transcriptional cooperation arises only in the presence of a specific SNP in the 
promoter of the VEGFR-1 gene. The C>T transition (GGACACGCTC à 
GGACATGCTC) changes a critical mismatch that generates a ½-site p53-RE, 
named as p53RE-T, responsive to p53. When the SNP occurs the FLT1 promoter 
can be modulated in response to genotoxic stress, resulting in a possible biological 
diversity within a population. An additional angiogenesis gene can therefore be 
part of p53 target genes and expand the p53 transcriptional network. The p53 
responsiveness leads however to a weak FLT1 transactivation. A higher level of 
responsiveness, called synergy, can be instead achieved when ligand-activated 
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ERs act in cis at the level of the VEGFR-1 promoter (Figure 6). ERs can bind the 
FLT-1 promoter through two ½-site EREs located in close proximity of the ½-site 
p53-RE. The first ½-site ERE annotated was the one located 225 bp upstream the 
½-site p53-RE (GGTCAggaTcACt) and a second one is instead located 145 bp 
downstream the ½-site p53-RE (GGTCAggagcggC) 38-41. 
Consequently, the p53/ER functional interaction appeared to be dependent only 
on non-canonical cis-promoter REs for both transcription factors. Occupancy 
analysis, suggested that p53 was required for ER recruitment to the two ½-site 
EREs and therefore for ER-dependent transcription. ½-site EREs are located 
within 250 bp, a sufficient distance to assure the positioning of a nucleosome and 
assuring a topographical proximity 38-41. 
 
 
Figure 6. Example of mechanism of transcriptional synergy between p53 and ERα at the level of 
the FLT1 promoter. Menendez et al., 2007. 
 
Based in part on these findings, non-canonical p53 REs, consisting of ½- or ¾-
sites, can be included in the p53 target network providing for moderate or weak 
p53 responsiveness, but at the same time for the opportunity of conditional, 
context-dependent transactivation 11. Also in the case of ERs, the anatomy of an 
estrogen receptor element (ERE) can also deeply influence the binding affinity as 
well as the gene expression 21-23. Hence, p53 and ER networks need to maintain 
enough plasticity to adapt their transcriptional response according to the cellular 
context. 
Investigation of general functional interactions between the tumor suppressor 
p53 and ligand-bound estrogen receptors, and specifically, a positive 
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transcriptional cooperation mediated by cis response elements, became the focus 
of this work. For this reason, the hypothesis that FLT1 would not be a unique 
example of a synergistic transcriptional cooperation between p53 and ERs 
mediated through non-canonical, but possibly also through canonical REs, was 
sought out. 
Transcriptome analyses were performed using the above mentioned breast 
adenocarcinoma-derived MCF7 cell line. The specific MCF7 clone employed is 
p53 wild type, positive for ERα and weakly positive for ERβ 38. A genome-wide 
transcriptome analysis was performed to address cooperation between the two 
TFs on a global scale. Cells where cultured in an estrogen-depleted medium 
allowing the possibility to add ER ligand when needed. In normal condition p53 
level is barely detectable in MCF7 cells and p53 requires to be activated and 
stabilized to function properly. This allowed the simultaneously treatment of MCF7 
cells with ER and p53 activators. Whole-genome expression changes were 
determined following exposures to doxorubicin (DOX) and 5-Fluorouracil (5FU), 
genotoxic chemotherapeutic drugs commonly used in cancer therapy and to study 
p53-dependent responses, two different concentrations of 17β-estradiol (E2) as 
ER ligand, and the combination of DOX and E2 to systematically compare whole-
genome expression changes.  
Despite the awaited responsiveness of well-established p53 target genes, a 
different impact after 10 hours-treatment with DOX or 5FU was observed, 
confirming previous reports showing that each cell type has a distinct response to 
drugs treatment as well as each genotoxic compound might lead to a different 
expression change that underlies the mechanisms of action of these agents 42, 43. 
This limited overlap between DOX and 5FU differentially expressed genes 
confirmed previous studies that were however based on experiments conducted 
with different cell lines or endpoints. E2-concentration-dependent changes in gene 
expression were also different. Results obtained with both concentrations of E2 
reflect expected estrogen response, comprising differentiation, proliferation, 
survival and hormonal responses. The higher E2 concentration, named as 
pharmacological concentration, had a more general repressive effect with also 
some unexpected functional regulations. The analysis was therefore focused on 
treatments with DOX and the lower E2 concentration (physiological concentration).  
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Finally, 201 genes that were up-regulated with a more than additive effect after 
DOX and E2 treatment were identified and these 201 genes showed a predicted 
functional enrichment for cellular differentiation and development, cell-cell 
communication, cell adhesion, and inflammation responses. For ten out of sixteen 
genes examined further, the synergistic transactivation was statistically validated 
using a quantitative real time PCR (qPCR) approach. An extensive analysis was 
performed including also nutlin-3a (a non-genotoxic drug, used as MDM2 
antagonist) as direct p53 activator 44. 
Two out of the ten genes showed the synergistic transcriptional cooperation 
after the combined treatment with all the p53 activators used (DOX, 5FU or nutlin-
3a) and E2 administration. Using MCF7 cells with reduced p53 expression, it was 
also addressed that p53 participates directly in the modulation of their expression 
and in the cooperation with ER, and three new p53 target genes (GDNF, KRT15, 
SOX9) were discovered. The cis-mediated cooperation at the level of the promoter 
of three of those genes was studied, performing a chromatin immunoprecipitation 
assay. KRT15 expression appeared to be regulated in cis through p53 and ERα 
response elements. However, chromatin immunoprecipitation does not provide 
temporal resolution for different TFs that can occupy promoters in a population of 
cells. Dissection of the mechanism that regulates the synergistic expression at the 
level of the promoter of the genes identified is part of future directions. This might 
be addressed using mutant ERs that lack some protein functions, such as 
tethering mechanism and binding affinity.    
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METHODS 
This section reflects my personal contribution to the work. The complete 
description of the Materials and Methods can be found in the manuscript enclosed 
(p100).  
 
Cell lines and culture conditions 
The human breast adenocarcinoma-derived MCF7 cell lines were normally 
maintained in Dulbecco’s modified Eagle’s (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 2mM glutamine, 100 units/ml penicillin, and 100 µg/ml 
streptomycin at 37°C under 5% CO2. 
For the experiments performed in estrogen-depleted medium MCF7 cells were 
instead maintained in DMEM without phenol red supplemented with 10% charcoal 
filtered FBS for two days before seeding onto 6-well plates, 100 or 150 mm Petri 
dishes or E-Plates 16 (Roche Applied Science, Milan, Italy). 
Human breast adenocarcinoma cells MCF7 stably expressing shRNA to p53 
from the pSUPER vector, designated as “MCF7-p53i”, or only carrying pSUPER 
vector as a control (“MCF7-vector”) 63 were cultured in DMEM medium 
supplemented with 10% FBS, 100 U/ml of penicillin, 100 µg/ml of streptomycin 
(Invitrogen, Carlsbad, CA)  and 0.2 µg/ml  of puromycin at 37°C under 5% CO2. 
 
Cells treatment 
MCF7 cells were cultured in estrogen-depleted medium and treated for 10 or 24 
hours with 1.5 µM doxorubicin (DOX) or 375 µM 5-fluorouracil (5FU) or 10 µM 
Nutlin-3a for p53 stabilization and/or 10-9/10-7 M 17β-estradiol ERs activation. 
Dimethyl sulfoxide (DMSO) and ethanol (EtOH) were included as control in the 
mock condition. All the treatments were done on cells at 70-80% of confluence.  
 
Microarray data analysis and functional annotation clustering 
In order to select differentially expressed genes (DEGs), every condition 
corresponding to a treatment was first compared to the mock. Three different 
thresholds were set in order to select differentially expressed genes for each 
comparison: a) t-test unpaired unequal variance p value < 0.01; b) Rank Product 
percentage of false positive  (pfp) < 0.05; c) absolute log2 (fold change) >  log2 (2) .  
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Genes up-regulated by the concomitant treatment of doxorubicin and E2 (10-9 M) 
with more than an addictive effect were identified among those satisfying the 
condition log2[FCdouble treatment] > 2 subtracting the two fold changes corresponding 
to the single treatments to the fold change corresponding to the double treatment 
and selecting those with a positive result: (log2 [FCdouble treatment] – log2[FCdoxo] – 
log2[FCE2]) > 0.1. 
Functional annotation clustering analyses were performed using the Ingenuity 
Pathway Analysis (IPA, http://www.ingenuity.com) as well as DAVID 
(http://david.abcc.ncifcrf.gov/) 45 (enrichment score ≥ 1.5, medium classification 
stringency) with default settings  Results from DAVID functional cluster were then 
summarized as a Table with the indicated enrichment score. Results from IPA 
Canonical Pathways and Upstream Regulators are presented as screen 
snapshots. In particular, the IPA Upstream Regulator analysis presented in the first 
three columns names and function of upstream regulators that may be responsible 
for gene expression changes and their relative expression (Fold Change) 
observed in the data set. Predicted activity of these regulators with IPA-provided 
statistical assessment is included in column 4 and 5. A partial list of gene names 
and the total number in each group is also provided along with the Fisher’s Exact 
Test results of the extent of overlap between DEGs and total number of genes 
considered as targets of the upstream regulator. In the IPA Canonical Pathways 
are instead displayed pathways as bar chart. The –log(p value) results of a right-
tailed Fisher’s Exact Test is indicated. The ratio, calculated as number of genes in 
a given pathways that meet cut-off criteria divided by the total number of genes 
that make up the pathway, is overlaid as an orange line. The first 10 top pathways 
are shown. 
 
Western blot analysis 
Proteins were extracted using RIPA (RadioImmunoPrecipitation Assay) buffer 
supplemented with protease inhibitors and quantified using the BCA protein assay 
kit (Thermo Scientific, Pierce Protein Research Products, Milan, Italy). Proteins 
separated on 12% SDS-PAGE gels were transferred to a nitrocellulose membrane 
(GE Healthcare, Milan, Italy) using an iBlot® Dry Blotting System (InvitrogenTM, 
Life Technology) and checked by Ponceau S staining. Membranes were blocked 
using 5% skim milk + PBS-Tween20 (0.1%) for 1 hour at room temperature and 
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then probed with the primary antibodies in 1% skim milk + PBS-Tween 20. 
Immune complexes were visualized using Amersham ECL™ Advance Western 
Blotting Detection Kit (GE Healthcare) or SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA). The relative 
molecular mass values of the immunoreactive bands were determined using 
PageRulerTM Plus Prestained Protein Ladder (Fermentas, Milan, Italy).  
 
Quantitative Real Time PCR (qPCR) 
MCF7 cells, MCF7 p53i and vector were seeded onto 6-well plates and allowed to 
reach 70–80% of confluence before treating them with different drugs as described 
before. 10 or 24 hours after the treatment cells were washed twice with PBS and 
harvested using 1X trypsin (BioWhittaker®, Lonza). Total RNA was extracted using 
the RNeasy mini Kit (Qiagen®) according to the manufacturer’s instructions and 
quantified using the NanoDrop spectrophotometer. For quantitative real time PCR 
experiments 1 µg of total RNA was reverse transcribed in 20 µl of reaction using 
the ‘RevertAidTM First Strand cDNA Synthesis Kit’ (Fermentas, Milan, Italy) or 
TaqMan reverse transcription reagents from Applied Biosystems (Foster City, CA). 
qPCR was carried out using 384-well plates in a final volume of 10 µl either on a 
CFX384 Touch™ Real-Time PCR Detection Systems (Bio-Rad, Milan, Italy) or on 
ABI prism HT7900 system (Applied Biosystems). KAPA Probe FAST qPCR 
Kit/TaqMan Universal PCR Master Mix (Applied Biosystems, Branchburg, USA) or 
KAPA SYBR® FAST qPCR Kit (Kapa Biosystems, Resnova, Rome, Italy) was 
used to perform the reaction together with TaqMan® Gene Expression Assays 
(Applied BiosystemTM, Life Technology, Milan, Italy) or primers purchased from 
Eurofins (MWG, Operon, Ebersberg, Germany). 
Relative mRNA quantification was obtained using the comparative Ct method 
(ΔΔCt), where glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-
2microglobulin (B2M) or β-actin genes served as internal controls. Calculations 
were performed using QbasePLUS software (Biogazelle) that uses the geNorm 
method [39] to evaluate the expression stability of candidate reference genes.  
A statistical analysis considering the log2 of the fold of induction was used to 
confirm the synergistic effect. The means of two normally distributed populations 
composed of log2 [FCdouble treatment]  and log2[FCdoxo] + log2[FCE2] were analysed 
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using a t-test approach (p < 0.05). Quantitative real time PCR for ChIP samples is 
described in the next session. 
 
Promoter pattern search 
An in silico analysis was performed in order to identify putative canonical or non-
canonical p53 and ERα response elements (REs) couples with a maximum 
distance of around 500 bp within the promoters of the selected genes. Three 
different approaches were used and combined together: a) manual pattern 
matching analysis (½ p53 RE: RRRCWWGYYY; ½ ERα RE: (A)GGTCA, 
TGACC(T) or GGCTA) b) pattern matching analysis with ½ site position weight 
matrixes derived from TransFac using the online Regulatory Sequence Analysis 
Tool (RSAT) 64 and c) R tool analysis using TransFac matrixes. 
Chromatin immunoprecipitation (ChIP) assay  
MCF7 cells were cultured in estrogen-depleted conditions in a 150 mm Petri dish 
and treated for 10 hrs with doxorubicin and/or the physiological concentration of 
E2 (10-9 M). Cells were cross-linked in 1% formaldehyde for 10 minutes at room 
temperature and the reaction was then quenched with glycine to a final 
concentration of 0.125 M for 5 minutes. Cells were then washed twice with cold 
PBS and scraped using PBS plus protease inhibitors (PI). Pellet was resuspended 
in 500 µl of lysis buffer (1% SDS, 0.1 mg/ml ssDNA, PI 1x) and centrifuged for 10 
minutes at 14-15°C. Pellet was then resuspended in 500 µl of sonication solution 
buffer (0.25% SDS, 200 mM NaCl, 0.1 mg/ml ssDNA, PI 1x) and sonicated using 
the Misonix S4000 Sonicator (Misonix Inc., Farmingdale, NY, USA) in order to 
obtain DNA fragments in a range of 200-500 bp. After removal from the 
supernatant of the non-specific binding using Dynabeads® Protein G (Life 
Technology), immunoprecipitation (IP) was performed using 1 µg of the 
appropriate antibody on 150 µl of sample diluted 10 times with dilution buffer (16.7 
mM Tris HCl, 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 167 mM NaCl, 0.1 
mg/ml ssDNA, PI 1x) + 40 µl of agarose beads o/n at 4°C. 15 µl of sample was 
also collected (1/10) as input (In).After many steps of washing the IP, crosslinks 
were reversed firstly in elution buffer (50 mM Tris HCl, 1 mM EDTA, 1% SDS) at 
65°C for 10 minutes and then in TE 1x + 0.65% SDS for 10 minutes at 65°C. The 
collected solutions were incubated at 65°C o/n as well as the input samples + 
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elution buffer + TE 1x + 0.65% SDS. After RNase A and proteinase K treatment 
DNA was purified using PCR purification kit supplied by Qiagen®.  
The purified DNAs were used for quantitative real time PCR analysis. Input 
samples were used for the normalisation and the fold enrichment was calculated 
over the mock condition in order to obtain a ΔΔCt value. IgG DNAs were not taken 
into account for the normalisation step. qPCR was carried out using 384-well 
plates in a final volume of 10 µl on a CFX384 Touch™ Real-Time PCR Detection 
Systems (Bio-Rad, Milan, Italy). KAPA SYBR® FAST qPCR Kit (Kapa Biosystems,) 
was used to perform the reaction together with primers purchased from Eurofins 
(MWG	  Operon, Ebersberg, Germany).  
 
Cell proliferation assay 
Toxicity of the chemicals and drugs used for the experimental approach was 
tested using the Real-Time Cell Analyzer (RTCA) DP supplied by Roche Applied 
Science , Milan, Italy. Cells were seeded onto an E-Plate 16 and allowed to reach 
70–80% of confluence (checked by cell index value, almost 22-24 hours) before 
treating them with different drugs as described in Cells treatment. The proliferation 
rate was checked in the first 10 hours of  treatment. A cell index normalization was 
imposed at the time point before the drugs administration. Mock condition was 
used as baseline. The experiment was conducted in triplicate for each condition.  
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RESULTS 
This section presents an extended summary of the results included in the 
accompanying manuscript (p92 Lion et al.). For clarity some of the Figures of the 
manuscripts are also reproduced here. The complete description of the Materials 
and Methods can be found in the manuscript (p100). The Methods section in the 
thesis body reflects my personal contribution to the work. Specifically, I was not 
involved in the experimental part of the microarray analysis (RNA extraction, 
labeling and hybridization) and the processing of data acquisition. I did all the other 
data analyses and experiments described here and in the paper. 
 
Validation of the experimental approach: p53, ER activation under the 
different treatment protocols and impact on cell growth 
The functional effect of the drugs used in the experiments carried out was checked 
in this model system, the breast adenocarcinoma-derived MCF7 cells (p53 wild 
type; ERα - and weakly ERβ positive). The validation was performed both by 
western blot and quantitative real time PCR (qPCR) analysis.  
p53 was stabilized after treatment with doxorubicin (DOX), 5-Fluorouracil (5FU) 
and nutlin-3a (nutlin) and its endogenous levels increased in comparison to mock 
or E2 condition. The ERα protein levels in total extract did not change after any of 
the 10 hour-stimuli used (Figure R1A). 
Gene expression of the canonical p53 target p21/CDKN1A10 and the canonical 
ERα target pS2/TFF122 was tested to confirm their mutual transcriptional activation 
by qPCR (Figure R1B&C). p21 was indeed induced only when p53 activators were 
administered whereas pS2 only in the presence of E2. Fold of induction may differ 
according to the type of treatment. Notably, nutlin treatment resulted in higher 
relative p21 expression that was increased 1.5 fold with the addition of E2 (Figure 
R1C). 
Absence of a real toxicity during the 10 hours-administration of the p53 activator 
drugs or E2 alone was confirmed by monitoring cell number and surface 
attachment in real time using Xcelligence (Figure R2). Nutlin and 5FU treatments 
were slightly toxic compared to the mock condition used as baseline. The 
combination of a p53 activator with E2 increased the overall cell index value, 
consistent with a role of estradiol in promoting proliferation. 
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Figure R1. p53 and ERα protein levels and transactivation activities upon DOX, 5FU, nutlin, 
E2 single or combined treatments. A) Western blot analysis showing p53 and ERα protein levels 
10 hours after the indicated treatments at the following doses: DOX, 1.5 µM; 5FU, 375 µM, nutlin, 
10 µM; E2, 10-9 M. Figures B-C) qPCR results for the p53 target gene p2110 (B) and the ERα target 
gene pS2/TFF122 (C). Presented in the bar graphs are fold-induction relative to the mock condition 
and the standard errors of three biological and two technical replicates for each condition. For 
qPCR, GAPDH, B2M and β-actin housekeeping genes served as internal controls. 
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Figure R2. Cell Index Analysis to follow up treatment-specific toxicity. Impact of the chemicals 
and drugs used in the experimental approach was tested using the Real-Time Cell Analyzer 
(RTCA) DP supplied by Roche Applied Science, Milan, Italy. Cells were seeded onto an E-Plate 16 
and allowed to reach 70–80% of confluence (checked by cell index value at ~22-24 hours) before 
treating them with drugs as described in the Methods section. The proliferation rate was checked in 
the first 10 hours of treatment. A cell index normalization was imposed at the time point before drug 
administration. Mock condition was used as baseline. Presented are the average and standard 
deviation of three replicates for each condition. A) 1.5 µM doxorubicin B) 375 µM 5-fluorouracil, C) 
10 µM nutlin +/- 10-9 M 17β-estradiol (E2). 
 
Different stimuli or concentrations led to different transcriptome changes: 
microarray results followed by pathway and ontology analyses  
Global gene expression profiling was determined using an Agilent 4x44k platform 
(see p100 Material and Methods in Lion et al.) upon single treatment with specific 
chemotherapeutic agents (DOX or 5FU) or with the ER ligand 17β-estradiol (E2), 
using two different concentrations. The two different E2 concentrations tested are 
referred respectively to physiological (10-9 M) and pharmacological dosage (10-7 
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M). Statistical analysis of the microarray data was performed as described in 
Material and Methods (p100). Complete raw and normalized data are available on 
the GEO Gene Expression Omnibus database repository (GEO, 
http://www.ncbi.nlm.nih.gov/geo/; GEO accession: GSM591738).  
To further investigate functional annotation clusters for each specific treatment, 
data from the lists of differentially expressed genes (score cut off ≥ 2) were 
analyzed using the tools Ingenuity Pathway Analysis (IPA, 
http://www.ingenuity.com) and DAVID (http://david.abcc.ncifcrf.gov/ 45). These 
analyses allowed to decide the p53 activator and the concentration of E2 to use in 
the investigation of p53/ER cooperation. 
DOX and 5FU treatments stabilize and activate p53, although with a different 
pattern in terms of protein levels (Figure R1A), and extent of induction of its target 
gene p21 (Figure R1C). A different impact on gene expression was instead 
observed. Figure R3 and R4 clearly show the differences in transcriptome changes 
in terms of gene numbers after the two genotoxic drug administrations. Both 
treatments led to a more extensive repression of gene expression, particularly 
emphasized by the 10 hr-stimulus of 5FU. Only a small number of differentially 
expressed genes (DEGs) is shared between the two treatments with the two 
agents; specifically only 2.3% of the up-regulated and 10.9% of the down-
regulated DOX DEGs are in common with up- and down-regulated 5FU DEGs. 
Considering the predicted transactivation behavior of 373 genes that are included 
in the IPA p53 signaling pathway, on average a correlation coefficient of 0.59 
between DOX and 5FU DEGs was calculated (Figure R5). Gene ontology (GO), 
pathway enrichment and network analysis were therefore used in the selection 
phase of the chemotherapeutic drug treatment that resulted in a more distinct 
signature of p53 activation. The translation of the large amount of data coming 
from microarray analysis into a biological interpretation can offer a more general 
insight into the cellular mechanisms elicited from a given condition. The analyses 
performed in Figure R6 (using DEGs filtered with the parameters highlighted in 
Materials and Methods) compare the microarray results obtained with the two 
chemotherapeutics. Overall, doxorubicin treatment resulted mainly in enrichment 
for the p53-pathway/signaling activation, including regulation of transcription, cell 
cycle and mitosis, cell response to stress, DNA damage checkpoint and response, 
BRCA1 function, apoptosis and ATM pathway. Both DAVID and IPA analyses 
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confirm this enrichment. Hence, for the further genome-wide experiments the 
analysis was focused on DOX genotoxic stimulus only. 
 
 
 
 
 
 
Figure R3. 2 colors-stacked bar graph 
showing the total number of DEGs and the 
up- and down-regulated genes in every 
condition.  
 
  
Figure R4 A&B) Venn diagrams showing the number of DEGs in common between different 
conditions. 
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Figure R5. Predicted transactivation behavior of genes related to IPA p53 pathway. Activated 
state=…..; Inhibited state=…... DEGs values (log2): FC>2=….. FC<-2=…..; -2<FC<2=……. From 
the log2 FC values coming from the array analysis a correlation coefficient between the DOX and 
5FU treatment was calculated using Pearson correlation. 
 
 
 
 
 
	  
	  
33	  
R6 A) DAVID ANALYSIS  
 
 
R6 B) DOXORUBICIN & 5-FLUOROURACILCOMPARISON (IPA UPSTREAM REGULATOR  
          ANALYSIS) 
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R6 C) DOXORUBICIN & 5-FLUOROURACIL COMPARISON (IPA CANONICAL PATHWAYS) 
 
 
Figure R6 DOX and 5FU functional annotation clustering. Analyses were performed using the 
Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com) as well as DAVID 
(http://david.abcc.ncifcrf.gov/45) (enrichment score ≥ 1.5, medium classification stringency) with 
default settings starting from the lists of differentially expressed genes corresponding to the 
treatment: doxorubicin (1.5 µM) and 5FU (375 µM). Results from DAVID functional cluster are 
summarized as a table with the indicated enrichment score. Results from IPA Canonical Pathways 
and Upstream Regulators are presented as screen snapshots. 
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A different response after the treatment with two concentrations of 17β-estradiol 
was also awaited. The purpose of the data analysis was to decide between the 
physiological (10-9 M) and pharmacological (10-7 M) E2 concentration to further 
investigate the interaction between p53 and an estradiol pathway related to a more 
canonical ER signature. An analysis similar to the one performed above for DOX 
and 5FU treatment was followed. Different transcriptome responses were identified 
for the E2 doses (Figure R7&8). The lower E2 concentration (10-9 M) resulted in 
the same number of up- and down-regulated DEGs, whereas the pharmacological 
concentration (10-7 M) was generally more repressive (Figure R7); although a 
bigger number of differentially expressed genes was shared (Figure R8A&B). 
Indeed comparing the predicted transactivation behavior of 76 genes included in 
the IPA ER signaling pathway, the two treatments resulted in a comparable 
response (DEGs not filtered using p-value or FDR). Among the 76 genes a high 
correlation coefficient of 0.89 between the two conditions was identified (Figure 
R9). 
It is not surprising that both concentrations of E2 resulted in DEGs exhibiting 
functional clusters enrichment (DAVID and IPA analyses, Figure R10) that reflects 
expected estrogen responses, including induced differentiation, proliferation, 
survival, hormonal responses and inhibition of p53 and SMARCB1 (Figure R10B). 
Unexpected functional clusters were however observed after 10-7 M E2 treatment, 
including positive regulation of apoptosis and negative regulation of cell growth as 
well as inhibition of SP1 (Figure R10A&B). Therefore, the analysis was focused on 
10-9 M E2 stimulus, since it resulted in a signature much closer to that of typical 
estrogen responses (Figure R10). 
 
 
 
 
 
 
Figure R7. 2 colors-stacked bar graph 
showing the total number of DEGs and the 
up- and down-regulated genes in every 
condition.  
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Figure R8 A&B) Venn diagrams showing the number of DEGs in common between different 
conditions. 
 
 
Figure R9 Predicted transactivation behavior of genes related to IPA ER pathway. Activated 
state=…..; Inhibited state=…... DEGs values (log2): FC>2=….. FC<-2=…..; -2<FC<2=…... From the 
log2 FC values coming from the array analysis a correlation coefficient between the E2 10-9 M and 
E2 10-7 M treatment was calculated using Pearson correlation. 
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R10 A) DAVID ANALYSIS 
 
 
R10 B) E2 (10-7 M) & E2 (10-9 M) COMPARISON (IPA UPSTREAM REGULATOR ANALYSIS) 
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R10 C) E2 (10-7 M) & E2 (10-9 M) COMPARISON (IPA CANONICAL PATHWAYS) 
 
Figure R10. E2 (10-9 M) and E2 (10-7 M) functional annotation clustering. Analyses were 
performed using the Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com) as well as DAVID 
(http://david.abcc.ncifcrf.gov/ 45) (enrichment score ≥ 1.5, medium classification stringency) with 
default settings starting from the lists of differentially expressed genes corresponding to the 
treatment: E2 (10-9 M) and E2 (10-7 M). Results from DAVID functional cluster are summarized as a 
table with the indicated enrichment score. Results from IPA Canonical Pathways and Upstream 
Regulators are presented as screen snapshots. 
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Genome-wide transcriptome analyses identify a combinatorial effect 
between genotoxic stress and proliferation stimulus in response to DOX and 
E2 
Drawing upon the results obtained with FLT-1 38-40, possible additive or 
cooperative interactions between p53 and ER was investigated using combination 
of DOX and physiological concentration of E2 (10-9 M) treatment, again with a 
genome scale approach.  
Lingering over the doxorubicin treatment it is evident that the combined 
treatment shared a common pattern of DEGs in terms of overall transcriptome 
response (Figure R11&R13A). Furthermore 66% among the up-regulated and 75% 
among the down-regulated genes were common DEGs (Figure R12). The overall 
transcriptome changes were however heavily influenced by both treatments 
(Figure R13). The same could in fact be observed with E2 treatment even though 
they shared a smaller number of genes (24% and 13% for the up-regulated and 
down-regulated groups, respectively; Figure R11&R12). Indeed, IPA upstream 
regulator analysis indicated both TP53 and ESR1 as activated (Figure R13B&C). A 
large number of genes still remained univocal in the combinatorial stimulus (Figure 
R12). Interestingly, 66 up-regulated and 167 down-regulated DEGs were uniquely 
identified following DOX+E2 treatment. Conversely, for 380 up-regulated and 369 
repressed DOX DEGs the differential expression was not observed in the double 
treatment. Only 29 up-regulated and 57 repressed DEGs were in common for the 
DOX and E2 single treatments, of which 27 up- and 54 down-regulated genes 
were also DEGs with the double treatment (Figure R12).	   Functional annotation 
clusters obtained with groups of selective genes are summarized from p110 
supplemental tables in Lion et al., although no relevant biological outputs were 
identified probably due to the small numbers of DEGs that limited the statistical 
power.
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Figure R11 2 colors-stacked bar graph 
showing the total number of DEGs and 
the up- and down-regulated genes in 
every condition.  
 
  
Figure R12 Specific gene signatures of the DOX+E2 combination treatment. Venn diagrams 
showing up-regulated genes (A) or down-regulated genes (B) comparing DOX, E2, and DOX+E2 
DEGs. The number of genes differentially expressed in common or unique after doxorubicin or E2 
(10-9 M) treatment or after their combination is indicated. 
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R13A) DOX+E2 combination treatment (DAVID ANALYSIS) 
 
R13 B)  DOX+E2 combination treatment (IPA UPSTREAM REGULATOR ANALYSIS)  
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R13 C) DOX+E2 combination treatment (IPA CANONICAL PATHWAYS) 
 
Figure R13. DOXORUBICIN + E2 (10-9 M) functional annotation clustering. Analyses were 
performed using the Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com) as well as DAVID 
(http://david.abcc.ncifcrf.gov/ 45) (enrichment score ≥ 1.5, medium classification stringency) with 
default settings starting from the lists of differentially expressed genes corresponding to the 
treatment: doxorubicin (1.5 µM) + E2 (10-9 M). Results from DAVID functional cluster are 
summarized as a table with the indicated enrichment score. Results from IPA Canonical Pathways 
and Upstream Regulators are presented as screen snapshots. 
 
The question that was raised after the genome-wide analysis was how 
combinatorial effect could be detected in a synergistic way. An approach based on 
the algebraic sum of logarithmic (log2) fold-changes in expression was adopted. 
Genes were selected considering a delta fold change with a more than an additive 
effect in a such way that the fold change associated to the double treatment must 
be greater than two (a parameter used for a more reasonable validation) and 
greater than the sum of the fold change associated to the single treatments (see 
Methods section). The delta based on the difference between the logarithmic 
values of the fold change of the double treatment and the sum of the single stimuli 
was therefore calculated and filtered (Δ > 0.1). [(log2[FCdouble treatment] – log2[FCDOX] 
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– log2[FCE2]) > 0.1]. A Δ value equal to 0 is considered as additive effect. See 
p135 Supplemental Table III in Lion et al. for the complete list of genes. 
 
A cooperative regulation enhanced the expression of genes involved in 
differentiation, cell-cell communication and cell adhesion or inflammatory 
response 
201 up-regulated and 142 down-regulated genes met the criteria mentioned above 
and therefore exhibited a more than additive response following the combined 
p53/ER inducing treatments (see Figure R12). Analysis revealed that the 
functional cluster outcome appeared to be specific for the combined-treatment-
specific genes, and grouped genes involved in cell-cell communication, cell 
adhesion, development/differentiation and inflammatory response pathways within 
the up-regulated genes, while cell cycle and mitosis functions were enriched in the 
repressed group (Figure R14). The enrichment scores were not high enough to 
assess if the functional clusters identified expand the p53/ER transcriptional 
network. It has been already addressed that ER can regulate growth and 
development 16-18 and that p53 can be involved in the inflammation process 75, 76 
but the functional annotations obtained from these 201 genes can be still 
considered as a subclass of the DOX+E2 condition, strongly related to the 
synergistic cooperation analysis.  
Genes from the up-regulated group were further investigated, leaving the down-
regulated ones for a future study, especially since repression via cis elements has 
yet to be well established for both p53 and ERα. 
 
 
Figure R14. DOXORUBICIN + E2 (10-9 M) functional annotation clustering of genes with a 
more than additive effect. Analyses were performed using DAVID (http://david.abcc.ncifcrf.gov/ 
45) (enrichment score ≥ 1.5, medium classification stringency).  
 
Some of the genes that came out from the analysis were particularly appealing for 
their canonical biological functions or their cellular context. From the group of 201 
genes exhibiting more than additive up-regulation after combined DOX+E2 
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treatment, 16 that represented the main biological functions were selected for 
further analysis. Some are usually expressed in a different biological environment 
than breast cells (SOX946, TEX1447, INPP5D79) and others belong to biological 
pathways that can expand the p53/ER transcriptional master network (TFF348, 
CA5A49, CDH2650, NOTCH151, GDNF52, INPP5D79). For some, a direct or indirect 
functional interaction with p53 (NOTCH187, IGF254, TLR575, 76, PML55, INPP5D79, 
EPHA256), with ER (NOTCH157, CDH2658, 59), or with other selected genes (IGF2 
& H1960, NOTCH1 & SOX961, 62, 58) has already been proposed. 
A quantitative real time PCR (qPCR) was performed to confirm microarray 
results after DOX treatment with or without the addition of E2 (Figure R15). The 
trend of the microarray results was confirmed for the majority of the genes tested 
upon DOX and/or E2 treatment (see scatter plots in Figure R15). T-test analysis 
on the log2 of the values obtained for relative expression confirmed for 10/16 
genes the synergistic effect (p < 0.05) of DOX + E2 combination (see p132 
supplemental tables in Lion et al.).   
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Figure R15. Treatment-selective transcriptional cooperation between doxorubicin and 
estradiol, correlation between microarray and qPCR analyses. qPCR reactions for the 16 
chosen genes were carried out using 384-well plates in a final volume of 10µl using TaqMan® 
Gene Expression Assays (Life Technologies) with 3 biological and 2 technical replicates for each 
condition. GAPDH, B2M and β-actin housekeeping genes served as internal controls. Asterisks 
indicate statistically significant, more than additive effects in the combined treatment as described 
in Methods section. Same RNAs used in the microarray experiments were tested. Scatter plot 
graphs highlight the correlation between data coming form microarray and qPCR analyses (based 
on both log2  and fold of change values). The correlation between microarray results and qPCR is 
shown as scatter plots generated both using the log2 scale and the fold change conversion to better 
visualize the correspondence between the two methods. 
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Gene expression of the 16 genes was also investigated following treatment with 
5FU, another commonly used genotoxic agent that results in p53 activation. The 
responses clearly differed between DOX and 5FU (Figure R15&R16). Speculation 
about the remarkable difference observed between the two chemotherapeutic 
targets will be discussed more extensively below in the Discussion chapter. Only 
CDH26, INPP5D, NOTCH1 were responsive to 5FU (fold change > 1.5) of which 
INPP5D and NOTCH1 were also DOX responsive. The synergistic effect observed 
after DOX+E2 administration was observed only for H19, INPP5D, and in part also 
for GDNF after 5FU + E2 treatment (Figure R16 and p134 supplemental table in 
Lion et al.). Unlike for DOX, the combined treatment did not affect TLR5 or EPHA2 
that are already considered p53 target genes 56, 76. Thus, the E2 enhancing effects 
on expression differed between the two different inducers of p53 as discussed 
below in the next section. 
 
 
Figure R16. Treatment-selective transcriptional cooperation between 5FU stimulus and 
estradiol. qPCR reactions for the 16 chosen genes were carried out using 384-well plates in a final 
volume of 10µl using TaqMan® Gene Expression Assays (Life Technologies) with 3 biological and 
2 technical replicates for each condition. GAPDH, B2M and β-actin housekeeping genes served as 
internal controls. Asterisks indicate statistically significant, more than additive effects in the 
combined treatment as described in Methods section.  
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Genotoxic stress plays an important role in the synergy with ER: Nutlin-3a 
treatment synergizes with estradiol pathway only on a subset of genes 
Doxorubicin and 5FU are two different drugs acting in a different way but both 
creating a genotoxic stress within the cell. Genotoxic stress is an important 
stimulus to activate p53 protein, but it can also lead to the activation of a lot of 
other components or pathways, a matter that can alter the precise responses. 
Nutlin-3a (nutlin) on the other hand is able to directly target the complex p53-
MDM2 stabilizing the tumor suppressor without inducing apparently any kind of 
genotoxic stress 44. For that reason MCF7 cells were treated also with nutlin alone 
or in combination with E2 (10-9 M) to check whether the results obtained using 
doxorubicin were reproducible. Stabilization of p53 was observed after treatment 
with nutlin alone or in combination with E2 as well as its transcriptional activation 
(Figure R1). Quantitative real time PCR analysis (Figure R17) showed an up-
regulation for 6/16 genes (EPHA2, INPP5D, KRT15, NOTCH1, SOX9, TEX14) 
after nutlin treatment alone (fold of induction > 1.5) as obtained using doxorubicin 
alone apart from KRT15 that previously resulted only as an E2 responsive gene 
(Figure R15-17). Statistically only three genes (EPHA2, H19, INPP5D) presented a 
more than additive effect in the combined treatment (see p134 of supplemental 
tables in Lion et al.). These three genes were also statistically up-regulated in a 
synergistic way by DOX+E2 and two of those consistently exhibited transcriptional 
cooperation with all the p53-inducing stimuli (H19, INPP5D; see p132-134 
supplemental tables in Lion et al.). Further analyses to investigate the p53-
dependency after DOX and nutlin treatment are required to elucidate data 
observed in qPCR (see next paragraph).   
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Figure R17. Treatment-selective transcriptional cooperation between nutlin stimulus and 
estradiol. qPCR reactions for the 16 chosen genes were carried out using 384-well plates in a final 
volume of 10µl using TaqMan® Gene Expression Assays (Life Technologies) with 3 biological and 
2 technical replicates for each condition. GAPDH, B2M and β-actin housekeeping genes served as 
internal controls. Asterisks indicate statistically significant, more than additive effects in the 
combined treatment as described in the Methods section. 
 
Silencing of p53 in MCF7 cells establishes a direct role of p53 in doxorubicin 
and nutlin responsiveness of the target genes 
Many ways can be adopted to test the p53-dependency of a gene transactivation.  
Changing the cellular context or adding an additional drug to the treatments, for 
instance pifithrin-α (PFTα) that inhibits p53 function, could in principle introduce an 
extra bias on the experimental system. For that reason, direct p53 inducible 
expression of the novel genes was validated using a stable MCF7 cell line 
expressing shRNA to p53 63.  MCF7 clone silenced for p53 was named as MCF7 
p53i and the control MCF7 vector. Functionality of the cell model was validated 
both by western blot analysis and qPCR, at time point 10-hours and 24-hours 
stimuli (Figure R18&R19). Cells were cultured in normal medium and p53 was 
stabilized and activated after DOX and nutlin treatment, as expected, in MCF7 
vector and it was undetectable in MCF7 p53i (Figure R18). p53 mRNA level do not 
vary over treatment compared to the mock condition, in the relative clone (Figure 
R19). ERα protein expression did not change after any of the 10 hour-stimuli used, 
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confirming what previously observed with the original MCF7 cell line (Figure R18).  
After 24-hours, however, doxorubicin repressed ERα protein levels (Figure R18) a 
result confirmed also by mRNA level analysis (Figure R19). This repression 
eventually would affect estradiol responses including the transcriptional 
cooperation with p53. Gene expression for the p53 target gene p21 is greatly 
reduced after DOX or nutlin treatment both at 10- and 24-hour stimulus in MCF7 
p53i (Figure R19). MCF7 p53i clone system was therefore confirmed to be 
silenced for p53, but the silencing does not totally abrogate p53 expression and 
transactivation activity.  
 
 
Figure R18. Changes in p53 and ERα protein levels. Western blot analysis showing p53 and 
ERα protein levels after 10 (A) and 24 (B) hours of DOX (1.5µM) or nutlin-3a (10µM) treatment. 
 
  
Figure R19. Changes in p21, p53 and ERα relative mRNA expression. Presented are results for 
p21, p53 and ER (ESR1) genes after 10 or 24 hours DOX (1.5µM) or nutlin-3a (10µM) treatment in 
MCF7 vector and p53i. The fold-induction relative to the mock condition for MCF7-vector or MCF7-
p53i is presented (H2O for DOX treatment or DMSO for nutlin-3a treatment). 
 
B) A) 
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Among the 16 genes investigated above, eight of them were selected to determine 
how gene expression changed in MCF7 p53i after 10- or 24-hours DOX and nutlin 
treatment. Nutlin treatment is an important control to discriminate between 
possible consequences of genotoxic effects that might occur at the gene 
expression level, in comparison with the quantitative real time performed 
previously (see Figure R15-17). At the 10-hour stimulus (the same of the previous 
experimental approach) EPHA2, GDNF, NOTCH1 and INPP5D were induced after 
either treatment in MCF7 vector cells but were non-responsive or slightly 
responsive in MCF7-p53i cells (Figure R20). The other five genes did not show 
any p53-specific responsiveness although TLR5 has been already shown to be a 
p53 target gene 75, 76.  
 
  
Figure R20. Changes in relative mRNA expression for the selected genes. Presented are 
results for eight selected genes after 10 hours DOX (1.5µM) or nutlin-3a (10µM) treatment in MCF7 
vector and p53i. The fold-induction relative to the mock condition for MCF7-vector or MCF7-p53i is 
presented (H2O for DOX treatment or DMSO for nutlin-3a treatment). 
 
Then, DOX and nutlin responses after 24-hr was also examined. At this time point 
both treatments enhanced expression of p53, compared to the 10-hour treatment. 
p53-depedent induction for seven of the eight genes examined following either 
treatment was observed (Figure R21). DOX treatment led to a residual induction of 
several of the genes in the MCF7-p53i cells, while only INPP5D was slightly 
responsive upon nutlin treatment. The residual responsiveness was presumably 
due to a residual level of p53 induction in MCF7-p53i cells while the differences 
between DOX and nutlin could be ascribed to differences in p53 post-translational 
modifications elicited by the treatments or to the reduced residual levels of p53 
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expression observed after nutlin treatment. CDH26 gene expression offers another 
example of treatment dependencies as the gene was not regulated by p53 at 
either time point with either DOX or nutlin but was inducible by 5FU treatment 
alone (see Figure R16). INPP5D79, NOTCH187, EPHA256 and TLR575, 76 were 
established as p53 target genes and therefore confirmed what already seen in 
literature. 
 
   
Figure R21. Changes in relative mRNA expression for the selected genes. Presented are 
results for eight selected genes after 24 hours DOX (1.5µM) or nutlin-3a (10µM) treatment in MCF7 
vector and p53i. The fold-induction relative to the mock condition for MCF7-vector or MCF7-p53i is 
presented (H2O for DOX treatment or DMSO for nutlin-3a treatment). 
 
MCF7 vector and p53i clones did not reproduce the cooperation between p53 
and estradiol pathway at the experimental conditions 
MCF7 vector and p53i cells were cultured in estrogen-depleted medium and the 
synergistic effect after DOX or nutlin treatment in combination with E2 (10-9 M) was 
investigated, as previously performed for the original MCF7 clone (see Methods 
section). Cells were stimulated for 10 hours with one of the p53-inducing agent 
and/or estradiol. Gene expression of the canonical ERα target, GREB123, clearly 
shows the transrepression activity due to p53 or the genotoxic stress on ER 
transactivation activity (Figure R22). Nutlin indeed could not affect GREB1 
expression in MCF7 p53i, probably due to the low activation of p53 protein. p21 
expression was induced by DOX and nutlin in a p53-dependent manner. As 
expected the treatments did not affect the expression of p53 nor ESR1 (ERα). 
Hence, it can be hypothesized that MCF7 vector and p53i are a good model 
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system to study p53-dependency but there might be important differences with the 
original MCF7 cell line in the responses to estradiol.  For example, the decrease of 
ER activity could also impact on the possibility to study the transcriptional 
cooperation with p53. 
 
 
Figure R22. Changes in GREB1 mRNA expression. Presented are results after 10 hours DOX 
(1.5µM) or nutlin-3a (10µM) treatment and/or E2 (10-9 M) in MCF7 vector and p53i. The fold-
induction relative to the mock condition for MCF7-vector or MCF7-p53i is presented (H2O for DOX 
treatment or DMSO for nutlin-3a treatment). 
 
TLR5 is an example of transcriptional cooperation observed in MCF7 vector cell 
line after doxorubicin treatment (Figure R23). But, as previously observed in Figure 
R19, the p53-dependency of TLR5 expression could not be detected after 10-hour 
treatment in MCF7 p53i. Consistently, a reduction in the effect of the combinatorial 
treatment was not observed. This is a limitation of the MCF7 p53i cell model used 
that does not allow easily to investigate the combinatorial role of p53 and estradiol 
pathway in gene transactivation at least at the 10-hour time point.  
 
 
 
 
Figure R23. Changes in TLR5 mRNA 
expression. Presented are results after 10 
hours DOX (1.5µM) treatment and/or E2 (10-9 
M) in MCF7 vector and p53i. 
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An example confirming that p53 takes part in the transcriptional cooperation 
observed with estradiol-induced pathway is CDH26 after treatment with nutlin in 
combination with E2 (10-9 M). The combinatorial effect is completely lost in MCF7 
p53i (Figure R24). In the results shown above, CDH26 was strongly E2-responsive 
and only 5FU responsive among the p53-inducing stimuli (see Figure R15-17). For 
the remaining six genes tested, the transcriptional cooperation was not reproduced 
(data not shown). 
 
 
Figure R24. Changes in CDH26 and KRT15 
mRNA expression. Presented are results 
after 10 hours nutlin-3a (10µM) treatment 
and/or E2 (10-9 M) in MCF7 vector and p53i. 
The fold-induction relative to the mock 
condition for MCF7-vector or MCF7-p53i is 
presented (DMSO treatment). 
 
MCF7 clone silenced for ERα are also required to better understand the role of 
estrogen receptors after E2 treatment and to light up the mechanism of synergy. 
MCF7 cell line expressing shRNA to ERα are currently beeing selected.  
 
The biological impact and expression responses due to p53 and estradiol pathway 
led the in-depth investigation of the promoter regions of the INPP5D, TLR5A and 
KRT15 genes for the presence of canonical and non-canonical p53 and ER 
response elements in order to identify a more direct role of the TFs involved in the 
specific gene expression regulation. 
 
The transcriptional responsiveness of INPP5D, TLR5 and KRT15 is 
associated with p53 and ER response elements 
An in silico analysis was performed in order to identify putative canonical or non-
canonical p53 and ERα response elements couples with a maximum distance of 
around 500bp within the promoters of the selected genes. Three different 
approaches were used and combined: a) manual pattern matching analysis (½ 
p53 RE: RRRCWWGYYY; ½ ERα RE: (A)GGTCA, TGACC(T) or GGCTA) b) 
pattern matching analysis with ½ site position weight matrixes derived from 
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TransFac using the online Regulatory Sequence Analysis Tool (RSAT) 64 and c) R 
tool analysis using TransFac matrixes (see Methods section).  
Putative non-canonical p53 and ERα REs couples were identified in almost all the 
genes’ promoters selected (promoter defined as -3000bp ↔ + 2000bp from the 
transcription start site, TSS). The analysis was focused on the promoter regions of 
the INPP5D, TLR5A and KRT15 genes and two distinct regions were identified 
within the promoter of each of these genes (called A & B, see Figure R25). 
 
 
 
 
Figure R25. Predicted p53 REs and EREs at TLR5A, INPP5D and KRT15 promoter regions. 
Sequence, organization and position of mapped p53 and ER target sites. Promoters of selected 
genes were evaluated combining 3 approaches (pattern matching analysis; RSAT analysis and R 
tool analysis using TransFac matrixes). Blue dashed arrows mark ERE half sites, while tail-to-tail 
red arrows denote the p53 RE half site. The chromosomal position, strand and the distance from 
the transcriptional start sites are also indicated. Two promoter fragments (denoted as #A and #B) 
were examined separately for each gene. 
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The promoters were then examined by chromatin immunoprecipitation assay 
(ChIP) followed by qPCR for p53 and ER occupancy. Primers based on the 
annotated p53 and ER REs at p21 and pS2 promoters were used as controls.  As 
expected, there was p53 occupancy at the canonical p53 target p21, as well as at 
the canonical ERα target pS2 (Figure R26). Interestingly, E2 led to p53 recruitment 
at p21 promoter (confirmed also at the level of other p53 target promoters, see 
p99 Figure 6B in Lion et al.). This might be explained with the fact that the addition 
of E2 after 72 hours in stripped medium could provide a proliferative stimuli that 
may be sensed by the cell and, therefore, resulting in enhanced p53 occupancy at 
some sites not necessary related to transcription. The mouse immunoglobulin G 
(IgG) used as negative control could give an additional explanation due to the fact 
that the fold over mock in the E2 condition was usually higher compared to DOX 
alone or DOX+E2 condition. DO-1 antibody, used to pull down p53, was also a 
mouse antibody. 
p53 occupancy at the promoter regions was also found for the INPP5D, TLR5 
and KRT15 genes following DOX treatment. However, ERα occupancy was only 
detected at the KRT15 promoter for fragment B (Figure R26). It appears that there 
is independent occupancy by the two transcription factors in that the binding of 
one is not required for the recruitment of the other. Thus, while transcriptional 
synergy is established, it could not be ascribed to effects at the level of binding, at 
least for the sites examined. See Discussion for further considerations, including 
the analysis of histone marks associated with gene activation or repression. 
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Figure R26. Relative occupancy of p53 and ERα. Chromatin Immunoprecipitation and 
quantitative real time PCR analyses. ChIP assays were performed using either an antibody against 
p53 (DO-1) or ERα (H-184) or control IgG (sc-2025). PCR was carried out in 384-well plates in a 
final volume of 10µl using primers designed to amplify regions containing validated REs and ERE 
for established p53 and ERα target genes, or to generate amplicons centered around the identified 
p53 REs and EREs in TLR5, INPP5D or KRT15. 
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DISCUSSION 
Breast cancer treatment strategies involve surgery, radiotherapy, chemotherapy 
and hormonal/endocrine therapy 65. The latter is used specifically for estrogen 
receptor-positive tumors, which accounts for more than 60% of all breast cancer 
32. Estrogen and ERs are implicated in the development of breast cancer 
according to two hypotheses, one related to the stimulation of proliferation due to 
the effect of estrogen acting through ER, and the other one related to estrogen 
metabolites that can exert genotoxic stress 16. ERα is a prognostic marker and 
therefore can also be considered a therapeutic target 65, 66. Genotoxic estrogen 
metabolites could play an important role in carcinogenesis in a ER-independent 
way in concert with the ER-dependent proliferation effects 65. Indeed, high doses 
of estrogens were extensively used in breast cancer treatment prior to the 
introduction of selective estrogen receptor modulators (SERMs) 67, 68. ER 
antagonist and inhibitors of estrogen synthesis are commonly used in endocrine 
therapy and include SERMs that can act as anti-estrogen, selective estrogen 
receptor down-regulators (SERDs) or aromatase inhibitors (that block specifically 
hormone synthesis) 68-70. ER agonists, instead, are frequently used in hormonal 
replacement in postmenopausal women 71. Endocrine therapy can however lead to 
unwanted side-effects; and in particular receptor agonists can increase the risk of 
breast cancer development 71. In the context of pharmacological treatments, such 
as multi-drug cancer therapy or that comprises cocktails of genotoxic 
chemotherapeutics, the effect that endogenous or exogenous estrogen can exert 
in combination with other drugs must be taken into account. Doxorubicin and 5-
fluorouracil are currently used as chemotherapeutic drugs in different cancer types 
including also breast cancers (www.chemocare.com). The information coming 
from the functional role of the combination of these factors in tumorigenesis might 
have a potential to be used in clinic for treatments of patients with ER-positive 
breast cancer and in general to all the other cancers dependent on steroid 
hormones (prostate, testicular, ovarian and endometrial tumors).  
In this respect, the impact of doxorubicin on whole genome transcriptomes was 
determined in cells exposed or not to 17β-estradiol. MCF7 cells were used as an 
experimental model of luminal-A subtype breast adenocarcinoma (p53 wild type, 
MDM2 positive, ERα positive, FOXA1 positive, HER2 negative) 72. Based on 
previous work 38-41, genes were anticipated for which the inducible transcriptional 
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factors p53 and ERs could act collaboratively in cis at their respective REs. In fact, 
regardless of the mode of interaction, identifying genes that show a synergistic 
p53/ER response is expected to inform treatments of breast or other cancers.  
Overall, doxorubicin treatment resulted in profound changes in gene expression 
output with 647 up- and 1056 down-regulated genes and enrichment for the p53-
pathway activation, including regulation of transcription, cell cycle and mitosis, 
DNA damage checkpoint, apoptosis and stress response. While, deeply influenced 
by doxorubicin, the combination treatment with E2 resulted in 66 genes uniquely 
responsive and a total of 201 with more than additive changes. Interestingly, gene 
ontology and pathway analysis suggested a significant enrichment for cell-cell 
communication, epithelial cell differentiation, inflammatory responses within this 
combinatorial up-regulated gene group. Combinatorial down-regulation was also 
observed for 142 genes with an enrichment for cell cycle, mitosis and metabolic 
functions. 
16 among the 201 genes exhibiting a more than additive response were 
selected in order to better understand the additive responses towards p53 and 
estrogen inducing agents. While DOX or 5FU treatment resulted in similar p53 
levels and p21 induction, there were marked differences in microarray expression 
after single treatments, as well as in qPCR when combined with estradiol. 
Previous studies have established cell type specific responses to DOX and 5FU as 
well as other drugs 71. A different impact on p53-induced responses and 
expression changes was awaited 42, 43 and it was confirmed in the microarray 
experiments as well. This huge variance has to be taken into account every time 
an experiment is performed. Several factors can contribute to the different 
responses observed. The concentration of the drug and the duration of the 
treatment strongly influence the expected outcome. Post-translational modification 
are also involved in this mechanism. Different stimuli can activate the same protein 
but convert the information into a different biological response. It is not surprising 
to expect a different impact when DOX and 5FU are also combined with estradiol 
pathway. To further investigate that and to confirm microarray analysis, a 
quantitative real-time PCR (qPCR) for the 16 selected genes was performed. 
Results obtained after DOX treatment are in agreement with microarray data, and 
ten of these genes present also a statistically significant transcriptional 
cooperation. 5FU treatment, instead, is not completely in line with results observed 
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previously with DOX stimulus and the combination with estradiol led, statistically, 
to a synergistic expression only for three out of sixteen genes (H19, INPP5D, 
GDNF). Another drug, still in clinical trial, related to p53-activation is nutlin-3a 
(nutlin). Nutlin was chosen to be tested in the experimental model to activate and 
stabilize p53 without the involvement of genotoxic stress. In fact, nutlin is thought 
to directly activate p53 because it inhibits the interaction of the tumor suppressor 
with its negative regulator MDM2 44. The investigation of gene expression after 
combination of nutlin with estradiol becomes therefore extremely interesting. 
qPCR analysis showed an up-regulation for six genes (EPHA2, INPP5D, KRT15, 
NOTCH1, SOX9, TEX14) after nutlin treatment alone, confirming a possible direct 
role of p53 in their gene transactivation. Also for nutlin, only three genes (EPHA2, 
H19, INPP5D) presented statistically a more than additive effect in the combined 
treatment. All together these results highlight that six genes (CDH26, EPHA2, 
H19, INPP5D, KRT15 and NOTCH1) showed responsiveness to E2 combined with 
5FU and nutlin, but only two genes (H19, INPP5D) consistently exhibited a 
statistically significant transcriptional cooperation between E2 and all p53-inducing 
treatments (DOX, 5FU, nutlin). Notably, for the remaining eight genes (CA5A, 
PML, SOX9, SYNM, TEX14, TLR5, GDNF and TFF3) a dependency on the 
DOX+E2 treatment was observed. Results obtained after nutlin treatment must 
also be contextualized with possible post-translational modifications that might 
occur after its administration. For instance KRT15 was not responsive after DOX 
and 5FU treatment, but it was instead after nutlin alone.  A p53 monoubiquitination 
that promotes its cytoplasmic localization and translocation to mitochondria upon 
nutlin treatment has been described 74. The results emphasized once again the 
different gene expression response that can occur when different genotoxic drugs 
are administered and the importance of understanding the mode of action in 
particular when these drugs are used as p53-pathway activators.  
To address the dependency on p53 as a transcriptional regulator, a panel of 
selected targets was investigated using a stable MCF7 clone silenced for p53 63. 
The p53-dependent induction after DOX and nutlin treatment was examined for 
eight genes and confirmed for the newly identified p53 target genes GDNF, 
KRT15, and SOX9 as well as the recently previously reported TLR5 75, 76, INPP5D 
79, NOTCH1 87 and EPHA2 56. CDH26 was 5FU responsive but a requirement for 
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p53-dependent induction was not confirmed in MCF7 cell system, highlighting 
once again the specificity of drug response. 
The synergistic effect identified is still under investigation, in particular the 
mechanism through which estradiol pathway and p53 cooperate. As described in 
the Introduction section, results from many studies highlighted a highly complex 
interplay between p53 and estrogen receptors. Physical negative interaction 
between the two proteins, a ligand-dependent positive effect of ER on p53 protein 
levels, an effect of p53 on ER protein level, an indirect, negative effect of ER on 
p53 levels via modulation of the intronic MDM2 promoter, in cooperation with Sp1, 
p53-enabled ER recruitment at half sites EREs resulting in transcriptional 
cooperation are notable, reported functional interactions 24-32.  
Given the earlier results obtained with the FLT1 gene 38-41, three (TLR5, 
INPP5D, KRT15) of the 16 genes were examined for the possibility of cis-
interactions by assessing p53 and ER occupancy. These genes were particularly 
appealing for their biological functions in respect also to the canonical pathways 
usually controlled by p53 and ER. TLR5 gene is involved in the innate immunity 
and its expression has been shown to be regulated by DNA damage and p53 
activation 75, 76. TLR5 has been indeed very recently shown to be a p53 target 
gene, along with several other toll-like receptors, indicating a link between DNA 
damage signaling mediated by p53 and innate immunity responses leading to 
activation of NFkB 75, 76. Results obtained so far extend this observation in MCF7 
cells and reveal a contribution of the estradiol pathway in further modulating TLR5 
expression in response to the combination with doxorubicin treatment. High 
expression of TLR5 has been reported in breast carcinomas, and the activation of 
its pathway through the ligand flagellin seems to inhibit cell proliferation in breast 
cancer 77. INPP5D on the other side is not directly related to TLR5 but it is 
considered as a toll-like receptor pathway inhibitor, particularly a TLR2/TLR4 
inhibitor 78. It is also known as SHIP1, for lipid phosphatase SH2 domain-
containing inositol-5'-phosphatase 1, and it has been proposed to act as tumor 
suppressor gene, and its expression has been previously linked to p53 status in 
head and neck cancer, as responsive to cisplatin treatment 79, 80. p53-dependency 
was in fact confirmed and INPP5D was responsive to all the p53 activators used in 
the experiments performed and showed a more than additive transactivation in all 
the three combined treatments. However, it has also been shown that 5'-
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phosphatase activity towards inositol is not equivalent to the PTEN function (a 3’-
phosphatase) as PI(3,4)P2 could still lead to the activation of the serine-threonine 
protein kinase AKT. Loss of INPP5D elevates AKT activation due to the increased 
of PI(3,4,5)P3 production. Both the lipid phosphatases (PTEN and SHIP1) are 
instead crucial in controlling neutrophil chemotaxis through the regulation (with 
different receptor-regulated processes) of PI(3,4,5)P3 81. INPP5D expression is not 
usually observed in breast tissues but it seems restricted mostly to hematopoietic 
cells 79-81. KRT15 on the other hand is an intermediate filament type I protein 
responsible for the mechanical integrity of epithelial cells. KRT15, together with 
other keratins is a marker of epithelial differentiation, but particularly of squamous 
epithelia, where the p53-related protein p63 can be an important transcriptional 
regulator 82. Its expression is regulated by E2 as well as nutlin in the experiments 
performed, and a synergistic up-regulation in DOX+E2 condition and an additive 
response in nutlin+E2 treatment was identified. Also, KRT15 expression is p53-
dependent in the cell model used. KRT15 expression is also been observed in 
breast tissues and breast carcinomas. No evidences of a correlation with 
malignant status have been addressed, rather it has been suggested that KRT15 
can be a neutral keratin whose expression can be detected also in luminal 
progenitors 83. KRT15 is often co-expressed along with KRT14 and KRT19 82, 83. 
The experiments also highlight the presence of other two keratins, named as 
KRT13 and KRT14, whose expression was up-regulated with a more than additive 
effect after combination of doxorubicin and estradiol pathway. In concert with 
KRT15 they might specifically have a biological impact.  
It can be hypothesized that non-canonical p53 REs, consisting of ½ or ¾ sites, 
or ERα response element ½ sites can provide for moderate or weak 
responsiveness, but at the same time if they are close enough (within 500bp) they 
can provide a cooperative interaction between p53 and ERα. The occupancy 
analysis confirmed once again the direct role of p53. In fact, p53 bound directly to 
p53 related target sequences in the promoters of the TLR5, INPP5D and KRT15 
genes. ERα occupancy was observed only at the level of KRT15 promoter gene, 
upon E2 single and combined treatment, supporting the evidence of a functional 
interaction between p53 and ER via cis-elements.  
The absence of a detectable ERα occupancy upon combined treatments at the 
level of TLR5 and INPP5D promoter could be explained either by the lack of a cis-
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mediated cooperation at the level of the promoter areas examined or with a 
temporal shift between transcription and transcription factors occupancy. 
Functional interactions with p53 could involve other members of the large 
superfamily of nuclear receptors including, for example, the glucocorticoid or 
androgen receptors, connected through a multi-protein mediator complex 39. 
Furthermore, these initial studies suggest that for a subset of promoters, crosstalk 
with ER could be affected by other members of the p53 family, p63 and p73 40. 
p53 splice variants and various kinds of p53 stresses or ER activators might be 
expected to have different effects on the ER/p53 synergistic responses. The type 
of interaction that can occur between p53 and ERα might also differ between 
genes: ERα can in fact binds other transcription factors on a ERE-independent 
manner; and a non-genomic estrogen signaling pathways must also be 
considered. The role that ERβ can exert in the modulation of the synergistic 
cooperation with p53 was not yet investigated and could also explain the lack of 
ERα occupancy at the level of the promoters chosen. Another important remark to 
consider is the resolution provided by immunoprecipitation assays. Dynamics of 
the complexes formed at the level of the promoter could not be easily detected 
using ChIP assays due to the fact that a temporal resolution is not provided. ChIP 
data do not provide kinetics and do not measure TF function at a given locus. The 
two proteins might not be present at the same time in the same complex after 10-
hr treatment 84. Since changes in chromatin around regulatory regions of 
transcribed genes can modulate the activity and cooperativity between 
transcription factors, chromatin status was analyzed at the TLR5, INNP5D, KRT15 
genes (see Figure 7 and 8 –p101, p103- and Figure S3 –p109- in the Lion et al 
manuscript in Appendix). The same promoter regions analyzed for p53 and ER 
occupancy along with regions encompassing the transcription start site (TSS) 
were examined for changes in histone tail post-translational modifications 
associated with gene activation or repression using ChIP approaches. The results 
indicated that all three genes were in an active chromatin state even in the mock 
condition, which is consistent with their basal expression levels. The treatments 
had an impact on several histone marks, although there was not a specific 
signature apparent for the double treatment. (Detailed description of these results 
can be found in the Results and Discussion sections of the accompanying paper in 
Appendix). 
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While a positive transcriptional cooperation between ERs and p53 was 
described on a global scale by this study, the precise mechanisms underlying the 
synergistic interaction between these two transcription factors seem to be 
promoter dependent and need further investigation. ChIP experiments provided 
additional evidences for the contribution of p53 and ERα occupancy at target REs 
in the transcriptional cooperation. As the p53 response (doxorubicin-driven in this 
study) is mainly triggered through the binding to full-site p53-RE, the pursuit of 
non-canonical p53 REs associated in cis, in close proximity, with ERE sites was 
undertaken. The next step will involve the pursuit of the sources of interaction. A 
structure-function analysis will light up the mechanism behind the interaction 
between p53 and the estradiol pathway. ChIP data about KRT15 promoter are the 
first evidences that an in-cis p53/ER cooperation might occur and that involves a 
p53 half-site and half-site EREs, extending the previous findings beyond the FLT1 
gene and model plasmid based systems 39. A structure-function analysis is 
necessary not only to understand the nature of the mechanisms through which 
these two proteins can interact but also to provide new insights about the 
functional processes that different mechanisms can exert. For this reason, putative 
identified regions of the TLR5, INPP5D and KRT15 promoters are now being 
cloned into a reporter plasmid that can allow to perform functional analysis. On this 
respect, the use of mutant ERs is planned in combination with wild-type p53 to 
clarify the nature and the mode of interaction between the two TFs, if it is really 
present. ER mutants (Figure D1) lacking either the DNA binding activity or the 
tethering activity or both functions will determine the type of interaction, if 
cooperativity is present, if the two TFs act independently and will help to dissect 
the general mechanism that might be different for different promoter regions. 
 
 
Figure D1. Scheme provided by K. Korach (unpublished results). 
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Conclusions and implications 
Transcriptional programs within cells are continuously shaped by myriad signal 
transduction pathways and the architecture of promoter and enhancer sequences 
underlies the potential for such integration of multiple concomitant signals. 
Extensive transcriptional cooperation between ERs and p53 across the genome 
was found. Given the importance of activators of these two genes in cancer 
treatments, these findings provide opportunities for investigations of treatments 
involving many newly identified targets of synergy, although the mechanisms of 
synergy remain to be established. The findings are also likely relevant to 
understanding combined ER hormonal responses and any of the various stresses 
that can induce p53 as well as general biological and cancer implications. 
It is still not clear, however, whether this mechanism is important for the 
selective regulation of the transcription of genes involved in specific biological 
processes that may play a role in the tumor physiology, such as progression or 
invasion. Possibly, the synergy might lead to increase aggressiveness or tumor 
metastasis (such as epithelial–mesenchymal transition, EMT) or alternatively 
influence inhibition of classical tumor hallmarks such as proliferation. A clear 
answer has not been identified yet and further studies are required. Although it is 
difficult to unambiguously predict phenotypic outcome, the relevance of potential 
interaction between p53 and estradiol pathway is extremely prominent. Despite the 
apparent random heterogeneity of functions that these genes exert, it cannot be 
discarded the possibility that their concomitant activation could result in new 
functions leading to yet unexplored biological consequences. Indeed there are 
some evidences that the expression or the function of some of the selected genes 
is impaired in breast cancer. For example, among the 16 candidate genes 
examined in depth, H1985, 86, NOTCH187, SYNM88, TLR589, and cadherins90 are 
found either over-expressed or down-regulated in breast cancer. More generally 
many of these selected genes are somehow related to tumors. PML91, INPP5D92 
and APC293 are thought, for instance, to be tumor suppressor genes. EPHA2, 
instead, has been reported to play a role in angiogenesis and tumor 
neovascularization as well as being a positive mediator of UV-induced and largely 
p53-independent apoptosis 94, 95. Several cadherins are usually down-regulated in 
tumors 90 whereas IGF2 is usually overexpressed in many types of cancers and 
thought to be an oncogene 96.  
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Finally, these findings suggest the opportunity to identify additional luminal 
breast tumor markers. Expression of some of the sixteen selected genes is usually 
weak or moderate in normal breast tissues (Human Protein Atlas, 97). 
Understanding the functional roles that altered expression of those genes can play 
in different tissues could also aid in understanding the role that they may have in 
tumorigenesis. A systems biology approach could reveal the intricate scenario 
created by the combination of stress-dependent signaling (p53 pathway) and 
proliferative stimulus (estradiol pathway).   
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SECONDARY TASK 
p53 FUNCTIONAL INTERACTIONS:  
IMPACT OF COFACTORS AND  
SMALL MOLECULES ASSAYED USING A 
SIMPLIFIED YEAST-BASED SCREENING SYSTEM  
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INTRODUCTION 
Inactivation of the p53 pathway in cancer frequently occurs through the expression 
of mutant p53 proteins. In tumors that retain wild type p53, the pathway can be 
altered at the level of upstream modulators, particularly the p53 negative 
regulators MDM2 and MDM4 (MDMX) 5-11. These two proteins play a crucial role 
during development, homeostasis, and the response to stress, through regulation 
of p53 activity and are very often overexpressed in many types of cancers that 
retain wild type p53 98-100. They are structurally related proteins (Figure II.1), but 
with non-redundant functions. It is not surprising that MDM2 and MDMX are now 
appealing targets for cancer treatment. A combination of drugs that can inhibit 
both proteins at the same time represents a strategy for reactivating p53 in tumors 
that retain the wild type form  98-100. 
 
 
Figure II.1. Structure comparison of the MDM2 and MDMX proteins according to functional 
domains. Perry 2010 
 
An intricate regulation and interaction, occurring also between MDM2 and MDMX, 
control the level and function of p53. The classical way through which MDM2 
exerts its function is by binding the N-terminal domain of p53 and blocking the 
transcriptional activity, and by directly ubiquitinating p53, targeting it for the 
proteosomal degradation. MDM2 is indeed a RING-finger domain E3 ubiquitin 
ligase and it is thought to be the main p53 negative regulator. Furthermore, it also 
catalyzes the ubiquitination of MDMX and of itself. p53 controls its protein level 
and stability and therefore its activity, directly transcribing the MDM2 gene, thus 
generating a negative feedback loop 7, 98-100. MDMX expression, vice versa, is not 
directly upregulated by p53, although p53 occupancy in its promoter region has 
been reported 101. MDMX inhibits p53 physically by binding to and masking the N-
terminal domain (transactivation domain) but it does not have any appreciable 
ubiquitin ligase activity. Some evidences report a heterodimer formation between 
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MDM2 and MDMX that can prevent MDM2 autoubiquitination. MDMX binds MDM2 
through its own RING-finger domain 98-100.  
DNA repair and cell cycle arrest (or apoptosis) must follow after DNA breaks, 
and it involves p53 activity. The affinity of p53 with its negative regulators MDM2 
and MDM4 is drastically reduced when the p53 N-terminal region is 
phosphorylated by ATM. ATM plays its role after DNA damage and its activation 
(autophosphorylation) is also favored by 53BP1, as the acronym says - p53-
binding protein 1-, another protein that directly binds p53. 53BP1 plays a crucial 
role in signaling the presence of DNA double strand breaks (DSBs) 103-104. It is 
literally a sensor that detects DNA damages and lesions upstream of ATM (Figure 
II.2). Suppression of 53BP1 directly correlates with a decrease of ATM activation. 
53BP1 participates in the organization of nuclear foci and contacts DSBs through 
its two tandem Tudor domains. These two domains were also reported to mediate 
interaction with p53 C-terminal domain 103. 53BP1 also binds p53 through its 
BRCT domains at the level of the DNA binding domain, acting as a co-activator, 
and therefore enhancing p53-mediated transcriptional activation. It is not 
surprising that 53BP1 can be expressed at low levels in several tumors 103-104.        
                 
 
Figure II.2. The complexity of ATM signaling pathway. Zgheib et al., 2005 
 
Yeast, as a model organism, can be easily used to investigate interactions 
between p53 and cofactors and to study the impact of small molecules. 
Saccharomyces cerevisiae can serve as an in vivo test tube to address the 
transactivation capacity of highly controlled p53 protein levels toward specific REs 
cloned upstream a quantitative reporter gene. In fact, the rheostatable control 
(GAL1,10 promoter) of wild type p53 or mutant p53 cloned in a centromeric, 
selectable vector allows for the investigation of p53-transactivation capacity at 
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different protein levels. The yeast system displays advantages, including the 
absence of endogenous p53 and its coregulators (and consequently of p53-
induced biological consequences). It is therefore a suitable system to study the 
factors that influence p53 function, including expression levels, mutations, 
cofactors and small molecules. It is also a very clean tool that allow unbiased 
screening opportunities for functional assays with luminescent reporters  105. 
In this work 105 a highly defined (small-volume format) dual luciferase yeast-
based functional assay was set up to investigate the impact of small molecules on 
p53 transactivation potential or on the functional interaction between p53 and 
cofactors. A specific p53 response element was placed upstream of the minimal 
promoter of the firefly luminescent reporter whereas the renilla luminescent report 
was under the control of a minimal promoter to assess sensitivity and robustness 
of the assay system. These yeast strains were also enhanced for chemical uptake 
modifying the ABC-transporters in yeast. This small-volume yeast screening 
system provides for rapid assessment of p53 transactivation potential and can be 
applied to high-throughput screening of chemicals toward a matrix of factors that 
can influence p53 protein levels (including small molecules), nature of the p53 
REs, and level of p53-interacting proteins.  
Once the potential of the yeast-based system was established, the ability of the 
dual luciferase assay system was examined to discriminate the functional 
interaction of wild type and mutant p53 when co-expressed with MDM2 or 53BP1 
(lacking the N-terminal portion of 960 amino acids) and the effects of RITA 
(reactivation of p53 and induction of tumor cell apoptosis) and nutlin-3a (nutlin). 
Details are provided in the attached paper. Briefly, it appeared that co-expression 
of MDM2 can lead to reduced p53 transactivation at low levels of p53 protein 
expression, and that nutlin and RITA both relieve the MDM2-dependent inhibition 
of wild type p53 transactivation function similarly to what is usually observed in 
mammalian cells. The co-expression of 53BP1 with p53 also leads to a reduction 
in p53-dependent transactivation, and only RITA partially impacts p53/53BP1 
functional interactions. Nutlin had no effect on the p53-53BP1 interaction. The 
mode of action of nutlin has been extensively described previously in the results 
and discussion sessions. The small molecule RITA induces p53-dependent 
apoptosis through p53 accumulation and subsequent activation in tumor cell lines. 
RITA binds the p53 N-terminus and reduces p53/MDM2 interaction. RITA and 
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nutlin target p53/MDM2 interaction but in a different way and they seem also to 
lead to a different transcriptional response 106. The experiments were also 
extended to the p53 cofactor MDM4 as well as to the full length 53BP1 using the 
small-volume luciferase assay. MDM4 inhibited p53 function but both nutlin and 
RITA did not relieve such effect. Similarly to the truncated construct, full length 
53BP1 also inhibited p53-mediated transactivation contrary to the expectation from 
mammalian cells’ studies. Taken collectively, the yeast-based assay represents a 
versatile tool to study p53 interactions with cofactors and the impact of small 
molecules targeting those interactions. 
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MATERIALS AND METHODS 
A more extensive description of the Materials and Methods can be also found in 
the manuscript enclosed (p142).  
 
Yeast strains 
Isogenic yeast strains (yLFM) containing different human p53 response element 
sequences cloned upstream the reporter Firefly luciferase gene were tested. yLFM 
PUMA/yRFM I2 yeast strain, carrying the PUMA response element upstream the 
Firefly luciferase gene and the Renilla ORF under the control of the minimal CYC1 
promoter, was also used.   
 
Luciferase assay in yeast 
Traditional assays were performed starting from a 2 ml overnight (O/N) cultures of 
the appropriate yeast strain cultured in synthetic selective medium containing 2% 
raffinose as carbon source and the desired amount of galactose (see Results 
section) for the induction of the GAL1,10 promoter that drives p53 expression. 
Luciferase activity was determined either using extraction of soluble proteins by 
mechanical lysis (glass beads, Sigma-Aldrich) and centrifugation, or 
permeabilizing cells using Passive Lysis Buffer 1x (PLB 1x) in agitation for 15 min 
at room temperature.  
The newly developed miniaturized assay was performed starting from a 100 µl 
overnight (O/N) culture (in a 96-well plate) cultures of the appropriate yeast strain 
cultured in synthetic selective medium containing 2% raffinose and the desired 
amount of galactose (see Results section) for the induction of the GAL1,10 
promoter.  Luciferase activity was determined permeabilizing cells using Passive 
Lysis Buffer 2x (PLB 2x) in agitation for 15 min at room temperature.  
Time course experiments were performed starting from a 2 ml O/N culture in 
synthetic selective medium containing 2% dextrose (to prevent GAL1,10 
activation) and then switching for 6 hours to a culture containing synthetic 
selective medium (with 2% raffinose) and the desired amount of galactose. 
Luciferase assay was conducted in a white 384-well plate using 10µl of Bright 
Glo reagent (Promega, Milan Italy). Optical density at 600nm (OD) was measured 
and used as normalizing factor. The dual luciferase assay was developed 
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similarly, except for the use of 10 µl of the Firefly substrate followed by additional 
10 µl of Stop&Glow Renilla substrate to measure renilla activity. 
 
Yeast transformants and GAP repair technique  
5ml O/N yeast cultures were cotransformed with the linearized targeting pTSAd 
plasmid and the gene ORF of interest or just transformed with the appropriate 
plasmids, using lithium acetate transformation protocol (see manuscript for further 
details). Transformants  were then  selected on a synthetic selective medium 
plate.  
 
Drug treatment 
2 ml O/N culture in synthetic selective medium containing 2% dextrose and a 
switch for 16 hours to 100µl of synthetic selective medium (with 2% raffinose), the 
desired amount of galactose and the desired drug was conducted (in a 96-well 
plate). RITA and Nutlin were prepared in DMSO that was included as control.  
Sensitivity to cycloheximide was performed similarly with the only exception that 
serial dilutions (1:5) were made before transferring yeast cells to plates containing 
synthetic medium (SD) with different concentrations of cycloheximide (0.005, 0.01, 
0.015, 0.02 ng/µl) using a 48-pin replicator. A rich (YPDA) and an SD control 
plates were spotted for comparison. Plates were incubated for two days at 30o C. 
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RESULTS and DISCUSSION 
	  
Small-volume, dual-luciferase assay in yeast 
The yeast-based assay has been improved in efficiency and miniaturized 
(materials, methods, and interpretation of results obtained are extensively 
described in the paper attached, p141). My personal contributions were to 
investigate a p53 induction-time course and to perform the comparison between 
three different dual-luciferase yeast-based assays: 
- traditional assay I (using glass beads) 
- traditional assay II (using Passive Lysis Buffer 1x, PLB 1x) 
- newly developed miniaturized assay (using PLB 2x)  
Briefly, the finely-tuned inducible GAL1,10 promoter (“rheostatable”) was 
investigated to address transcriptional response on PUMA response element that 
is dependent upon p53 protein levels. 4 time points (0, 6, 12 and 24 h) and two 
galactose concentrations (0.032% and 0.128%) were used to achieve respectively 
a moderate and high p53 protein levels. T=0h was in 2% dextrose that inhibits 
GAL1,10 promoter function (Figure II.3). This provides robust measurement of 
p53-dependent transactivation. In particularly, the ability of firefly and renilla 
luminescent proteins was shown to serve as reporters for p53 transactivation. 
 
 
Figure II.3. p53 induction-time course. Dual luciferase reporter assay with a strain expressing 
wild type p53 and containing the Firefly luciferase as p53 reporter gene (PUMA RE) and the renilla 
luciferase as constitutive reporter. Presented are the average and standard error of the Firefly 
luciferase activities normalized for renilla and compared to empty vector at various time points after 
shifting 100 ml yeast cultures to galactose-containing media in the 96-well plate format. 
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The previous yeast assay system based on the 2 ml O/N cultures and soluble 
protein extraction to quantify luciferase activity limited the experimental 
opportunities. An alternative system to protein extraction was found out: cells of 
both the haploid and diploid strains could be permeabilized for uptake of luciferase 
substrate if resuspended in PLB. Also, results coming from a 2ml O/N culture or 
from a small culture volume (100 µl, miniaturized system) were comparable. The 
transactivation potential was investigated both for wild type p53 and the Δ368 
deletion mutant lacking the regulatory domain in the p53 carboxy terminus (C-ter). 
All these data support the use of luminescent reporters, permeabilized cells, and 
small volumes to assess p53 transcriptional functions as well as providing a high-
throughput format (Figure II.4 & II.5).  
 
  
Figure II.4.  Generation of a small volume format for p53 functional assays. Relative 
transactivation capacity of WT and the R282Q mutant p53 have been compared towards four 
different p53 REs obtained with the traditional assay based on 2ml liquid cultures in individual 
tubes (A) or with the miniaturized assay format based on 100 µl cultures prepared directly in 96-
well plates (B). p53 proteins were induced at different levels by varying the amount of galactose 
(indicated below the chart). A strong (p21), two moderate (PUMA, GADD45) and a weak p53 RE 
(AIP1) were compared.  
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Figure II.5. Comparison of relative p53-dependent transactivation in the different assay 
formats. Relative transactivation capacities of WT p53 and the R282Q mutant in the “2 ml vial” 
experimental set-ups were measured using either protein extraction or permeabilization. Direct 
permeabilization of cells was conducted in a 384-well format following transfer from a 96-well 
growth plate that was used for cell growth. Experiments were conducted using 0.032% galactose 
inducer.  
 
Genetic modifications at the ABC transporter system 
Genetic modifications at the ABC transporter system could improve drug 
accumulation in these reporter strains and could allow the study of the impact of 
small molecules on p53 transactivation and interaction with other cofactor. The 
disruption of the cassette for the PDR (pleiotropic drug resistance) genes was the 
technique adopted to directly affect the ABC transporter system. Materials, 
methods, and interpretation of results obtained are described in the supporting 
information, p157. My personal contribution was the examination of cycloheximide 
toxicity on the ABC mutants to further investigate if drug uptake (and therefore the 
toxicity) was actually enhanced in the double mutant (prd1, pdr5 mutant). Results 
confirmed that both PDR1 and PDR5 disruption rendered the cells more sensitive 
to the drug. The pdr5 mutant was the most sensitive although, surprisingly, the 
double mutant pdr1, pdr5 exhibited a slightly reduced sensitivity compared to pdr5 
(Figure II.6). Based on these observations, all the modifications of the yeast-based 
assay were performed using the pdr5 mutant.  
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Figure II.6. Impact of genetic modifications at the ABC transporter system on cell sensitivity 
to cycloheximide.  
Based on the experiments described by Stepanov et. al., 2008, cycloheximide treatment was used 
to evaluate whether the disruption of PDR1 and replacement with a PDR1-repressor construct, the 
disruption of PDR5, or the combined modifications would result in enhanced toxicity in the strain 
background. Cells from the indicated strains were resuspended in sterile water and transferred to a 
96-well plate. Serial dilutions (1:5) were prepared and cells were transferred to plates containing 
synthetic medium (SD) with different concentrations of cycloheximide using a 48-pin replicator. A 
rich (YPDA) and an SD control plates were also spotted for comparison. Plates were incubated for 
two days at 30o C.  
 
Gap repair cloning of MDM4 and 53BP1 genes in yeast 
Gap repair is considered a simple and useful in vivo cloning approach in yeast. It 
is based on the advantage of using homologous sequences that can recombine to 
restore the integrity of a linearized targeting plasmid resulting at the same time in 
the incorporation of the selected sequence. In fact, flanking short homologous 
sequences are added to the selected sequence via PCR and the unpurified PCR 
product is cotransformed in yeast together with the linearized plasmid. The gap 
repair process is RAD52 dependent. 
Gap repair technique was used to clone MDM4 and 53BP1 genes in the yeast 
expression vector pTSAd, that is based on the centromeric pRS314, contains the 
TRP1 selection marker and the transcription of the cloned cDNA is under the 
control of a constitutive promoter (pADH1).  
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Impact of nutlin and RITA in the functional interactions between wild type 
p53 and MDM4 
In this work 105, the interaction between p53 and its negative regulator MDM2 was 
extensively investigated. Similarly to what happens in mammalian cells, it clearly 
appeared that MDM2 can reduced p53 transactivation also in yeast, and that both 
nutlin and RITA relieve the MDM2-dependent inhibition of wild type p53 
transactivation function.  
Aside from the paper, I started to examine the functional interaction between 
p53 and the other negative regulator MDM4. The conditions utilized were similar to 
the ones used in the paper attached. p53 expression was therefore modulated 
varying the amount of galactose (0.008% or 0.024% galactose; p53 was cloned in 
a pLLS89 vector, containing the LEU2 selectable marker) while MDM4 expression 
was maintained at constitutive level. Dual luciferase assay was performed on the 
yeast strains carrying the PUMA response element (yLFM PUMA/yRFM I2). The 
effect of nutlin (20 µM) and RITA (1 µM) was also evaluated. A negative impact on 
p53 transactivation was confirmed when p53 protein was co-expressed (at 
different levels) with MDM4 (Figure II.7A). Nutlin treatment does not seem to have 
an impact on the inhibitory effect of MDM4, as previously shown in mammalian 
cells 98. RITA, as already shown in the paper attached, has a severe negative 
impact on the firefly reporter activity that might lead to a misinterpretation of the 
results. The initial results suggest that RITA could not restore the negative impact 
of MDM4 on the p53 transactivation at the dose used (Figure II.7B). 
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Figure II.7. Functional interactions between wild type p53 and MDM4 and the impact of 
nutlin and RITA. Dual-luciferase assay was performed on yeast transformed with an empty vector 
or with a p53-expression plasmid alone or in combination with an MDM4 expression vector. Results 
are plotted as average fold of reporter induction, relative to the empty vector, and standard errors 
of four biological repeats. A) Three galactose concentrations were used to modulate the expression 
of p53. B) The impact of nutlin and RITA was examined using 0.024% galactose as p53-inducer in 
a reporter strain containing the moderate PUMA p53 RE. 
 
Functional interaction between p53 and 53BP1 
Data obtained in this work show that the co-expression of 53BP1 (lacking the N-
terminal region) with p53 also leads to a reduction in p53-dependent 
transactivation, and only RITA partially impacts p53/53BP1 functional interactions. 
Nutlin had no effect on the p53-53BP1 interaction. In mammalian cells the 
interaction between 53BP1 and p53 has been shown to have a positive impact on 
p53 transactivation activity. Hence, the results of the yeast-based assays appear 
to be in contrast with the expectation from mammalian cells. Since the 53BP1 
expression plasmid that was used in the initial study was not full-length, to 
investigate whether the unexpected results were due to the absence of the N-
terminal region of 53BP1 protein, a new expression plasmid was prepared 
containing the entire 53BP1 gene cloned in a pTSAd vector and the pLLS89 
plasmid was used to express p53. A negative impact on p53 transactivation was 
also observed, confirming the results obtained previously (Figure II.8). The impact 
of 53BP1 was slight, particularly at higher p53 expression levels. To exclude the 
possibility of a target-specific effect, the impact on five yLFM reporter strains was 
also investigated to address the control of different p53-dependent promoters. 
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These strains do not carry the renilla reporter gene (RE::firefly). All the data were 
therefore normalized using OD600nm values only. Two time points were chosen (4 
or 24 hours) with two different concentrations of galactose (0.008% and 0.032%). 
The results obtained confirmed again that no stimulatory effect of 53BP1 can be 
detected in yeast using this assay, and for some of the reporters an inhibitory 
effect of 53BP1 was observed (53BP1-effect is RE-dependent). Values obtained 
after 24hr from the galactose switching are lower in absolute value, due to a higher 
OD600nm number that is not linearly correlated to firefly activity (Figure II.9).   
 
 
Figure II.8. Functional interactions between wild type p53 and 53BP1. Dual-luciferase assay 
was performed on yeast transformed with a p53-expression plasmid alone and/or in combination 
with a 53BP1 expression vector. Results are plotted as average of relative light unit (RLU), 
normalized with OD600nm, and standard errors of four biological repeats. Two galactose 
concentrations (0.008% and 0.016%) were used to modulate the expression of p53 using a 
reporter strain containing the moderate PUMA p53 RE. 
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Figure II.9. Functional interactions between wild type p53 and 53BP1 on different p53-
response promoters.  Dual-luciferase assay was performed on yeast transformed with a p53-
expression plasmid alone and/or in combination with a 53BP1 expression vector. Results are 
plotted as average of light unit (RLU), normalized with OD600nm, and standard errors of four 
biological repeats. Two galactose concentrations (0.008% and 0.032%) were used to modulate the 
expression of p53 on five different yLFM reporter strains (p21, PUMA, TIGAR, AIP1, MDM2). 
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Introduction
The transcriptional activity of a sequence-specific transcription 
factor (TF) can be modulated in many ways including post-
transcriptional and post-translational modifications, interactions 
with components of the basal transcription machinery or specific 
cofactors as well as the chromatin state.1,2 Equally important is 
the “quality” of the response element sequences and the coopera-
tion/interaction with other transcription factors.1,2
The tumor suppressor p53, which has been described as the 
“guardian of the genome,” controls several biological outcomes 
that include cell cycle, growth, apoptosis, senescence, angiogen-
esis and genome stability.3,4 Also, it can regulate many other cel-
lular processes such as autophagy, energy metabolism, mTOR 
signaling, immune responses, cell motility/migration and cell-
cell communication, in part through modulation of several 
microRNA genes.5-7
The estrogen receptors (ERs) are nuclear receptor transcrip-
tion factors that exert hormonal responses through the activa-
tion of proliferation pathways. While ERs are master regulators 
Estrogen receptors (ERs) and p53 can interact via cis-elements to regulate the angiogenesis-related VEGFRI (FLT1) gene, 
as we reported previously. Here, we address cooperation between these transcription factors on a global scale. Human 
breast adenocarcinoma MCF7 cells were exposed to single or combinatorial treatments with the chemotherapeutic 
agent doxorubicin and the ER ligand 17β-estradiol (E2). Whole-genome transcriptome changes were measured by 
expression microarrays. Nearly 200 di!erentially expressed genes were identi"ed that showed limited responsiveness 
to either doxorubicin treatment or ER ligand alone but were upregulated in a greater than additive manner following 
combined treatment. Based on exposure to 5-fuorouracil and nutlin-3a, the combined responses were treatment-
speci"c. Among 16 genes chosen for validation using quantitative real-time PCR, seven (INPP5D, TLR5, KRT15, EPHA2, 
GDNF, NOTCH1, SOX9) were con"rmed to be novel direct targets of p53, based on responses in MCF7 cells silenced for 
p53 or cooperative targets of p53 and ER. Promoter pattern searches and chromatin IP experiments for the INPP5D, 
TLR5, KRT15 genes supported direct, cis-mediated p53 and/or ER regulation through canonical and noncanonical p53 
and ER response elements. Collectively, we establish that combinatorial activation of p53 and ER can induce novel gene 
expression programs that have implications for cell-cell communications, adhesion, cell di!erentiation, development 
and in#ammatory responses as well as cancer treatments.
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essential for development and maintenance of normal sexual and 
reproductive functions, they can also play a role in the cardiovas-
cular, musculoskeletal, immune and central nervous systems.8-10
These two diverse networks exhibit crosstalk that can be due 
to direct interaction between p53 and the ERs, with the more 
frequently described outcome being repression of p53 activity,11-14 
although p53 can also inhibit ERα.15,16 The inhibitory crosstalk, 
which can be mediated by physical interactions between the two 
proteins, can be relieved by stress-dependent post-translational 
modifications of p53.12,14 The p53/ER interactions can also result 
in mutual positive regulation at the level of target gene expression 
level.17,18 Most of the studies addressing p53/ER interaction were 
performed in breast cancer cell lines, implicating regulation of 
the activity and expression of p53 and ERs in tumorigenesis. This 
was supported by findings of a correlation between the presence 
of wild type p53 and ER-positive breast cancer and a correlation 
between mutant p53 and ER-negative breast cancer.19,20 The two 
transcription factors can also share co-regulators, such as p300 
and MDM2. Both inhibition21 and positive regulation22 of ERα 
can result from the p53 negative regulator MDM2.
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consisting of ½ or ¾ sites can expand the p53 target network pro-
viding for moderate or weak p53 responsiveness, but at the same 
time providing the opportunity of conditional, context-depen-
dent transactivation.5,25,27 Also, in the case of ERs the structural 
organization of the response element (ERE) has been shown to 
influence the binding affinity as well as the modulation of the 
expression of target genes. The consensus half-site ERE is consid-
ered the minimal target site for ERs, and other transcription fac-
tors as well as cofactors can promote binding and transcriptional 
modulation.28-30
Based on our finding at the FLT1 locus, we have taken a 
global approach to address whether similar scenarios might exist 
elsewhere in the genome using breast adenocarcinoma-derived 
MCF7 cells. Whole-genome expression changes were determined 
following combinations of exposures to doxorubicin (DOX), a 
genotoxic chemotherapeutic drug commonly used in cancer 
therapy that induces p53, and the ER ligand 17β-estradiol (E2). 
We identified 201 genes for which combined DOX/E2 treat-
ment led to greater than additive upregulation. The genes were 
involved in cellular differentiation/development, extracellular 
matrix, cell adhesion and inflammation responses. For 10 out of 
16 genes examined further, the synergistic transactivation was 
validated using quantitative real-time PCR. Using MCF7 cells 
with reduced p53 expression, we demonstrated that p53 partici-
pates directly in the modulation of their expression and in the 
cooperation with ER, and we discovered three new p53 target 
genes (GDNF, KRT15, SOX9). The cis-mediated cooperation at 
the level of the promoter of three of the 16 genes was interrogated 
by chromatin immunoprecipitation. KRT15 expression appeared 
to be regulated in cis through p53 and ERα response elements.
Results
Genome-wide transcriptome analyses identify a combinatorial 
effect of p53 and ERs activation in response to DOX and E2. 
We established the utility of our MCF7 cell system for detecting 
p53 and/or ER responses following treatment with DOX and/
or the ER ligand E2. The chemotherapeutic agent 5-fluorouracil 
(5FU) and the non-genotoxic MDM2 inhibitor nutlin-3a31 were 
included to further support p53-specific effects on gene expres-
sion. The ERα protein levels in total extracts did not change after 
any of the 10-h stimuli used, while p53 protein was stabilized by 
DOX, 5FU and nutlin-3a but not by E2 (Fig. 1A). Both path-
ways were activated based on qPCR analysis of expression of the 
standard p53 target p21/CDKN1A and the ERα target pS2/
TFF1 genes (Fig. 1B and C). p21 was induced to similar levels by 
DOX and 5FU, while E2 had no effect on expression. Nutlin-3a 
treatment resulted in higher relative p21 expression that was 
increased 1.5-fold with the addition of E2 (Fig. 1C). pS2/TFF1 
was upregulated only in the presence of E2 and as a function of 
its concentration (10-7 or 10-9 M) with no further increase with 
DOX, 5FU or nutlin-3a (Fig. 1B). Under these conditions, there 
was no apparent toxicity for the p53 activator drugs or E2 alone 
while the combination of a p53 activator with E2 increased the 
overall cell index value, consistent with a role for estradiol in pro-
moting proliferation (Fig. S1).
We recently identified transcriptional cooperation between 
activated p53 and ligand-bound ERs at the promoter of the 
VEGFR-1/FLT1 gene.23,24 The functional interaction appeared 
to occur through noncanonical cis-promoter REs for both tran-
scription factors located in close proximity within the target pro-
moter, where the p53 was a half-site created by an infrequent single 
nucleotide polymorphism.25-27 Neither p53 nor ER alone could 
significantly upregulate FLT1, but the combination resulted in 
synergistic activation.24 We proposed that noncanonical p53 REs 
Figure 1. p53 and ERα protein levels and transactivation activities upon 
DOX, 5FU, nutlin-3a, E2 single or combined treatments. (A) Western blot 
analysis showing p53 and ERα protein levels 10 h after the indicated 
treatments at the following doses: DOX, 1.5 μM; 5FU, 375 μM, nutlin-3a, 
10 μM; E2, 10-9 M. (B and C) qPCR results for the p53 target gene p21 (B) 
and the ERα target gene pS2/TFF1 (C). Presented in the bar graphs are 
fold-induction relative to the mock condition and the standard errors of 
three biological and two technical replicates for each condition. GAP-
DH, B2M and β-actin housekeeping genes served as internal controls.
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Global gene expression profiling and statistical analysis of 
the microarray were performed as described in “Materials and 
Methods.” MCF7 cells cultured in estrogen-depleted media 
were subjected to single or combined treatments with DOX (1.5 
μM) and E2 (at a pharmacological concentration 10-7 M, or a 
more physiological concentration 10-9 M). Gene ontology (GO), 
pathway enrichment and network analyses were conducted using 
DAVID (http://david.abcc.ncifcrf.gov/)32 as well as the Ingenuity 
Pathway Analysis (IPA, www.ingenuity.com).
Differences in transcriptome responses were identified in rela-
tion to the E2 doses (Fig. 2A and B). The lower E2 concentration 
(10-9 M) resulted in the same number of up and downregulated 
DEGs, whereas the pharmacological concentration (10-7 M) was 
generally more repressive. Both concentrations of E2 resulted in 
differentially expressed genes (DEGs) exhibiting functional clus-
ters enrichment that reflect expected estrogen-induced differenti-
ation, proliferation, survival, hormonal responses and inhibition 
of p53 and SMARCB1 (Table S1A and B). Unexpected func-
tional clusters were observed after 10-7 M E2, including positive 
regulation of apoptosis and negative regulation of cell growth as 
well as inhibition of SP1 (Table S1B). Therefore, we decided to 
focus our analysis on 10-9 M E2, since it resulted in a signature 
much closer to that of typical estrogen responses (Table S1A).
The clusters identified with DOX DEGs were consistent with 
genotoxic stress and p53 pathway activation, including cell cycle 
and apoptosis regulation, modulation of transcription, regulation 
of DNA damage checkpoints, BRCA1 functions and ATM sig-
naling (Table S1C).
Next, we focused on the DOX + E2 (10-9 M) treatments 
to examine crosstalk between p53 and ERs. The overall 
Figure 2. Graphical overview of E2 treatment-speci"c transcriptome 
changes. Di!erentially expressed genes (DEGs) were identi"ed by Agi-
lent microarray feature extraction, bioinformatics and statistical analy-
ses, as described in the “Materials and Methods” section. Presented are 
Venn diagrams showing the number of upregulated (A) or downregu-
lated (B) DEGs speci"c or in common between the di!erent treatments 
with E2, 10-9 M and 10-7 M.
Figure 3. Speci"c gene signatures of the DOX+E2 combination treat-
ment. Venn diagrams showing upregulated genes (A) or downregu-
lated genes (B) comparing DOX, E2 and DOX + E2 DEGs. The number of 
genes di!erentially expressed in common or unique after doxorubicin 
or E2 (10-9 M) treatment or after their combination is indicated.
transcriptome changes were heavily influenced by both treat-
ments (Table S1D), although a greater overlap was observed 
between DEGs for DOX and DOX + E2 for both upregulated 
(66%) and downregulated (75%) genes (Fig. 3A and B). There 
was much less overlap between E2 and DOX + E2 DEGs (24% 
and 13% for the upregulated and downregulated groups, respec-
tively). Stem cell pluripotency appeared as a distinctive IPA 
pathway (Table S1D). Interestingly, 66 upregulated and 167 
downregulated DEGs were uniquely identified following DOX + 
E2 treatment. Conversely, for 380 upregulated and 369 repressed 
DOX DEGs the differential expression was not observed in the 
double treatment. Only 29 upregulated and 57 repressed DEGs 
were in common for the DOX and E2 single treatments, of 
which 27 up and 54 downregulated genes were also DEGs with 
the double treatment (Fig. 3A and B). The functional annota-
tion clusters obtained with these gene groups are summarized in 
Table S1E–H, although the small numbers limited the statistical 
power.
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Methods,” we adopted a conserva-
tive approach based on the algebraic 
sum of logarithmic (log2) fold-change 
in expression. Statistical analysis for 
synergistic impact of combined treat-
ments is presented in Table S3.
Notably, 201 upregulated and 142 
downregulated genes met these crite-
ria and exhibited a greater than addi-
tive response following the combined 
p53/ER-inducing treatments (Fig. 3). 
Analysis revealed enrichment for 
cell-cell communication, cell adhe-
sion, development/differentiation 
and inflammatory response pathways 
(Table S1I) for the upregulated genes, 
while cell cycle and mitosis functions 
were enriched in the repressed group 
(Table S1J). We chose to pursue fur-
ther the genes from the upregulated 
group, especially since repression 
via cis elements has yet to be estab-
lished for p53 and ERα interactions 
(Table S3).
From the group of 201 genes exhib-
iting more than additive upregulation 
after combined DOX+E2 treatment 
(bold, Table S3), 16 that represented 
the main biological functions were 
selected for further analysis (Table 
S1I). Some are usually expressed in 
a different biological environment 
than breast cells (TEX14, SOX9, 
INPP5D), and others belong to bio-
logical pathways that can expand the 
p53/ER transcriptional master network (TFF3, CA5A, CDH26, 
NOTCH1, GDNF, INPP5D) (see Table S2A for references). 
For some, a direct or indirect functional interaction with p53 
Cooperative p53, ER-mediated upregulation of genes 
involved in differentiation, cell-cell communication, adhesion 
and inflammatory response. As described in the “Materials and 
Figure 4. Treatment-selective transcrip-
tional cooperation between p53-induc-
ing stimuli and estradiol. qPCR reactions 
for the 16 chosen genes were performed 
using 384-well plates in a "nal volume 
of 10 μl using TaqMan® Gene Expression 
Assays with 3 biological and 2 technical 
replicates for each condition. GAPDH, 
B2M and β-actin housekeeping genes 
served as internal controls. Asterisks in-
dicate statistically signi"cant, more than 
additive e!ects in the combined treat-
ment as described in the “Materials and 
Methods.” The same RNAs used in the 
microarray experiments were tested in 
(A and B), where the experiment served 
also as a validation of the array results, 
while all results in (C) were obtained 
from independent treatment and RNA 
extractions.
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the MCF7 vector cells but were non-responsive or only slightly 
responsive in MCF7-p53i cells. The other five genes did not show 
any p53-specific responsiveness, although TLR5 is a p53 target.35
We also examined DOX and nutlin-3a responses after 24 h. 
Both treatments enhanced expression of p53. However, DOX 
repressed ERα levels both at the protein and mRNA level, which 
would affect estradiol responses including the transcriptional 
cooperation with p53 at that time point (Fig. 5C). There was 
p53-dependent induction for seven of the eight genes following 
either treatment (Fig. 5D). DOX treatment led to residual induc-
tion of several of the genes in the MCF7-p53i cells, while only 
INPP5D was slightly responsive upon nutlin-3a treatment (Fig. 
5D). This was presumably due to the low amount of p53 expres-
sion. CDH26 gene expression offers another example of treat-
ment dependencies, as the gene was not regulated by p53 at either 
time point with either DOX or nutlin-3a, but was inducible by 
5FU treatment alone (Fig. 4B and Fig. 5B and D).
The transcriptional responsiveness of INPP5D, TLR5 and 
KRT15 is associated with p53 and ER response elements. The 
biological impact and expression responses due to p53 plus estra-
diol led us to investigate in depth the promoter regions of the 
INPP5D, TLR5 and KRT15 genes for the presence of canonical 
and noncanonical p53 and ER response elements. An in silico 
search identified two distinct regions within the promoter of each 
of these genes (called A and B in Fig. 6) containing at least one 
putative ½-site p53 RE and one putative ½-site ERE (Fig. 6A).
The promoters were also examined by ChIP qPCR for p53 
and ER occupancy. As expected, there was p53 occupancy at the 
canonical p53 target REs of the p21, PUMA and BAX genes (Fig. 
6B). Interestingly, E2 led to p53 recruitment at these promoters. 
p53 occupancy at the promoter regions was also found for the 
INPP5D, TLR5 (fragment A) and KRT15 genes (Fig. 6C–E) 
following DOX treatment. However, we were only able to detect 
ERα occupancy at the KRT15 promoter for fragment B (Fig. 6E) 
as well as the canonical ERα target pS2 (Fig. 6A). It appears that 
there is independent occupancy by the two transcription factors, 
in that the binding of one is not required for the recruitment of 
the other.
Histone marks associated with DOX and/or E2 treatment. 
While transcriptional synergy was established, it could not be 
ascribed to levels of p53 or ER binding, at least for the sites exam-
ined. Since changes in chromatin around regulatory regions of 
transcribed genes can modulate the activity and cooperativity 
between transcription factors, we analyzed chromatin status at 
the TLR5, INNP5D, KRT15 genes as well as at the control genes 
CDKN1A and TFF1. Promoter regions containing putative or 
known p53 REs and EREs along with regions encompassing the 
transcription start site (TSS) were examined for changes in his-
tone tail post-translational modifications as well as total histones 
employing ChIP approaches and the same experimental condi-
tions used to address p53 and ER occupancy.
Treatment with DOX resulted in a significant increase of the 
dimethylation H3K9me2 mark, which is associated with repres-
sion, for all tested genes. The increases were generally restricted 
to regions upstream of the TSS, but in the case of INPP5D and 
KRT15 were visible also at TSS. However, E2 treatment alone 
(NOTCH1, IGF2, TLR5 PML, INPP5D, EPHA2), with ER 
(NOTCH1, CDH26), or with other selected genes (IGF2 and 
H19, NOTCH1 and SOX9) has already been proposed (Table 
S2A). A summary of functional interactions predicted by text 
mining of the literature is shown in Figure S2 (http://stitch.
embl.de/).33
Quantitative real-time PCR (qPCR) was performed to con-
firm the microarray results after DOX treatment with or without 
the addition of E2 (Fig. 4A). The trend of the microarray results 
was confirmed for 14/16 genes upon DOX and/or E2 treatment. 
T-test analysis on the log2 of the values obtained for relative 
expression confirmed for 10/16 genes the synergistic effect (p < 
0.05) of DOX + E2 combination (Fig. 4A; Table S2A).
Expression of the 16 genes was also investigated follow-
ing treatment with 5FU, another commonly used genotoxic 
agent that results in p53 activation. The responses clearly dif-
fered between DOX and 5FU (Fig. 4A and B). Only CDH26, 
INPP5D, NOTCH1 were responsive to 5FU (Fig. 4B); of these 
INPP5D and NOTCH1 were also DOX-responsive. The syner-
gistic effects observed after DOX + E2 administration were also 
observed for H19, INPP5D and, in part, also for GDNF after 
5FU + E2 (10-7 M) (Fig. 4B; Table S2B). Unlike for DOX, the 
combined treatment did not affect TLR5 or EPHA2, which are 
p53 target genes.34,35 Thus, the E2 enhancing effects on expres-
sion differ between two different inducers of p53.
Nutlin-3a treatment can synergistically cooperate with E2, 
but only on a subset of genes. Unlike genotoxic stress, nutlin-
3a can directly activate p53. It targets the complex p53-MDM2, 
which results in p53 stabilization and activation without appar-
ently inducing any kind of genotoxic stress.31 Given the differ-
ence in mechanism of p53 activation, we investigated possible 
interactions between E2 (10-9 M) and p53 following nutlin-3a 
treatment.
Among the 16 genes described above, the following six were 
upregulated by nutlin-3a treatment alone (fold-induction > 1.5; 
Fig. 4C) based on qPCR: EPHA2, INPP5D, KRT15, NOTCH1, 
SOX9, TEX14. The KRT15 gene was not responsive to DOX 
or 5FU (Fig. 4A and B), possibly indicating a differential effect 
of genotoxic post-translational modifications on p53-targeted 
expression. Only EPHA2, H19 and INPP5D showed a greater 
than additive effect for nutlin-3a + E2 (Fig. 4C; Table S2C). The 
synergy was also found for the H19 and INPP5D genes with E2 + 
DOX or 5FU and for EPHA2 with DOX + E2 (Figs. 4A and B).
Silencing of p53 in MCF7 cells establishes a direct role of 
p53 in doxorubicin responsiveness of the target genes. We vali-
dated direct p53 inducible expression of the novel genes using a 
stable MCF7 cell line expressing shRNA to p53.36 As shown in 
Figure 5A, the p53 protein level in MCF7-p53i is greatly reduced 
based on western blot analysis and gene expression of the p53 
target gene p21, as compared with the control cells (“MCF7 vec-
tor”) after DOX treatment. Neither the p53 nor the ERα mRNA 
levels are changed after 10-h treatment with DOX or nutlin-3a 
(Fig. 5A). Expression of 8 of the 16 genes was determined at 10 
h after DOX or nutlin-3a treatment of MCF7-p53i and -vector 
cells cultured in normal medium (Fig. 5B). EPHA2, GDNF, 
NOTCH1 and INPP5D were induced after either treatment of 
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Figure 5. Changes in p53 and ERα protein levels and relative expression. Presented are results for p21, p53 and ER genes and of eight selected genes 
after 10 or 24 h DOX (1.5 μM) or nutlin-3a (10 μM) treatment in MCF7 vector and p53i. (A and C), left panel: western blot analysis showing p53 and ERα 
protein levels after 10 (A) and 24 h (C) of treatment. (A and C) right panel: qPCR results for the p53 target gene p21, the p53 and ERα (ESR1) genes after 
10 (A) and 24 (C) hours of treatment. (B and D) qPCR results for the indicated eight genes after 10 or 24 h of treatment (left panels, DOX; right panels, 
nutlin). The fold-induction relative to the mock condition for MCF7-vector or MCF7-p53i is presented (H2O for DOX treatment or DMSO for nutlin-3a 
treatment).
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influenced by DOX, combined treatment with E2 resulted in 66 
genes uniquely responsive and a total of 201 upregulated genes 
with greater than additive changes. Based on ontology and path-
way analysis, the upregulated genes with greater than additive 
responses were enriched for cell-cell communication, epithelial 
cell differentiation and inflammatory response. Greater than 
additive downregulation was observed for 142 genes with enrich-
ment for cell cycle, mitosis and metabolic functions (Table S1). 
Thus, we have identified interesting candidates for increased 
responses to genotoxic plus estrogen treatments.
We chose to focus on 16 upregulated genes in order to better 
understand the greater than additive responses toward p53 and 
estrogen inducing agents. While DOX or 5FU treatment resulted 
in similar p53 levels and p21 induction, there were marked dif-
ferences in expression after single treatments, as well as when 
combined with estradiol (summarized in Table S4). Previous 
studies have established cell type-specific responses to DOX and 
5FU as well as other drugs.42 Notably, only H19 and INPP5D 
consistently exhibited transcriptional cooperation between E2 
and DOX, 5FU and nutlin treatments. Using p53-deficient 
MCF7 cells, the dependency on p53 was examined for eight 
genes and confirmed for the newly identified p53 target genes 
GDNF, KRT15, and SOX9 as well as the previously reported 
TLR5,35 INPP5D,43 NOTCH1 (49) and EPHA2.34 CDH26 was 
5FU-responsive (Fig. 4B), but a requirement for p53-dependent 
induction was not confirmed in our cell system, highlighting 
once again the specificity of drug response.
Given our earlier results with the FLT1 gene,23,24 we examined 
three of the 16 genes for the possibility of cis interactions by assess-
ing p53 and ER occupancy. p53 bound directly to p53-related tar-
get sequences in the promoters of the TLR5, INPP5D and KRT15 
genes. We further confirmed their p53-dependent induction after 
DOX and nutlin-3a treatment using MCF7 cells silenced for p53. 
TLR5 gene is involved in innate immunity.35 INPP5D affects reg-
ulation of inositol signaling43,44 and showed a more than additive 
transactivation in all three combined treatments. KRT15 is an 
intermediate filament type I protein responsible for the mechani-
cal integrity of epithelial cells,45 and its expression is regulated by 
E2. Direct evidence for possible functional interaction between 
p53 and ER via cis-elements was only established for the KRT15 
gene, which also showed ERα occupancy upon E2 single treat-
ment. There are several reasons that might explain a lack of 
detectable ERα occupancy upon combined treatments, if it truly 
contributes to the greater than additive gene responses. Included 
is the possibility of a role for ERβ, which was not examined. Also, 
the type of interaction that can occur between p53 and ERα 
might differ between genes. ERα can in fact bind other transcrip-
tion factors in an ERE-independent manner.9,10 Furthermore, 
non-genomic estrogen signaling pathways9,10 must also be consid-
ered for their contribution to the observed transcriptional coop-
eration. This might be particularly relevant in the early phase of 
E2 responses. The sources of interaction would be interesting 
to pursue in future structure-function analyses. Importantly we 
establish that the in-cis p53/ER cooperation involves a p53 half-
site and half-site EREs, extending our previous findings beyond 
the FLT1 gene and model plasmid-based systems.26
led to only a small increase in H3K9me2 at some sites and E2 
was capable of reducing the DOX effect (Fig. 7A). No major 
changes were observed for the H3K4me2 mark, which is associ-
ated with active transcription. However, DOX treatment resulted 
in a slight increase at the TSS for TFF1 and INPP5D. E2 treat-
ment was associated with an increase at TFF1 and CDKN2A 
TSS (Fig. 7B).
There were increases associated with DOX and DOX + E2 
treatments in H3 and H4 acetylation marks, corresponding 
mainly to open chromatin, in the region surrounding the p53 
RE present -2.2 Kb from CDKN1A TSS (Fig. 8A and B). The 
E2 treatment led to an increase in H3 acetylation at TFF1 TSS 
and H4 acetylation both at the TSS and in the ERE-containing 
sequence located ~250 bp upstream from TSS. In both genes, 
these modifications are consistent with the enhanced transcrip-
tion observed after DOX or E2 treatments. DOX counteracted 
the effect of E2 on these marks in TFF1. No significant changes 
were observed for the TLR5 and INPP5D genes, except for a 
consistent decrease in acetylation for INPP5D after combined 
treatment (Fig. 8A and B). For KRT15, the E2 and DOX + E2 
treatments led to an increase in acetyl marks, especially near the 
TSS.
The total levels of H3 were also examined (Fig. S3). They 
appeared to be reduced near the TSS of the CDKN1A and 
TFF1 genes with all treatments For KRT15, the same trend was 
observed for all three regions analyzed. However, no changes 
were observed for the promoters of TLR5 and INNP5D, and an 
apparent increase was detected at TSS, particularly after DOX 
treatment.
Overall, our results indicate that all the genes analyzed were 
in an active chromatin state even in the mock condition, which 
is consistent with their basal expression levels. The treatments 
had an impact on several histone marks, although there was not a 
specific signature apparent for the double treatment.
Discussion
We have addressed the consequences of DOX and E2 on whole 
genome transcriptomes using p53 wild type and ERα-positive 
MCF7 cells as an experimental model of luminal-A subtype breast 
adenocarcinoma.37 Based on our previous work, we anticipated 
genes for which the inducible transcription factors p53 and ERs 
could act collaboratively in cis at their respective REs. Regardless 
of the mode of interaction, identifying genes for which there is a 
synergistic p53/ER response is expected to inform treatments of 
breast or other cancers. Therapeutic protocols often include mod-
ulation of either or both transcription factors, using p53-induc-
ing drugs, such as DOX or 5FU, as well as ER antagonists or 
inhibitors of estrogen synthesis (www.chemocare.com).9,38 Other 
examples of crosstalk between different drugs in breast and other 
cancer types have been recently reported.39-41 Those findings 
exemplify the relevance of examining the impact of combinato-
rial treatments at the genome level.
DOX treatment resulted in dramatic changes in gene expres-
sion with 647 upregulated and 1056 downregulated genes and 
enrichment for the p53-pathway activation. While, strongly 
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p53 activators can vary in their impact on p53 post-translational 
modifications and alter transcriptome responses.58,59 It is impor-
tant to note that, while p53 has been implicated, there may be 
other reasons for the genotoxic stress/ER synergistic responses.
Overall, we have found extensive transcriptional coopera-
tion between ERs and p53 across the genome. Given the impor-
tance of activators of these two genes in cancer treatments, these 
findings provide opportunities for investigations of treatments 
involving many newly identified targets of synergy, although 
the mechanisms of synergy remain to be established. The find-
ings are also relevant to understanding combined ER hormonal 
responses and any of the many4,6 stresses that can induce p53 as 
well as general biological and cancer implications. Although it is 
difficult to predict phenotypic outcome, the relevance of poten-
tial p53/ER biological outcomes is apparent. For example, among 
the 16 genes examined in depth, H19,60 NOTCH1,61 SYNM,62 
TLR563 and cadherins64 are found either overexpressed or down-
regulated in breast cancer. The synergy might lead to increased 
aggressiveness or tumor metastasis (such as EMT) or, alterna-
tively, influence inhibition of classical tumor hallmarks such as 
proliferation. EPHA2 has been reported to play a role in angio-
genesis and tumor neovascularization as well as being a positive 
mediator of UV-induced and largely p53-independent apopto-
sis, but it can also affect oncogenesis in melanocytes.65,66 Other 
genes, such as PML,67 INPP5D68 and APC269 are thought to be 
tumor suppressor genes. Cadherins are usually downregulated in 
tumors,64 whereas IGF2 is often overexpressed in many types of 
cancers and thought to be an oncogene.70
Finally, our findings suggest the opportunity to identify addi-
tional luminal breast tumor markers. Expression of some of the 
16 selected genes is usually weak or moderate in breast tissues 
(Human Protein Atlas).71 Understanding the functional roles 
that altered expression of those genes can play in different tissues 
could also aid in understanding the role that they may have in 
tumorigenesis.
Materials and Methods
Cell lines and treatments. The human breast adenocarcinoma-
derived MCF7 cell line (p53 wild type; ERα, ERβ-weakly posi-
tive) was obtained from ICLC and maintained in Dulbecco’s 
modified Eagle’s (DMEM), 10% FBS, 2 mM glutamine, 100 
units/ml penicillin and 100 μg/ml streptomycin. Estrogen-
depleted medium consisted of DMEM without phenol red sup-
plemented with 10% charcoal filtered FBS. MCF7 cells stably 
expressing an shRNA targeting p53 (MCF7-p53i), or control cells 
(MCF7-vector), were kindly provided by Dr. Agami.36 Media and 
reagents were supplied by BioWhittaker® or Invitrogen. MCF7 
p53 and ER occupancy levels were examined and did not cor-
relate directly with the observed cooperation in expression. In 
our experiments the same time point (10 h) was chosen both for 
transcriptome and ChIP assays. Possibly, chromatin changes had 
occurred earlier that would influence the subsequent expression. 
However, in a comparison of the impact of DOX and DOX + 
E2 treatments in MCF7 cells, there was also a lack of correlation 
between p53 occupancy and transactivation levels46 for the case 
of ChIP analysis at 4 h and qPCR 12 h.
We also investigated changes in chromatin, since drug treat-
ments could elicit epigenetic changes related to transcriptional 
reprogramming and DNA damage responses. Chromatin could 
change in a gene-specific manner without a direct correlation 
to TF occupancy levels of expression. The H3K4me2 mark is 
usually associated with actively transcribed genes and positioned 
around the TSS and the promoter area,47 and H3K9me2 is associ-
ated with gene silencing, especially when the mark is widespread 
along the gene. H3K9me2 can also be associated with openness/
gene activity when present at the 5' region of a gene47 and can 
reflect changes elicited by DNA damage responses.48,49
p53 and ER have been functionally and physically related to 
proteins involved in chromatin methyl mark changes, such as 
G9a and LSD1.50-55 However, the outcome of the induced epigen-
etic changes is variable. For example, G9a, considered the major 
euchromatin H3K9 methyltransferase, can act both as corepres-
sor and as a coactivator for nuclear receptor functions, in coopera-
tion with CARM1 and p300.50 Notably, both CARM1 and p300 
can be recruited by p53 contributing to transcriptional activa-
tion.51 Acetylation marks at H3 and H4 histone tails are consid-
ered chromatin activation markers. Both p53 and ER can recruit 
histone acetyltransferases contributing to gene activation.51,56,57
Thus, the complexity of histone tail epigenetic changes can-
not be easily related to alterations of transcription. However, the 
results obtained allowed us to propose that all genes analyzed 
are in an active chromatin state already in the mock condition. 
While treatments had an impact on histone marks, a specific 
signature of increased promoter openness after double treatment 
was not evident.
There are other mechanisms that can account for tran-
scriptional cooperation that would be interesting to pursue. 
Functional interactions with p53 could involve other members of 
the large superfamily of nuclear receptors, including, for exam-
ple, the glucocorticoid or androgen receptors, connected through 
a multi-protein mediator complex. Furthermore, our initial stud-
ies suggest that for a subset of promoters, crosstalk with ER could 
be affected by p63 and p73 members of the p53 family.26 p53 
splice variants and various kinds of p53 stress or ER activators 
might be expected to affect the ER/p53 synergistic responses. 
Figure 6 (See opposite page). Predicted p53 REs and EREs and relative occupancy of p53 and ER at TLR5A, INPP5D and KRT15 promoter regions. (A) 
Sequence, organization and position of mapped p53 and ER target sites. Promoters of selected genes were evaluated combining three approaches 
(see “Materials and Methods” for details). Red arrows mark ERE half sites, while tail-to-tail blue arrows denote the p53 RE half site. The chromosomal 
position, strand and the distance from the transcriptional start sites are also indicated. Two promoter fragments (denoted as #A and #B) were exam-
ined separately for each gene. (B–E) Chromatin immunoprecipitation and quantitative real-time PCR analyses. ChIP assays were performed using 
either an antibody against p53 (DO-1, Santa Cruz) or ERα (H-184) or control IgG (sc-2025). PCR was performed in 384-well plates in a "nal volume of 10 
μl using primers designed to amplify regions containing validated REs and ERE for established p53 and ERα target genes (B), or to generate amplicons 
centered around the identi"ed p53 REs and EREs in TLR5 (C), INPP5D (D) or KRT15 (E).
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Figure 7. Treatment-induced histone methylation changes at TLR5A, INPP5D and KRT15 promoter regions. Chromatin immunoprecipitation assays 
were performed using antibodies against H3K9me2 (07–441, Millipore) (A) or HeK4me2 (07–030) (B). IgG was used as control (sc-2027, Santa Cruz). Two 
or three regions of the promoter containing established or predicted p53 REs and EREs and the TSS were examined by quantitative PCR analysis. The 
distance from TSS of the promoter portions is indicated (see also Fig. 6A). Presented for each amplicon are average and standard deviation of changes 
relative to the mock condition. The colors of the bars indicate the promoter regions that were ampli"ed and match the boxes that are placed in the 
schematic drawing of the genes on the top of each "gure. The distance from TSS of the promoter regions that were examined is indicated.
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Bioconductor library of biostatistical packages. Probes with low 
signals were removed in order to filter out the constantly unex-
pressed genes and keep only probes flagged as present in the 
majority of replicates in at least one condition. Signal intensi-
ties across arrays were normalized with the quantile normaliza-
tion algorithm. In order to select differentially expressed genes, 
every condition corresponding to a treatment was first compared 
with the mock treatment. Three thresholds were set in order 
to select differentially expressed genes for each comparison: (1) 
t-test unpaired unequal variance p value < 0.01; (2) rank product 
percentage of false positive (pfp) < 0.05;72 (3) absolute log2 (fold 
change) > log2(2).
Using the DAVID resource,32 a functional annotation cluster-
ing analysis (enrichment score ≥ 1.5, medium classification strin-
gency) was performed on the lists of differentially expressed genes 
corresponding to each treatment.
Genes upregulated by the concomitant treatment of doxorubi-
cin and E2 (10-9 M) with more than an additive effect were iden-
tified among those satisfying the condition log2[FCdouble treatment] 
> 2 (a parameter allowing us for a more reasonable validation) 
subtracting the 2-fold changes corresponding to the single treat-
ments to the fold change corresponding to the double treatment 
and selecting those with a positive result: (log2[FCdouble treatment] - 
log2[FCDOX] - log2[FCE2]) > 0.1 (Table S2).
Quantitative real-time PCR (qPCR). One μg of total 
RNA was reverse transcribed in 20 μl of reaction using the 
“RevertAidTM First Strand cDNA Synthesis Kit” (Fermentas) or 
TaqMan reverse transcription reagents from Applied Biosystems. 
qPCR was performed using 384-well plates in a final volume of 
10 μl either on a CFX384 Touch™ Real-Time PCR Detection 
Systems (Bio-Rad) or on the ABI prism HT7900 system (Applied 
Biosystems). KAPA Probe FAST qPCR Kit/TaqMan Universal 
PCR Master Mix (Applied Biosystems) or KAPA SYBR® FAST 
qPCR Kit (Kapa Biosystems, Resnova) was used to perform 
the reaction together with TaqMan® Gene Expression Assays 
(Applied BiosystemTM, Life Technology) or primers purchased 
from Eurofins (MWG, Operon). Relative mRNA quantifica-
tion was obtained using the comparative Ct method (ΔΔCt), 
where glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
β-2microglobulin (B2M) or β-actin genes served as internal 
controls. Calculations were performed using QbasePLUS soft-
ware (Biogazelle) that uses the geNorm method73 to evaluate the 
expression stability of candidate reference genes.
A statistical analysis considering the log2 of the fold-induction 
was used to confirm the synergistic effect. The means of two 
normally distributed populations composed of log2[FCdouble treat-
ment] and log2[FCDOX] + log2[FCE2] were analyzed using a t-test 
approach (p < 0.05). The logarithmic values can flatten the dif-
ferences between the fold change values on one hand but, on the 
other hand, can make the results of our analysis more robust. 
The sum of logarithms is comparable to the multiplication of the 
fold changes and the subtraction of logarithms to the ratio of the 
fold-changes.
Promoter pattern searches. An in silico analysis was per-
formed in order to identify putative canonical or non-canonical 
p53 and ERα response elements (REs) couples with a maximum 
cells were treated with 1.5 μM doxorubicin (DOX) or 375 μM 
5-fluorouracil (5FU) or 10 μM nutlin-3a for p53 stabilization, 
+/-10-9/10-7 M 17β-estradiol. Stock solutions were dissolved in 
100% DMSO for 5FU (0.5 M) and nutlin-3a (10 mM), H2O 
for DOX (10 mM) and 100% EtOH for E2 (10-3 M). DOX, 
5FU and E2 were purchased from Sigma-Aldrich®; Nutlin-3a 
was obtained from Alexis® Biochemicals (Enzo Life Sciences). 
All treatments were done with cells at 70–80% confluence.
Antibodies and western blot analysis. Antibodies used for 
ChIP assays and western blotting analysis were: p53 (DO-1), 
ERα (H-184), Actin (I-19 or C-11) and IgG (sc-2025 or sc-2027) 
(Santa Cruz Biotechnology®) Anti-dimethyl-Histone H3 (Lys9) 
(07–441), anti-dimethyl-Histone H3 (Lys4) (07–030), anti-
acetyl-Histone H3 (06–599), anti-acetyl-Histone H4 (06–866), 
anti-Histone H3 (06–755) antibodies (Millipore). Proteins were 
extracted using RIPA buffer supplemented with protease inhibi-
tors and quantified using the BCA assay (Thermo Scientific, 
Pierce Protein Research Products). Proteins separated on 12% 
SDS-PAGE gels were transferred to a nitrocellulose mem-
brane (GE Healthcare) using an iBlot® Dry Blotting System 
(Invitrogen™, Life Technology) and checked by Ponceau S 
staining. Membranes were blocked using 5% skim milk + PBS-
Tween20 (0.1%) for 1 h at RT and probed with primary antibod-
ies in 1% skim milk + PBS-Tween20. Immune complexes were 
visualized using Amersham ECL™ Advance WB Detection Kit 
(GE Healthcare) or SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific). The relative molecular mass of the 
immunoreactive bands was determined using PageRuler™ Plus 
Prestained Protein Ladder (Fermentas).
Microarray hybridization and scanning, data acquisi-
tion and analysis. Cells were seeded and treated on 10 cm 
Petri dishes. Total RNA was extracted from 3–7 biologi-
cal replicates using the Agilent Total RNA Isolation Mini Kit 
(Agilent Technologies) according to the manufacturer’s proto-
col. RNA was quantified using the NanoDrop spectrophotom-
eter (NanoDrop Technologies), and quality was checked by 
gel electrophoresis as well as Agilent 2100 Bioanalyzer. Details 
on labeling, hybridization, analysis of TIFF images by Agilent 
Feature Extraction and the R software environment for statis-
tical computing and the Bioconductor library of biostatisti-
cal packages are provided with the Gene Expression Omnibus 
(GEO) (www.ncbi.nlm.nih.gov/geo/) submission (GSE24065). 
Briefly, hybridization, blocking and washing were performed 
according to Agilent protocol “One-Color Microarray-Based 
Gene Expression Analysis (Quick Amp Labeling).” Hybridized 
microarray slides (Agilent-014850 Whole Human Genome 
Microarray 4 × 44 K G4112F-Probe Name version) were then 
scanned with an Agilent DNA Microarray Scanner (G2505C) at 
5-micron resolution with the manufacturer’s software (Agilent 
ScanControl 8.1.3).
The scanned TIFF images were analyzed numerically for data 
extraction, background correction and flagging of non-uniform 
features using the Agilent Feature Extraction Software version 
10.7.7.1 according to the Agilent standard protocol GE1_107_
Sep09. The output of Feature Extraction was analyzed with 
the R software environment for statistical computing and the 
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Figure 8. Treatment-induced histone acetylation changes at TLR5A, INPP5D and KRT15 promoter regions. Chromatin immunoprecipitation assays 
were performed using antibodies against pan-H3Ac (06–599, Millipore) (A) or pan-H4Ac (06–866) (B), as described for Figures 6 and 7. The colors of 
the bars indicate the promoter regions that were ampli"ed and match the boxes that are placed in the schematic drawing of the genes on the top of 
each "gure. The distance from TSS of the promoter regions that were examined is indicated.
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distance of around 500 bp within the promoters of the selected 
genes. Three different approaches were used and combined: (1) 
pattern matching analysis (½ p53 RE: RRRCWWGYYY; ½ 
ERα RE: (A)GGTCA, TGACC(T) or GGCTA), (2) RSAT 
analysis74 and (3) R tool analysis using TransFac matrixes.
Chromatin immunoprecipitation (ChIP) assay. MCF7 cells 
were cultured in estrogen-depleted conditions in a 150-mm Petri 
dish and treated for 10 h with DOX and/or the physiological 
concentration of E2 (10-9 M). The procedure for crosslink-
ing, sonication, IP and analysis followed a previously described 
protocol.23,24,35
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Lion et al., Supplemental figure legends, supplemental figures and tables 
Figure S1.  Cell Index Analysis to follow up treatment-specific toxicity. Impact 
of the chemicals and drugs used for our experimental approach was tested using 
the Real-Time Cell Analyzer (RTCA) DP supplied by Roche Applied Science, 
Milan, Italy. Cells were seeded onto an E-Plate 16 and allowed to reach 70–80% 
of confluence (checked by cell index value at ~22-24 hours) before treating them 
with drugs as described in Materials and Methods. The proliferation rate was 
checked in the first 10 hours of treatment. A cell index normalization was imposed 
at the time point before drug administration. Mock condition was used as baseline. 
Presented are the average and standard deviation of three replicates for each 
condition. A) 1.5µM doxorubicin B) 375µM 5-fluorouracil, C) 10µM nutlin-3a +/- 10-
9 M 17β-estradiol (E2). 
Figure S2. Known and predicted associations for the 16 genes selected from 
the DOX + E2 DEGs with p53, ERs or the treatment drugs. The online Search 
Tool for Interactions of Chemicals (STITCH) network was used 
(http://stitch.embl.de/) (Kuhn et al., Nucleic Acids Research 2010). The confidence 
view is shown. Stronger associations are represented by thicker lines. The network 
nodes are either chemicals (represented as pills) or proteins (represented as 
spheres) and the network edges represent the predicted functional associations. 
Protein-protein interactions are shown in blue, chemical-protein interactions in 
green and interactions between chemicals in red. The prediction is based on text-
mining obtained from the literature. The established p53 and ER targets CDKN1A, 
TFF1 and GREB1 were included for comparison. The connection with p53 and/or 
ER for most of the chosen 16 genes is novel or largely unexplored. 
 
Figure S3. Treatment-induced changes in total histone 3 levels at TLR5A, 
INPP5D and KRT15 promoter regions. Chromatin Immunoprecipitation was 
performed using the anti-Histone H3 (06-755) (Millipore) antibody. IgG was used 
as control (sc-2027, Santa Cruz). Two or three regions of the promoter containing 
established or predicted p53 REs and EREs and the TSS were examined by 
quantitative PCR analysis. The distance from TSS of the promoter portions is 
indicated (see also Figure 6A). Presented for each amplicon are average and 
standard deviation of changes relative to the mock condition. PCR was carried out 
in 384-well plates in a final volume of 10µl –see Methods for details-. The colors of 
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the bars indicate the promoter regions that were amplified and match the boxes 
that are placed in the schematic drawing of the genes on the top of each figure.  
The distance from TSS of the promoter regions that were examined is indicated. 
Figure S1 
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Figure S2 
 
	   109	  
Figure S3 
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Table S1. Functional annotation clustering. Analyses were performed using the 
Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com) as well as DAVID 
(http://david.abcc.ncifcrf.gov/; Huang et al., Nat. Protocols 2008) (enrichment score 
≥ 1.5, medium classification stringency) with default settings starting from the lists 
of differentially expressed genes corresponding to the treatment: A) E2 (10-9 M), B) 
E2 (10-7 M), C) doxorubicin (1.5 µM), D) DOX + E2 (10-9 M), E) 66 unique up-
regulated genes upon DOX + E2 (10-9 M) treatment, F) 167 unique down-regulated 
genes upon DOX + E2 (10-9 M) treatment, G) 27 up-regulated genes shared by 
DOX, E2 (10-9 M) and DOX+E2 (10-9 M), H) 54 repressed genes shared by DOX, 
E2 (10-9 M) and DOX+E2 (10-9 M), I) 201 genes with an additive effect in DOX + 
E2 (10-9 M) up-regulation condition, J) 142 genes with an additive effect in DOX + 
E2 (10-9 M) down-regulation condition. Results from DAVID functional cluster are 
are summarized as a Table with the indicated enrichment score. Results from IPA 
Canonical Pathways and Upstream Regulators are presented as screen 
snapshots.  
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S 1A)   
DAVID ANALYSIS 
E2 (10-9 M) FUNCTIONAL ANNOTATION CLUSTER 
Annotation Cluster score 
regulation of ossification 4.00 
response to hormone stimulus 3.47 
Bcl-2 proteins (BH domain) 3.46 
regulation of apoptosis 3.41 
negative regulation of apoptosis 3.08 
insulin-like growth factor binding  proteins (IGFBPs) 2.95 
DNA replication 2.52 
mesoderm development / morphogenesis 2.44 
cytokine binding and control of the survival, growth and 
differentiation of tissues and cells 2.19 
positive regulation of cell differentiation/cell development 2.16 
chordate embryonic  development 2.07 
regulation of locomotion/cell migration 2.03 
positive regulation of inflammatory response/                            
response to external stimulus 2.00 
proteins with HLH domains 1.83 
nucleotide-binding 1.78 
protein dimerization activity 1.70 
vasculature/blood vessel development 1.68 
tube development 1.64 
components of membrane fraction 1.62 
positive regulation of ossification 1.53 
proteins with SH2 domains 1.52 
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S 1A) 
IPA UPSTREAM REGULATOR ANALYSIS 
Presented in the first three columns are the names, function of upstream 
regulators that may be responsible for gene expression changes and their relative 
expression (Fold Change) observed in the data set. Predicted activity of these 
regulators with IPA-provided statistical assessment is included in column 4 and 5. 
A partial list of gene names and the total number in each group is also provided 
along with the Fisher’s Exact Test results of the extent of overlap between DEGs 
and total number of genes considered as targets of the upstream regulator 
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S 1A) 
IPA CANONICAL PATHWAYS 
Canonical Pathways are displayed as bar chart. The –log(p value) results of a 
right-tailed Fisher’s Exact Test is indicated. The ratio, calculated as number of 
genes in a given pathways that meet cut-off criteria divided by the total number of 
genes that make up the pathway, is overlaid as an orange line. The first 10 top 
pathways are shown. 
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S 1B) 
DAVID ANALYSIS 
E2 (10-7 M) FUNCTIONAL ANNOTATION CLUSTER 
Annotation Cluster score 
response to hormone stimulus 4.34 
regulation of locomotion/cell migration 2.84 
constituent parts of the plasma membrane 2.49 
proteins with SH2 domains 2.35 
glycoproteins 2.34 
components of membrane fraction 2.34 
developmental maturation 2.32 
response to hypoxia 2.31 
Bcl-2 proteins (BH domain) 1.97 
vasculature/blood vessel development 1.90 
lipoproteins 1.89 
negative regulation of cell growth 1.85 
response to wounding/inflammatory response 1.64 
regulation of phosphate metabolic process 1.59 
positive regulation of apoptosis 1.58 
proteins with Pleckstrin homology-type domain (PH domain) 1.55 
components of the extracellular region part 1.52 
 
	   115	  
S 1B) 
IPA UPSTREAM REGULATOR ANALYSIS  
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S 1B) 
IPA CANONICAL PATHWAYS 
 
 
 
	   117	  
S 1C) 
DAVID ANALYSIS 
DOXORUBICIN FUNCTIONAL ANNOTATION CLUSTER 
Annotation Cluster score 
regulation of transcription 8.53 
components of cytoskeleton 7.59 
cell cycle/mitosis 7.28 
components of nuclear lumen/nucleoplasma 6.77 
cellular response to stress/DNA damage stimulus 5.97 
constituent parts of chromosomes / condensed chromosome 
kinethocore 5.07 
proteins with zinc finger domain/C2H2-like 4.23 
regulation of apoptosis 3.43 
components of microtubule cytoskeleton 2.93 
DNA damage / cell cycle checkpoint 2.74 
components of chromosome segregation 2.68 
positive regulation of transcription 2.66 
basic-leucine zipper (bZIP) transcription factors 2.65 
regulation of programmed cell death 2.62 
negative regulation of transcription 2.57 
proteins with BTB/POZ domain 1.95 
GTPase regulator activity 1.93 
regulation of meiotic cell cycle 1.90 
p53/ATM cell signalling pathway 1.86 
constituent parts of nuclear chromosomes 1.84 
tube development 1.79 
response to radiation 1.75 
double-strand break repair 1.74 
hemopoiesis / myeloid cell differentiation 1.74 
negative regulation of transferase activity 1.68 
positive regulation of cell migration 1.68 
regulation of cell growth 1.66 
nucleotide-binding 1.66 
DNA damage response, signal transduction by p53 class 
mediator 1.62 
growth factor activity 1.53 
ovulation cycle process 1.51 
regulation of DNA  metabolic process / DNA replication 1.50 
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S 1C) 
IPA UPSTREAM REGULATOR ANALYSIS  
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S 1C) 
IPA CANONICAL PATHWAYS 
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S 1D) 
DAVID ANALYSIS 
DOXORUBICIN + E2 (10-9 M) FUNCTIONAL ANNOTATION CLUSTER 
Annotation Cluster score 
regulation of transcription 6.48 
proteins with BTB/POZ domain 4.42 
basic-leucine zipper (bZIP) transcription factors 3.78 
cell cycle/mitosis 3.27 
components of microtubule cytoskeleton 3.63 
cellular response to stress/DNA damage stimulus 3.09 
proteins with zinc finger domain/C2H2-like 2.76 
components of the nuclear chromosome part 2.69 
proteins with sh3 domains 2.69 
components of the condensed chromosome kinethocore 2.24 
GTPase regulator activity 2.21 
negative regulation of transcription from RNA pol II promoter 2.14 
WNT receptor signalling pathway 2.12 
components of nuclear lumen/nucleoplasma 2.10 
regulation of apoptosis 2.03 
positive regulation of transcription/macromolecule metabolic process 1.74 
response to radiation/UV 1.62 
proteins with SH2 domains 1.57 
DNA-repair proteins/proteins with UmuC-like domain 1.53 
proteins with BTB/POZ domain/Kelch-like proteins 1.52 
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S 1D) 
IPA UPSTREAM REGULATOR ANALYSIS  
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S 1D) 
IPA CANONICAL PATHWAYS 
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S 1E) 
DAVID ANALYSIS 
 
DOXORUBICIN + E2 (10-9 M) FUNCTIONAL ANNOTATION CLUSTER 
Annotation Cluster (66 up-regulated genes selective responsiveness) score 
proteins with SH2 domain 2.21 
response to hormone stimulus 1.87 
adenylate cyclese activity 1.45 
protease inhibitor 1.38 
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S 1E) 
IPA CANONICAL PATHWAYS 
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S 1F)  
DAVID ANALYSIS 
 
DOXORUBICIN + E2 (10-9 M) FUNCTIONAL ANNOTATION CLUSTER 
Annotation Cluster (167 repressed genes selective responsiveness) score 
basic-leucine zipper (bZIP) transcription factors 2.04 
zinc/metal transition ion binding proteins 1.86 
regulation of transcription 1.60 
proteins with SH3 domain 1.50 
 
S II F) 
IPA CANONICAL PATHWAYS 
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S 1G)  
DAVID ANALYSIS 
 
FUNCTIONAL ANNOTATION CLUSTER (27 up-regulated genes in common) 
Annotation Cluster score 
ossification / bone development 1.74 
vasculature/blood vessel development 1.45 
positive regulation of transcription 0.98 
enzymes linked receptor protein signaling pathway 0.84 
regulation of apoptosis 0.72 
components of the extracellular matrix/growth factor 0.62 
 
S 1G) 
IPA CANONICAL PATHWAYS 
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S 1H) 
DAVID ANALYSIS 
 
FUNCTIONAL ANNOTATION CLUSTER (54 repressed genes in common) 
Annotation Cluster score 
cytokine-cytokine receptor interaction 1.65 
regulation of ossification / skeletal system development 1.55 
 
S 1H) 
IPA CANONICAL PATHWAYS 
 
 
 
	   128	  
S 1I) 
DAVID ANALYSIS 
 
ADDITIVE EFFECT (DOXORUBICIN + E2 UP-REGULATION) 
FUNCTIONAL ANNOTATION CLUSTER 
Annotation Cluster (201 more than additive genes) score 
ectoderm development/epithelial cell differentiation 2.94 
glycoproteins/proteins of the extracellular region 2.29 
components of the plasma membrane 1.84 
components of the extracellular matrix/cell adhesion proteins 1.59 
inflammatory/defense response 1.55 
mesenchymal/neural crest cells differentiation 1.54 
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S 1I) 
IPA UPSTREAM REGULATORS ANALYSIS 
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S 1I) 
IPA CANONICAL PATHWAYS 
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S 1J) 
DAVID ANALYSIS 
 
ADDITIVE EFFECT (DOXORUBICIN + E2 DOWN-REGULATION) 
Annotation Cluster (142 genes with greater than additive 
down-regulation) score 
cell cycle/mitosis 1.75 
mitotic spindle organization/mitotic cell cycle 1.59 
 
S 1J) 
IPA CANONICAL PATHWAYS 
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Table S2. Statistical analysis for synergistic impact of combined treatments. 
The log2 of the fold of induction was considered. The means of two normally 
distributed populations composed of log2 [FCdouble treatment] and log2[FCDOX] + 
log2[FCE2] were analyzed using a t-test approach (p < 0.05). Each population was 
composed of six values. A) doxorubicin B) 5FU C) Nutlin-3a (nutlin).  
S 2A) 
GENE NAME log2 (DOX & E2) log2 (DOX + E2) p-value Ref
1 Ref2 
CA5A -1.2673 1.4343 0.032620  (1) 
CDH26 2.0860 3.3118 0.006878 (2, 3) (4) 
EPHA2 1.2677 2.2043 0.001083 (5)  
H19 0.6006 1.6148 0.000755   
INPP5D 1.5231 3.3450 0.027126 (6) (7) 
KRT15 1.2927 3.2635 0.000240   
NOTCH1 2.5643 2.6851 ns (8-10) (11) 
PML 3.0089 2.7536 ns (12)  
SOX9 3.0460 3.4651 ns (13, 14) (15) 
SYNM 1.2360 2.4176 0.001560   
TEX14 2.0027 3.7901 0.003339  (16) 
TLR5 1.3543 2.6876 0.000068 (17)  
GDNF 2.1639 3.7281 0.000451  (18) 
TFF3 1.8022 1.7969 ns  (19) 
APC2 -0.5028 -0.0014 ns   
IGF2 -0.9161 -0.3698 ns (20)  
1 Previous studies where a direct or indirect functional interaction with p53, 
with ER or among the selected genes has already been proposed. 
2.	   Carroll	   JS,	   et	   al.	   (2006)	   Genome-­‐wide	   analysis	   of	   estrogen	   receptor	   binding	   sites.	   Nat	  
Genet	  38(11):1289-­‐1297.	  
3.	   Lin	  C-­‐Y,	   et	   al.	   (2007)	  Whole-­‐Genome	  Cartography	  of	   Estrogen	  Receptor	  α	  Binding	   Sites.	  
PLoS	  Genet	  3(6):e87.	  
5.	   Zhang	  G,	  et	  al.	  (2008)	  EphA2	  Is	  an	  Essential	  Mediator	  of	  UV	  Radiation–Induced	  Apoptosis.	  
Cancer	  Research	  68(6):1691-­‐1696.	  
6.	   Kerley-­‐Hamilton	   JS,	   et	  al.	   (2005)	  A	  p53-­‐dominant	   transcriptional	   response	   to	  cisplatin	   in	  
testicular	  germ	  cell	  tumor-­‐derived	  human	  embyronal	  carcinoma.	  Oncogene	  24(40):6090-­‐
6100.	  
8.	   Kim	   SB,	   et	   al.	   (2006)	   Activated	  Notch1	   interacts	  with	   p53	   to	   inhibit	   its	   phosphorylation	  
and	  transactivation.	  Cell	  Death	  Differ	  14(5):982-­‐991.	  
9.	   Hao	  L,	  et	  al.	   (2009)	  Notch-­‐1	  activates	  estrogen	  receptor-­‐[alpha]-­‐dependent	  transcription	  
via	  IKK[alpha]	  in	  breast	  cancer	  cells.	  Oncogene	  29(2):201-­‐213.	  
10.	   Secchiero	  P,	  et	  al.	  (2009)	  Nutlin-­‐3	  up-­‐regulates	  the	  expression	  of	  Notch1	  in	  both	  myeloid	  
and	   lymphoid	   leukemic	   cells,	   as	   part	   of	   a	   negative	   feedback	   antiapoptotic	   mechanism.	  
Blood	  113(18):4300-­‐4308	  .	  
12.	   Kurki,	  et	  al.	  (2003)	  Cellular	  stress	  and	  DNA	  damage	  invoke	  temporally	  distinct	  Mdm2,	  p53	  
and	  PML	  complexes	  and	  damage-­‐specific	  nuclear	  relocalization.	  J.	  Cell	  Science	  116:3917-­‐
3925.	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13.	   Mead	   TJ,	   et	   al.	   (2009)	   Notch	   pathway	   regulation	   of	   chondrocyte	   differentiation	   and	  
proliferation	   during	   appendicular	   and	   axial	   skeleton	   development.	   Proceedings	   of	   the	  
National	  Academy	  of	  Sciences	  106(34):14420-­‐14425.	  
14.	   Muto	   A,	   et	   al.	   (2009)	   The	   group	   E	   Sox	   genes	   Sox8	   and	   Sox9	   are	   regulated	   by	   Notch	  
signaling	  and	  are	  required	  for	  Müller	  glial	  cell	  development	  in	  mouse	  retina.	  Experimental	  
Eye	  Research	  89(4):549-­‐558.	  
17.	   Menendez	  D,	  et	  al.	   (2011)	  The	  Toll-­‐Like	  Receptor	  Gene	  Family	   Is	   Integrated	   into	  Human	  
DNA	  Damage	  and	  p53	  Networks.	  PLoS	  Genet	  7(3):e1001360.	  
20.	   Zhang	   L,	   et	  al.	   (1998)	  p53	   regulates	  human	   insulin-­‐like	  growth	   factor	   II	   gene	  expression	  
through	  active	  P4	  promoter	  in	  rhabdomyosarcoma	  cells.	  DNA	  Cell	  Biol	  17(2):125-­‐131.	  
 
 
2 Previous studies addressing expression of the genes in a different tissue type or 
implicating them in biological pathways that can represent an expansion of the 
p53/ER transcriptional master network.	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   Vullo	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S 2B) 
GENE NAME log2 (5FU & E2) log2 (5FU + E2) p-value 
CA5A -1.4128 -1.5072 ns 
CDH26 4.7005 4.3618 ns 
EPHA2 -0.1362 0.1798 ns 
H19 0.4730 1.1922 0.042541 
INPP5D 1.2796 3.2618 0.000252 
KRT15 1.6988 1.7465 ns 
NOTCH1 0.7222 0.9498 ns 
PML -1.0537 -0.2178 ns 
SOX9 -1.7045 -1.4752 ns 
SYNM -1.9345 -1.9135 ns 
TEX14 -0.6878 -0.4685 ns 
TLR5 -1.7295 -1.1135 ns 
GDNF -0.5720 0.6339 0.000526 
TFF3 0.7461 0.3822 ns 
APC2 -1.1356 -1.4878 ns 
IGF2 -0.2356 -0.9762 ns 
 
S 2C) 
GENE NAME log2 (nutlin & E2) log2 (nutlin + E2) p-value 
CA5A -1.1169 -0.2678 ns 
CDH26 2.3298 2.3505 ns 
EPHA2 0.9131 1.3605 0.000019 
H19 1.0365 1.7015 0.009644 
INPP5D 4.2265 5.1188 0.001312 
KRT15 3.3848 2.9788 ns 
NOTCH1 1.6481 1.7155 ns 
PML 0.2631 0.5322 ns 
SOX9 0.4598 0.6688 ns 
SYNM 0.2915 0.4822 ns 
TEX14 0.7431 0.6738 ns 
TLR5 0.5498 0.6155 ns 
GDNF 0.0508 0.1341 ns 
TFF3 0.2928 0.1127 ns 
APC2 -0.7422 -1.0940 ns 
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Table S3. List of the genes up-regulated by the concomitant treatment of 
doxorubicin and E2 (10-9 M) with more than an addictive effect.  To be part of 
this least the following conditions were satisfied: log2[FCdouble treatment] > 2 and log2 
[FCdouble treatment] – log2[FCDOX] – log2[FCE2]) > 0.1  
 
GENE 
FOLD OF CHANGE (log2 treatment vs mock) 
Doxorubicin + E2 
(10-9 M) Doxorubicin E2 (10
-9M) ADDITIVE EFFECT 
CA5A* 1.30 1.19 -0.94 1.05 
CDH26 4.30 0.09 3.22 1.00 
EPHA2 2.62 1.62 0.10 0.90 
H19 2.95 0.56 1.03 1.36 
INPP5D 3.10 2.27 0.34 0.50 
KRT15 3.24 -0.29 1.67 1.57 
NOTCH1 3.25 2.31 0.56 0.38 
PML 3.85 3.04 -0.68 0.81 
SOX9 3.79 2.38 0.50 0.91 
SYNM 3.27 2.01 -0.23 1.27 
TEX14 3.52 2.16 -1.16 1.36 
TLR5 2.88 1.08 0.06 1.74 
GDNF 4.53 3.24 0.05 1.25 
TFF3 2.53 0.70 1.04 0.80 
APC2 2.88 1.80 -0.04 1.08 
IGF2 2.27 1.24 -0.16 1.03 
FAM63A 2.02 -0.21 0.32 1.70 
KCNF1 3.91 0.66 1.55 1.69 
KRT14 3.18 0.00 1.63 1.55 
AHNAK2 3.61 2.30 -0.07 1.31 
VWF 2.69 -0.02 1.38 1.31 
FLJ45248 2.18 -0.24 0.88 1.30 
XYLT1 2.63 0.94 0.42 1.27 
KCNB1 3.26 2.03 -0.59 1.23 
NEUROD2 4.04 2.84 -0.71 1.20 
ITGB8 2.05 0.72 0.13 1.19 
MERTK 2.32 1.05 0.16 1.11 
MAMLD1 2.47 -0.23 1.45 1.01 
COL27A1 2.08 0.74 0.37 0.98 
POU3F1 3.24 2.29 -0.86 0.95 
LOC646976 4.07 2.84 0.32 0.91 
TNFAIP2 2.58 1.70 -0.54 0.88 
RAB37 3.67 1.82 0.98 0.87 
ICOSLG 3.03 2.06 0.13 0.84 
FLJ42627 2.02 1.07 0.12 0.83 
HEG1 3.07 -0.60 2.25 0.83 
EFNB1 2.31 1.49 -0.07 0.83 
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C20orf132 2.48 1.66 -0.55 0.82 
VWCE 4.24 3.21 0.23 0.80 
DLX3 2.46 1.00 0.66 0.80 
CDC42EP3 3.15 2.36 -0.35 0.79 
NPTX1 4.25 2.87 0.59 0.79 
FOSL1 3.18 2.39 -0.35 0.79 
LOC390595 2.43 1.67 -0.08 0.77 
PDE2A 4.12 3.08 0.30 0.74 
AMZ1 3.18 -0.18 2.44 0.74 
SIM2 2.24 1.49 0.01 0.74 
SMPD3 3.43 2.71 -0.45 0.72 
GLS 2.99 2.26 -0.39 0.72 
HOXA11AS 2.06 1.12 0.23 0.71 
INSM2 3.09 2.37 -0.09 0.71 
IQCD 2.95 2.25 -0.14 0.70 
MICALCL 2.65 0.67 1.29 0.70 
MAF 2.35 1.67 -0.67 0.69 
RGMA 4.87 3.25 0.94 0.68 
ANK1 3.59 2.91 -0.35 0.67 
DHRS3 2.35 1.68 -0.44 0.67 
AOC3 2.73 2.06 -0.08 0.67 
EGR1 2.30 1.63 -1.27 0.67 
LRRC17 3.01 2.35 -0.50 0.66 
PRDM2 2.60 1.94 -0.09 0.66 
SPSB1 2.39 1.63 0.11 0.66 
TMEM130 3.87 3.22 -1.27 0.66 
AP3B2 2.16 1.51 -0.13 0.65 
DLX2 2.70 2.06 -1.12 0.65 
SERPINB9 3.19 2.54 -0.01 0.65 
KLHL29 2.18 1.08 0.45 0.64 
TGM2 3.12 -0.48 2.48 0.64 
AMPD3 2.32 1.56 0.12 0.64 
CHST6 2.53 1.90 -0.34 0.63 
GGTA1 2.36 1.73 -0.33 0.63 
MYO10 2.21 1.11 0.46 0.63 
NUDT9P1 4.24 3.62 -0.25 0.62 
POLH 3.27 2.53 0.12 0.62 
AUTS2 3.32 2.34 0.35 0.62 
FLJ26850 5.45 4.71 0.12 0.62 
LOC402778 2.91 0.34 1.95 0.62 
PRODH 2.11 1.50 -0.05 0.61 
FGF18 2.82 1.13 1.08 0.60 
ZCCHC24 2.44 1.85 -0.29 0.59 
TMEM120B 2.17 0.38 1.19 0.59 
HLA-DPB1 2.54 1.97 -0.40 0.57 
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RNF150 2.19 0.16 1.45 0.57 
KIAA0562 2.97 1.99 0.44 0.55 
RHOBTB1 3.17 1.04 1.59 0.54 
RFC3 2.83 2.12 0.17 0.54 
SLC8A3 3.14 2.61 -0.45 0.53 
GGA2 2.14 1.31 0.30 0.53 
DUSP5P 2.45 1.58 0.34 0.52 
HES2 2.98 2.46 -0.79 0.52 
C2orf27A 2.17 1.65 -0.72 0.52 
KLRG2 2.27 1.48 0.29 0.51 
LOC157562 3.24 2.73 -0.50 0.51 
MIA 3.16 2.66 -0.19 0.50 
FLJ13224 2.72 2.23 -0.72 0.50 
RBPMS2 3.68 2.46 0.72 0.49 
EPB41L4B 2.28 1.74 0.05 0.49 
SLC6A8 4.39 3.76 0.14 0.48 
HPS1 2.16 1.55 0.13 0.47 
GRIN2C 4.60 4.14 -0.55 0.46 
ASPRV1 2.01 1.55 -0.52 0.46 
ETV7 3.96 3.20 0.30 0.46 
MAFB 2.83 2.37 -0.52 0.46 
SYTL4 3.01 0.44 2.11 0.46 
STX6 2.12 1.67 -0.15 0.45 
ACTA1 4.98 4.53 -0.09 0.45 
CD46 2.25 1.68 0.13 0.44 
PXK 2.10 0.73 0.94 0.43 
RAB31 2.49 0.44 1.62 0.42 
TP53I3 2.78 2.25 0.12 0.41 
SIRPA 4.24 3.74 0.09 0.41 
ELL2 2.81 2.40 -0.28 0.41 
PRDM15 3.52 2.64 0.47 0.41 
HGS 2.05 1.64 -0.07 0.41 
RGS20 2.85 2.45 -0.23 0.40 
PPP2R2D 2.42 2.02 -0.12 0.40 
ZFP2 2.10 1.67 0.03 0.40 
SERPINC1 4.04 3.60 0.06 0.38 
FOXQ1 2.84 2.47 -0.65 0.37 
LIMK2 2.35 1.99 -0.43 0.37 
NTN1 3.55 2.41 0.78 0.36 
CABYR 3.08 2.72 -0.06 0.36 
RGAG4 2.55 2.19 -0.44 0.36 
PARD6G 2.18 1.46 0.37 0.36 
PLIN5 3.64 1.37 1.91 0.36 
FLJ25006 2.48 1.41 0.72 0.35 
KLK10 2.68 -0.13 2.33 0.35 
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PLEKHO2 2.36 1.93 0.09 0.35 
FAM196A 7.27 6.70 0.22 0.35 
SLC6A13 2.37 2.02 -0.86 0.35 
RGS16 2.23 1.89 -0.11 0.34 
OLFML2A 2.10 0.34 1.42 0.34 
TFPI2 3.53 0.90 2.30 0.34 
SPATA18 3.15 2.64 0.18 0.33 
C20orf106 2.65 2.32 -0.02 0.33 
COL12A1 2.31 0.34 1.64 0.33 
SHANK3 2.92 1.84 0.76 0.32 
C7orf53 2.14 1.78 0.03 0.32 
THBD 2.41 1.62 0.47 0.32 
PGLYRP2 3.15 -0.29 2.82 0.32 
KRT13 3.29 0.09 2.88 0.32 
GLIPR2 2.16 1.84 -0.55 0.32 
GPR87 4.17 3.85 -0.35 0.31 
CCDC96 2.35 2.04 -0.26 0.31 
FDXR 2.91 2.60 -0.01 0.31 
LAMP3 3.49 3.18 -0.11 0.31 
PFKFB2 2.44 2.14 -0.32 0.30 
ERO1LB 3.17 2.87 -0.63 0.29 
ATP6V1C2 2.71 0.33 2.09 0.29 
IRX2 2.37 1.80 0.29 0.29 
C4orf49 3.30 3.01 -0.10 0.29 
TNXB 3.02 2.74 -0.87 0.28 
PRICKLE2 2.31 2.03 -0.63 0.28 
SLC30A1 2.48 2.20 -0.02 0.28 
MAN2A2 2.17 1.91 -0.22 0.26 
RBM24 2.85 0.79 1.81 0.26 
HSPA12A 2.12 1.41 0.45 0.25 
GLDC 2.51 0.51 1.75 0.25 
GADD45A 3.24 2.90 0.09 0.25 
ACTA2 4.25 4.00 -0.28 0.24 
C8G 2.66 2.42 -0.62 0.24 
BAIAP2 2.80 2.39 0.17 0.24 
AMIGO3 2.70 2.37 0.10 0.23 
BTG2 2.40 2.18 -1.96 0.22 
CCDC3 5.10 4.28 0.61 0.22 
ADCY9 2.11 0.99 0.90 0.22 
KCTD1 2.61 2.24 0.16 0.22 
KDSR 2.00 1.54 0.25 0.21 
FSCN1 2.61 2.29 0.11 0.21 
GPR64 2.02 1.41 0.41 0.20 
SLC47A1 2.84 0.91 1.74 0.19 
DPYSL4 4.74 3.79 0.76 0.19 
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ONECUT2 2.33 1.60 0.54 0.19 
FAM25A 2.76 0.55 2.03 0.18 
LAMA3 3.02 0.08 2.77 0.18 
CELF6 2.37 2.19 -0.49 0.17 
NPL 2.27 1.78 0.32 0.17 
PTPRH 2.38 2.12 0.09 0.17 
TRIM7 2.46 2.08 0.21 0.17 
PIK3CD 2.05 1.14 0.74 0.17 
LOC727916 2.70 2.54 -0.89 0.16 
RET 3.10 0.82 2.13 0.16 
TTC13 2.03 1.46 0.42 0.15 
HAS3 2.21 1.53 0.53 0.15 
UNC5B 3.38 2.61 0.62 0.15 
PLK3 4.99 4.62 0.22 0.15 
LIF 2.53 2.04 0.34 0.15 
PRSS23 2.15 0.53 1.47 0.15 
GPR155 3.14 2.77 0.23 0.14 
FLJ36031 2.36 2.22 -0.14 0.14 
KANK3 2.08 1.95 -0.41 0.14 
ITGA6 2.29 1.14 1.02 0.14 
HBEGF 3.13 3.00 -0.44 0.13 
INPP1 2.83 2.70 -0.10 0.13 
NCR3 3.17 3.04 -0.25 0.13 
LAT2 2.40 2.07 0.19 0.13 
RNF122 2.29 2.16 -0.79 0.13 
ZNF79 2.24 2.12 -0.05 0.12 
SLC6A10P 3.26 2.79 0.35 0.12 
LOC645277 2.17 2.06 -0.81 0.11 
RNF170 2.54 2.43 -0.26 0.10 
C13orf31 2.11 1.82 0.19 0.10 
 
* = for CA5A log2[FCdouble treatment] > 2 was based on data from  DOX + E2 (10-7 M)  
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Table S4. Summary of the expression data obtained after single or combined 
drug treatment. “+” indicates a fold of induction greater than 1.5 after single drug 
or chemical treatment. Asterisks indicate that the combined treatment with E2 
results in a more than additive effect that is statistically significant, as described in 
Methods section. Empty cell or missing symbol indicates that the above selection 
criteria are not fulfilled. 
 
TREATMENTS DOX / DOX+E2 
5FU / 
5FU +E2 
Nutlin/ 
Nutlin + E2 E2 p53^ 
Gene Name Gene responsiveness by qPCR 
CA5A + / *    n.i. 
CDH26 / * + /  + /  
EPHA2 + / *  + / *  + / 
H19 / * / * / * + / n.i. 
INNP5D + / * + / * + / *  + / 
KRT15 / *  + / + / + / 
NOTCH1 + / + / + /  + / 
PML + /    n.i. 
SOX9 + /  + /  + / 
SYNM + / *    n.i. 
TEX14 + / *  + /  n.i. 
TLR5 + / *    + / 
GDNF + / * / *   + / 
TFF3     n.i. 
APC2     n.i. 
IGF2     n.i. 
 
^p53 responsiveness is addressed based on experiments performed using the 
p53-deficient MCF7 cells. n.i. = gene expression was not investigated 
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Abstract
Background: The p53 tumor suppressor, which is altered in most cancers, is a sequence-specific transcription factor that is
able to modulate the expression of many target genes and influence a variety of cellular pathways. Inactivation of the p53
pathway in cancer frequently occurs through the expression of mutant p53 protein. In tumors that retain wild type p53, the
pathway can be altered by upstream modulators, particularly the p53 negative regulators MDM2 and MDM4.
Methodology/Principal Findings: Given the many factors that might influence p53 function, including expression levels,
mutations, cofactor proteins and small molecules, we expanded our previously described yeast-based system to provide the
opportunity for efficient investigation of their individual and combined impacts in a miniaturized format. The system
integrates i) variable expression of p53 proteins under the finely tunable GAL1,10 promoter, ii) single copy, chromosomally
located p53-responsive and control luminescence reporters, iii) enhanced chemical uptake using modified ABC-transporters,
iv) small-volume formats for treatment and dual-luciferase assays, and v) opportunities to co-express p53 with other
cofactor proteins. This robust system can distinguish different levels of expression of WT and mutant p53 as well as
interactions with MDM2 or 53BP1.
Conclusions/Significance: We found that the small molecules Nutlin and RITA could both relieve the MDM2-dependent
inhibition of WT p53 transactivation function, while only RITA could impact p53/53BP1 functional interactions. PRIMA-1 was
ineffective in modifying the transactivation capacity of WT p53 and missense p53 mutations. This dual-luciferase assay can,
therefore, provide a high-throughput assessment tool for investigating a matrix of factors that can influence the p53
network, including the effectiveness of newly developed small molecules, on WT and tumor-associated p53 mutants as well
as interacting proteins.
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Introduction
The sequence-specific transcription factor p53 is a key tumor
suppressor protein that can coordinate the expression of a large
number of target genes involved in different cellular responses to
stress conditions including cell cycle arrest, programmed cell death
and DNA repair [1,2]. More recently, a role of p53 in a diverse
spectrum of cellular pathways has been established, including
angiogenesis, autophagy, as well as carbon and lipid metabolism
[3,4,5]. p53 activity is finely tuned by a large number of signaling
pathways which respond to alterations in cellular homeostasis or
the microenvironment and result in the modulation of p53 protein
levels, the potential for protein:protein interactions and DNA
binding affinity/specificity. Modulation of the p53 network mainly
occurs via post-translational modifications of the p53 protein itself
[6]. The critical importance of p53 in tumor suppression in
humans is exemplified by the high frequency of human cancers
showing alterations in the p53 pathway, including p53 mutations
[7].
Many studies in a variety of cell lines and in vivo animal models
have provided striking evidence that the reconstitution of p53
activity can lead to tumor cell death as well as to the regression of
established tumors [8,9,10,11,12]. Over the past 15 years such
results have spurred a number of studies aimed at developing the
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20643
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means for restoring wild type p53 function in cells including viral
delivery of p53 cDNAs and the rational design of small molecules
or peptides that can stimulate p53 functions or reactivate tumor-
associated mutant p53 proteins [13,14,15]. In tumors that retain
wild type p53, the regulated pathway is frequently, if not always,
impaired by other genetic events that result in higher expression
and activity of the critical negative p53 regulator MDM2 or, to a
lesser extent MDM4 and other modulators of p53 protein
localization and activity [16,17,18,19]. The critical roles of
MDM2 and MDM4 as negative modulators of p53, which have
been elegantly established using knock-out models [20,21], as well
as the over-expression of these proteins in several cancer types
[17,22,23] raised expectations on the therapeutic potential of
restoring p53 functions by MDM2/4 in tumors. However, the
identification of chemicals that could disrupt protein:protein
interactions or protein:DNA interactions involving p53 has proven
challenging [24].
Small molecules that can inhibit the interaction between
MDM2 and p53 can result in increased p53 protein levels and
lead to p53-dependent growth suppression and apoptosis in
different cell-based as well as in vivo models [25,26,27]. For
example, Nutlin and the MI-43 compounds target the binding
pocket for p53 in the MDM2 protein. RITA, which was identified
in a cell-based screening assay, binds p53 and also inhibits the
p53:MDM2 interaction [25]. Structural studies have identified
similarities as well as shape differences between the p53-binding
pockets in MDM2 and MDM4 [28], supporting the selectivity of
Nutlin in p53:MDM2 interactions [29].
To investigate the impact of small molecules on p53
transactivation potential or on the functional interaction between
p53 and cofactors, we have developed a highly defined dual-
luciferase functional assay in the budding yeast Saccharomyces
cerevisiae. This greatly expands our previous system designed to
address functions of p53 mutants and target response elements by
varying the level of p53 [30,31]. The assay exploits the variable
expression of p53 proteins and utilizes the Firefly and Renilla
luminescent reporters integrated as single copies at different
chromosomal loci in haploid strains or at the same chromosomal
location in diploid strains, i.e., heteroalleles. While a common
minimal promoter controls low-level constitutive expression of
both reporters, p53-dependent expression of the Firefly reporter is
attained through a specific p53 response element (RE) placed
upstream of the minimal promoter [32,33].
The sensitivity and robustness of the assay system was
investigated with various protocols for induction of wild type and
mutant p53 protein as well as coincident measurement of the two
luciferases. This was followed by an examination of the ability of the
dual assay system to discern the functional interaction of wild type
and mutant p53 when co-expressed with MDM2 or 53BP1 and the
effects of RITA and Nutlin. Our results establish that the functional
interactions as well as the impact of the small molecules were distinct
and depend on the nature of the p53mutants. The responsiveness to
these chemicals did not extend to PRIMA-1 which has been
reported to restore apoptotic activity of specific tumor-associated
p53 missense mutants in engineered cancer cells [34,35,36]. We
propose that our dual-luciferase yeast assay can be applied to the
study of small molecules in order to investigate their differential
impact on a large number of tumor-associated p53mutations as well
as partial inactivation of wild type p53 [37]. Furthermore, unlike
other p53 screening systems, our genetically well-defined, cell-based
assay can be applied to high-throughput screening (HTS) of
chemicals toward a matrix of factors that can influence the p53
network including p53 protein levels, p53 mutations, nature of the
p53 REs, and level of p53-interacting proteins.
Materials and Methods
Drugs, plasmids and media
RITA was purchased from Cayman Chemical (Cayman
Europe, Tallinn, Estonia), Nutlin from Alexis Biochemicals (Enzo
Life Sciences, Milan, Italy), and PRIMA-1 was obtained from
Inalco (Inalco, Milan, Italy). Stock solutions of the compounds
were prepared at the concentration of 10 mM; RITA and Nutlin
were prepared in DMSO while PRIMA-1 was dissolved in water.
Working dilutions were freshly prepared in yeast culture media
immediately before treatment.
pTSG-hp53 was used to express human wild type or mutant
p53 protein under the control of the GAL1 inducible promoter.
The plasmid is based on the centromeric pRS314 vector and
contains the TRP1 selection marker. Plasmids pRB254 and
pRB759 were used to express MDM2 and 53BP1, respectively.
These HIS3-marked plasmids were obtained from Rainer
Brachmann (Irvine University, CA, USA) and contain full-length
MDM2 or a 53BP1 fragment lacking the first 970 amino acids,
that are constitutively expressed under the PGK1 and ADH1
promoter, respectively. Given that our luciferase reporter strains
could not support HIS3-based plasmid selection due to a cryptic
mutation in the histidine biosynthesis pathway, to conduct
experiments with the co-expression of p53 and MDM2 or
53BP1 we constructed a diploid yeast reporter strain by mating
our strain (whose construction is described below) yLFM-PUMA,
RFM-M2, Dpdr5 [Mata his-, leu2, trp1, ura3, ade2::cyc1-LUC,
pdr5::cyc1-REN] with the BY4704 strain (Mata ade2::hisG; Dhis3-
200; leu2-D0; lys2-D0; met15-D0; trp1-D63, where ‘‘D0’’ indicates
complete removal of the ORF sequence). The resulting diploid is
heterozygous for Dpdr5. Plasmids were transformed into yeast cells
using the standard LiAc protocol. Transformants were picked and
purified on selective plates containing glucose as carbon source.
To conduct the luciferase assays while exploiting variable
induction of p53 proteins, yeast cells were cultured in liquid
media containing 2% raffinose (Sigma-Aldrich, Milan, Italy) as
carbon source or 2% raffinose supplemented with different
amount of galactose (Sigma-Aldrich) as inducer of the GAL1
promoter (as indicated in the Results section and Figure Legends)
following the protocol developed previously [31,32,33,38]. All
media components were obtained from BD-Bioscience (BD-
Biosciences Italy, Milan, Italy) or Sigma-Aldrich. 5-Fluoroorotic
Acid was purchased from Toronto Research Chemicals Inc.
(North York, Ontario, Canada). The integrative plasmid
pdr1DBD-repressor (sin3) was a generous gift of Dr. John Nitiss
(St. Jude Children’s Hospital, TN, USA) and was used to disrupt
the regulator of the ABC transporter system PDR1 gene by
replacing it with a fusion construct whereby the PDR1 DNA
binding domain is fused with the SIN3 transcriptional repression
domain [39].
Development of dual-luciferase yeast reporter strains
The Renilla luciferase open reading frame (ORF) was amplified
from the pRL-SV40 vector (Promega, Milan, Italy) and integrated
at the ADE2 locus using the delitto perfetto approach [40] starting
from the available y-FM-cyc1-ICORE- strain [32]. This strain
contains the targeting module, consisting of the I-SceI recognition
site and GAL1-I-SceI expression cassette, that provides for
generation of a single, site-specific double strand break by the
homing endonuclease I-SceI. The targeting module also contains a
URA3 and a KANMX4 marker, respectively, for counter-selection
on plates containing 5-fluoro-orotic acid and forward selection for
G418 resistance [41]. The ICORE was integrated by exploiting
homologous recombination downstream of the minimal CYC1
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promoter and in place of the ADE2 ORF in the previously
developed yAFM strains [38]. ICORE replacement with the
Renilla ORF resulted in the yRFM (R = Renilla) strain which was
further modified by introducing the ICORE cassette upstream of
the minimal CYC1 promoter. The resulting yRFM-ICORE strain
was then used to develop desired p53 RE insertions upstream of
the CYC1 promoter by targeting the ICORE site with oligonucle-
otides containing the chosen RE sequences, as previously
described [38]. To develop dual-luciferase yeast reporter strains
two approaches were followed. To construct an isogenic diploid
reporter, the yRFM strain, in which Renilla is expressed at basal
levels, was transformed by pGAL-HO plasmid [42,43] and
cultured in galactose to induce expression of the HO endonuclease
in order to induce mating type switching. The yRFM, Mata
derivatives were identified by crosses with mating type testers,
purified and then used in a cross with the yLFM-PUMA p53
reporter strain. The resulting diploid strain is isogenic, but hetero-
allelic at the ADE2 locus, in that one chromosome contains the
Firefly luciferase, while the other contains Renilla. The diploid
version of the assay was used for the experiments investigating the
impact of MDM2 or 53BP1 on p53 transactivation potential.
A haploid dual-luciferase reporter strain was also developed
placing the CYC1-Renilla construct at the PDR5 locus. First, we
targeted the PDR5 gene that codes for a p-glycoprotein whose
disruption results in increased sensitivity to a broad spectrum of
chemicals [44]. To this aim the PDR5 gene was modified by PCR-
mediated integration of the ICORE disruption cassette starting
from the yLFM-PUMA strain. The resulting yLFM-PUMA
pdr5::ICORE strain was then further modified by replacing the
ICORE cassette with a PCR product obtained by amplifying the
Renilla reporter cDNA starting from the yRFM strain and using
PCR primers containing tails of homology for the ICORE
integration flanking sites at the PDR5 locus. Alternatively, the
ICORE cassette was removed from the PDR5 locus using a short
oligonucleotide to simply recycle the cassette and leave a complete
deletion of the targeted gene. Sequences of all primers for targeting
and colony PCR analysis are available upon request.
Small volume dual luciferase assays in yeast
Yeast transformants were selected on plates selective for the
presence of the p53/MDM2/53BP1 expression vectors. Overnight
cultures (1 ml) were grown in glucose liquid medium to keep p53
expression repressed. The cultures were then washed in selective
medium containing 2% raffinose as carbon source and diluted to
OD600nm ,0.1 in media containing 2% raffinose and a desired
amount of galactose (see Results section) for the induction of the
GAL1 promoter that drives p53 expression. 100 ml of cell
suspensions were placed in 96-well plates. When needed the
desired concentration of the small molecules RITA, Nutlin and
PRIMA-1 were added to the cell suspension in the 96-well format.
The 96-well plate was then incubated for 16 hrs at 30uC under
moderate (150 rpm) orbital shaking. Immediately prior to the
luciferase assays, cultures were resuspended and 10 ml were
transferred to a white 384-well plate. OD600 was directly measured
in the 96-well plate. For the luciferase assay, 10 ml of PLB buffer
2X (Passive Lysis Buffer, Promega, Milan, Italy) were added to the
10 ml cell cultures, and the 384-well plate was placed on a
thermomixer and incubated for 15 min at room temperature with
the shaker set at 500 rpm. 10 ml of Firefly luciferase Bright Glo
substrate (Promega, Milan, Italy) were then added to the cell
suspension and light units were measured in a plate reader
(Mithras LB940 plate reader -Berthold Technologies, Milan, Italy
or Infinite M-200, Tecan, Milan, Italy). For the dual-luciferase
assay, 5 ml of the Firefly luciferase substrate (Luciferase Assay
Reagent, LARII, Promega) followed by 5 ml of the Stop&Glow
buffer were used instead of the Bright Glo, (Promega) to measure
Renilla activity.
Larger volume luciferase assay in yeast
The results obtained with the newly developed small volume
luciferase assay were compared to those obtained with an
intermediate protocol that utilized 1 ml liquid cultures to induce
p53 expression. Luciferase activity was determined without the
laborious extraction of soluble proteins by mechanical lysis and
centrifugation. To this aim, 0.5 ml of the cultures were collected
by centrifugation after the 16-hour growth in the desired p53-
inducing conditions. Cells were suspended in 0.5 ml of 1x PLB (or
CCLR) lysis buffer and incubated for 15 min. at room
temperature. 10 ml of cell suspensions were then transferred to a
white 96-well plate and 50 ml of Bright Glo reagent were added for
the luciferase assay. 100 ml of the cell suspension were also
transferred to a transparent 96-well plate to measure the OD600nm
that was used as normalizing factor. The dual luciferase assay was
developed similarly, except for the use of 10 ml of the Firefly
substrate and 10 ml Stop&GlowH Renilla substrate.
Protein extraction and luciferase assay
The results obtained with the newly developed small volume
luciferase assay were also compared with the previously developed
protocol that relies on 1 to 2 ml liquid cultures of yeast
transformants and soluble protein extraction [31,45]. Briefly,
purified transformants with the desired p53 expression plasmids
were cultured to induce p53 expression for 16 hrs in 2 ml of
synthetic selective medium. Cells were then collected by
centrifugation, washed in sterile water and suspended in 100 ml
of GLO lysis buffer (Promega, Milan Italy) and an equal volume of
pre-chilled glass-beads (,0.5 mm, Sigma-Aldrich) was added.
Protein lysates were obtained from mechanical lysis of the cells
obtained using a vortex mixer. Protein extracts were cleared by
centrifugation (15 min at ,16000 g at 4uC) and quantified using
the BCA Protein Assay (Pierce Biotechnology, Milan, Italy).
Luciferase activity was measured using a multilable Mithras
LB940 plate reader (Berthold technologies, Milan, Italy) or Infinite
M-200 plate reader (Tecan) using 10 ml of extracts and 50 ml of the
Bright-Glo assay reagent (Promega).
Western Blot
Yeast transformants were grown overnight in selective galac-
tose-containing medium and an equivalent amount of cells, based
on the culture absorbance measurement (OD600nm), were collected
the day after in 1.5 ml tubes by centrifugation (1 min614000 g).
Cells were washed once with 1 ml of sterile water and harvested
again by centrifugation. Pellets were then resuspended in 300 ml of
lysis buffer (0.025 M Tris-HCl pH 6.8, 0.015 M NaCl, 10%
glycerol, additioned with 0.01 M PMSF and 1x complete protease
inhibitor cocktail (Roche, Milan, Italy). One volume of acid-
washed glass beads (0.4–0.5 mm diameter, Sigma, Milan, Italy)
was added to the cell suspension and lysis was obtained by 6 cycles
of 30 sec. vortex at high setting, each followed by 30 sec. on ice.
Soluble proteins were then obtained after centrifugation at 4uC for
10 min. at maximun speed. Supernants were transferred and
proteins quantified using the BCATM method (Pierce, Thermo
Scientific Milan, Italy). Protein extracts were boiled at 95uC for
5 min., resolved with SDS-Page on 7.5% BisTris Acrylamide gels
using a Biorad MiniProtean III apparatus (Bio-Rad, Milan, Italy)
and transferred to Nitrocellulose or PVDF membranes using the
semidry iBlot system (Life Technologies, Milan, Italy). After
blotting the quality as well as the equal loading and transfer of
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protein blots was determined by Ponceau S staining. The
membranes were probed with monoclonal or polyclonal antibod-
ies specific for p53 (pAb1801 and DO-1, Santa Cruz Biotechnol-
ogy) MDM2 (SMP14, Santa Cruz Biotechnology, D.B.A. Italia,
Milan, Italy) and actin (I-19-R, Santa Cruz Biotechnology). The
relative Molecular mass (Mr) of the immunoreactive bands was
determined using molecular weight markers (Fermentas, Milan,
Italy). After washing, blots were incubated with the appropriate
IgG- horseradish peroxidase conjugated secondary antibody
(Santa Cruz Biotechnology), and immune complexes were
visualized with ECL plus reagent (GE Healthcare) using a
Molecular Imager ChemiDoc XRS+ system (Bio-Rad). Band
intensities were quantified using the Image-Lab software (Bio-
Rad).
Results
Development of a small-volume, dual-luciferase assay to
study p53 transactivation potential
In previous studies [30,31,32,33,38], we reported several
modifications to the original yeast-based ADE2 color (red/white)
p53 functional assay [46]. The p53 gene was placed under the
control of the finely-tuned inducible GAL1,10 promoter (‘‘rheos-
tatable’’) to address transcriptional issues that are dependent upon
protein levels. This system revealed subtle differences in p53
function at many target sequences and identified mutants with
enhanced or altered transactivation capacity including change-of-
spectrum mutants [47]. The ADE2 reporter was replaced with the
more quantitative Firefly luciferase and the system incorporated a
convenient in vivo mutagenesis system based on oligonucleotides
[40] that enabled us to easily create isogenic yeast reporter strains
differing only in the p53 RE target sequence driving the luciferase
reporter [38]. The resulting system provided opportunities to
address the transactivation potential of p53REs, functional SNPs
in p53 REs and noncanonical REs [30,31,32,33].
While very informative, the requirement for 1 to 2 ml cultures
per experimental condition and soluble protein extraction to
quantify Firefly luciferase activity limited the experimental
opportunities. Thus, we sought to develop a miniaturized system
that did not require protein extraction. As described in the
following, we found that cells in growth phase as well as stationary
of both the haploid and diploid strains we developed could be
permeabilized for uptake of luciferase substrate if resuspended in
Passive Lysis Buffer (PLB) or Cell Culture Lysis Reagent (CCLR)
from Promega (Milan, Italy) without leading to the appearance of
soluble protein in the solution. There was a time-dependent loss of
viability in PLB buffer (survival was,10% after 1 hr incubation at
room temperature). Cells were incubated for 10 min in the PLB
prior to the addition of the Firefly luciferase substrate. Since the
permeabilized cells retained structural integrity, the optical
densities (OD600nm) of cell suspensions could be used for
normalization. The assay provides robust measurement of p53-
dependent transactivation, as shown in Figure 1A. The transacti-
vation potential of wild type (WT) p53 and the D368 deletion
mutant lacking the regulatory domain in the p53 carboxy terminus
(C-ter) were determined using three reporter strains and four
galactose concentrations to modulate p53 expression. The results
are in agreement with our previous analysis of the same p53
proteins and REs using luciferase measurements following protein
extraction [31].
We also examined the robustness of the system for detecting
luciferase activity within small culture volumes (100 ml) using 96-
well plates and sampling 10 ml aliquots. In these experiments both
WT and the partially functional R282Q mutant were expressed at
variable levels under the inducible GAL1 promoter (Figure 1B and
C) as well as under the constitutive ADH1 promoter (Supporting
Information S1). Relative transactivation potential was measured
from four p53 REs: the strongly responsive P21-59, the moderate
GADD45 and PUMA and the weaker AIP1 [38]. Again, the
results were comparable to those obtained with the traditional
protein extraction and luciferase protocol (compare Figure 1B with
Figure 1C) supporting the use of luminescent reporters, permea-
bilized cells, and small volumes to assess p53 transcriptional
functions as well as providing a high-throughput format.
Genetic modification of reporter strains to improve drug
accumulation
To make our assay more suitable to test different kind of
molecules, we modified the ABC transporter genes to increase the
accumulation of small molecules. Specifically, we took advantage
of a disruption cassette for the PDR1 (pleiotropic drug resistance)
gene, a regulator of the ABC-transporter system, that replaces the
WT gene with a chimeric construct in which the PDR1 DNA
binding domain is fused to a transcriptional repressor domain.
This chimeric gene provides dominant enhanced sensitivity to a
variety of chemicals [39] in yeast. We also disrupted the p-
glycoprotein gene PDR5, resulting in increased sensitivity to a
broad spectrum of chemicals [44,48,49]. Growth of the ABC
mutants was examined in liquid cultures under the same
conditions used for the luciferase protocol described above (see
Materials and Methods). As shown in Figure 1D, the growth rates
appeared comparable to WT in raffinose and galactose-containing
medium after an initial delay following transfer from glucose
medium (Figure 1D). The same results were observed both in rich
and synthetic, glucose-containing medium (Supporting Informa-
tion S1 and data not shown). For all the galactose concentrations
used in this study (up to 0.064%) we did not detect an impact of
p53 expression on growth parameters of the yeast cultures nor a
distinct impact of the genetic modifications targeting the ABC
transporter system (not shown). To examine the impact of these
genetic modifications on drug accumulation in our strain
background, we evaluated the toxicity of cycloheximide [39]
(Supporting Information S1). Results confirmed that both PDR1
and PDR5 disruption rendered the cells more sensitive to the drug.
The pdr5 mutant was the most sensitive although, surprisingly, the
double mutant pdr1, pdr5 exhibited a slightly reduced sensitivity
compared to pdr5. Although the specific impact of the PDR1 or
PDR5 deletions could be dependent on the nature of the small
molecule tested [48], based on the observed relative sensitivity in
this work we focused on the pdr5 mutant to develop the
modifications of the yeast-based assay.
Dual-luciferase system to study p53-dependent
transactivation
The system was further modified to include a Renilla reniformis
cDNA luminescent reporter that could be used for internal
normalization rather than relying on cell density. We established
that Renilla activity can also be measured in cell suspensions
prepared in PLB or CCLR lysis buffers by comparing p53-
dependent transactivation potential in a pair of strains containing
the Firefly or the Renilla reporters cloned downstream of the
moderate p53 RE derived from the human PUMA target gene
(the OD provided a normalizing parameter), as shown in
Figure 2A. To develop the Renilla reporter as an internal standard,
the Renilla cDNA was placed downstream from the minimal CYC1
promoter, previously used for the Firefly luciferase [38] without the
introduction of a p53 RE. This CYC1-Renilla minimal promoter-
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Figure 1. Generation of a small volume format for p53 functional assays. (A) Relative transactivation capacity of WT p53 and a carboxy
terminal deletion measured in permeabilized cell cultures and normalized to optical density OD. p53 proteins were induced at different levels by
varying the amount of galactose, as indicated. Three different p53 response elements (REs) that differed in relative transactivation capacity from very
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reporter cassette, which provides constitutive basal (low-level)
expression of the control luciferase, was cloned at the PDR5 locus
(pdr5:REN) in the yLFM-PUMA reporter strain. The p53
responsiveness of this dual-luciferase system is depicted in
Figure 2B. Luciferase activities could be detected using only
10 ml of cell suspension and 5 ml of standard luciferase substrate
and were comparable to those obtained using our previous
approaches that involved lysis by glass beads and larger volumes
[31,33].
To directly compare the different approaches for detecting p53
transactivation, the WT p53 and the R282Q mutant were tested
in the following manner: i) 2 ml cultures of cells were lysed with
glass beads; ii) 500 ml of the 2 ml cultures were transferred into
1.5 ml eppendorf tubes and permeabilized with 100 ml of 1x lysis
buffer; and iii) 100 ml cultures were incubated in 96-well plates of
which 10 ml were transferred into 384-well plates and permeabi-
lized by an equal volume of 2x PLB lysis buffer. As shown in
Figure 2C, the miniaturized dual-luciferase assay provides a
sensitive and robust system for addressing p53 dependent
transactivation in a format that is amenable to high-throughput
screens.
Functional interactions between p53 and MDM2 or
53BP1 using the yeast-based dual luciferase assay
A goal in the development of the dual luciferase system was to
obtain a suitable assay to address interactions of p53 with factors
that determine its stability and to identify chemicals that could
modify those interactions. Specifically, we addressed the functional
interaction between p53 and MDM2 and the impact of small
molecules targeting this interaction. MDM2 is a critical inhibitor
of p53 functions that can bind p53 in the amino terminal (N-ter)
region and lead to p53 protein degradation via its E3 ubiquitin-
ligase activity in human cells [50]. For these experiments we
generated diploid reporter strains that could select for the MDM2
expression vector (see Materials and Methods). The diploid cells
were heterozygous for the PDR5 deletion. Consistent with a
previous report [51], we found that in yeast MDM2 co-expression
resulted in a reduction of p53-dependent transactivation. Initially,
we explored the impact of MDM2 on the ability of increasing
amounts of p53 protein to transactivate the ADE2 red/white
reporter from an upstream p53 RE [30,38]. The MDM2 cDNA
was expressed constitutively under the moderate PGK1 promoter.
Reduction of p53-dependent transactivation by MDM2 was
observed only at very low levels of p53 expression (Supporting
Information S1, raffinose only vs raffinose + galactose plates) and
was affected by amino acid changes in the p53 N-ter mimicking
post-translational modifications. The MDM2 inhibition of p53
activity in this semi-quantitative assay was dependent on the p53
RE examined and was observed only with the highest p53 affinity
REs, p21-59 and CON, being suitable for the ADE2 reporter assay.
The impact of MDM2 on p53 WT and mutants was
subsequently evaluated using a luciferase-based assay. Specifically,
serine/threonine residues in the N-terminal domain were mutated
to mimic phosphorylation events in mammalian cells or to prevent
phosphorylation; these residues are modified as part of the
signaling pathways that activate p53 by influencing protein:protein
interactions including that with MDM2 [52,53,54]. As shown in
Figure 3A, we confirmed that MDM2 could inhibit p53-
dependent transactivation from different p53 REs. The impact
of the mutations was in part dependent on the nature of the p53
RE driving Firefly luciferase expression. In particular the T18E and
S20D p53 mutants were less sensitive to MDM2-dependent
inhibition of transcription at a moderate RE (Killer/DR5) than
with a strong RE (p21-59). On the contrary, transactivation at
either RE by p53 mutants mimicking constitutive phosphorylation
(referred to as ‘‘4D’’ and ‘‘6D’’ in the figure) was largely insensitive
to co-expressed MDM2. The transactivation potential of those N-
ter p53 mutants when expressed alone was comparable to WT p53
with the exception of the multiple mutant 6A, where the
concomitant change of Ser 15, 20, 33, 37, 46 as well as of
threonine 18 into alanine resulted in approximately three-fold
higher activity (Supporting Information S1).
The impact of MDM2 co-expression on WT p53 protein levels
was also assessed using western blot analysis (Figure 3B & C). p53
protein levels were determined from cells grown in glucose (steady-
state) or from cells grown in galactose for 16 hrs to induce p53 and
then transferred to glucose media to repress the transcription of
the p53 cDNA to estimate the p53 protein half life in yeast. p53
protein amounts were quantified relative to b-actin loading
control. A 10% reduction in steady-state p53 protein amount
due to the co-expression of MDM2 was observed in the galactose-
induced cultures (Figure 3B lanes 3 & 4). Furthermore, MDM2
appeared to reduce p53 half life in yeast, based on relative
quantitation of the immunoblot at the various time points after the
transfer of the cells to glucose medium. p53 half life was estimated
to be ,2.5 hours in cells that express MDM2 and 5 hours when
MDM2 was not expressed (Figure 3C). MDM2 protein levels also
appeared to vary during the experiment, in relation to the growth
phase of the cultures. A previous study reported that the PGK1
promoter that controls MDM2 cDNA expression in the vector we
used, could be severely repressed in stationary phase cells, while
remaining largely unaffected by changes of carbon sources in the
medium [55]. It is important to note that all the luciferase assays in
our work were conducted in cultures grown for 16 hrs in
galactose-containing medium, when cells are still in a late-
logarithmic culture phase. A previous study in yeast where
MDM2 and p53 were co-expressed under a GAL promoter
reported a similar impact of MDM2 on p53 protein half life [56].
Overall, these results strongly suggest that the functional
interaction between p53 and MDM2 is at least in part dependent
strong (CON, an optimized consensus sequence), to strong (P21, corresponding to the p21-59 site) and to moderate (GADD45). OD of the cultures was
used as normalizing factor. Presented are the average measurements and standard deviations of three biological replicates. (B, C) Small-volume yeast
cultures can determine p53 transactivation capacityRelative transactivation capacity of WT and the R282Q p53 have been compared towards four
different REs obtained with the traditional assay based on 2ml liquid cultures in individual tubes (B) and with the permeabilized assay format based
on 100 ml cultures prepared directly in 96-well plates (C). p53 proteins were induced at different levels by varying the amount of galactose, as
indicated. A strong (P21), two moderate (PUMA, GADD45) and a weak RE (AIP1) were compared. Cells collected from the two different culture
protocols were used for the measurement of luciferase activity as described in the Materials and Methods section. Presented are the average fold-
induction of luciferase by p53 proteins relative to the activity obtained with an empty vector; included is the standard deviations of three replicates.
(D) Impact of genetic modifications of the ABC-transporter systems on yeast growth. Overnight liquid cultures in synthetic medium containing
glucose were washed and resuspended in fresh medium containing raffinose (2%) as the carbon source and low levels of galactose (0.0032%) (time
zero) to induce p53 protein expression. Cultures were diluted to ,0.1 OD600nm, as measured by a plate reader. OD was measured at the 6, 12, 24hr
time intervals. Error bars plot the standard deviations of three biological replicates. The average absorbances are also presented to the right of the
graph.
doi:10.1371/journal.pone.0020643.g001
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on the same amino acids in the p53 N-ter domain as in
mammalian cells but does not lead to a strong reduction in p53
protein stability. Thus, the impact of MDM2 in yeast is likely due
to a competing effect for p53 binding to components of the
transcription machinery, as suggested previously [51].
We extended the study of p53 interactors in the dual-luciferase
system to 53BP1 using a yeast-expression vector containing a
53BP1 clone with N-ter deletion of the first 970 amino acids [51].
53BP1 was identified in a 2-hybrid screen by its ability to bind the
DNA binding domain (DBD) of p53 through the BRCT domains
present in the C terminal region (C-ter) of 53BP1 [57]. While
53BP1 was shown to act as a positive cofactor for p53 function in
human cells [58], its co-expression with p53 (WT or mutant) in our
yeast-based assay led to a reduction in p53-dependent transactiva-
tion (Figure 4 and 5C), consistent with a previous study [51]. This
result indicates that 53BP1 might compete with p53 for sequence-
specific binding to DNA. Unlike the general inhibition by MDM2,
the impact of 53BP1 differed towards specific partial-function p53
missense mutants, consistent with the p53:53BP1 physical
interaction. For example, transactivation by the R181L and
R282Q mutant proteins were slightly or not affected by 53BP1,
while the transactivation by A119V, P219L and R283H was
reduced by co-expression of 53BP1 (Figure 4).
The small molecules Nutlin and RITA can reduce the
inhibitory effects of MDM2 and 53BP1
Using the dual luciferase system we then investigated the
impact of two well-known small molecules than can affect p53,
namely Nutlin and RITA. The former can disrupt the interaction
between p53 and MDM2 by binding to MDM2 while RITA can
interfere on the same interaction by targeting p53, possibly
leading to conformational changes [59]. As summarized in
Supporting Information S1, we did not observe a significant
impact on yeast growth under the conditions used for the WT
strain or for the ABC-transporter mutants, although the mutants
experienced a delay in growth following the shift in media (also
described in Figure 1). While Nutlin had little impact on
transactivation by p53 alone it counteracted the negative impact
of MDM2 (Figure 5A).
Treatment with RITA led to a severe reduction in p53-
dependent Firefly luciferase activity (Figure 5B). However, also the
basal luciferase activity was affected by RITA, indicating that the
effect might not be related to p53. A negative impact of RITA on
Firefly luciferase activity was previously reported in mammalian
cells [60]. However, RITA had no impact on the basal activity of
the Renilla luciferase. We, therefore, constructed a dual luciferase
reporter strain in which the Renilla luciferase was placed under p53
transcriptional control. In this strain, treatment with RITA had no
effect on p53-induced transactivation detected by the Renilla
luciferase (Supporting Information S1). After taking into account
the impact of RITA on basal Firefly luciferase activity, we were
able to show that RITA could partially relieve the inhibition of
p53-dependent transactivation by MDM2 (Figure 5C). The
impact of Nutlin and RITA on the p53/53BP1 functional
interaction was also examined. Treatment with Nutlin did not
modify the 53BP1-dependent inhibition of p53-dependent trans-
activation (Figure 5C). However, the inhibition was partially
relieved by RITA. Western blot analysis confirmed that MDM2
co-expression had little impact on p53 protein levels after culturing
cells for 16 hrs in 0.012% galactose. Interestingly, treatment with
Nutlin but not RITA appeared to reduce MDM2 expression/
stability (Figure 5D).
PRIMA-1 exhibited an apparent lack of impact on p53
mutants
The dual luciferase system was investigated for its responsive-
ness to PRIMA-1, a small molecule identified in a mammalian
cell-based screen for chemicals that could induce apoptosis in a
mutant p53-dependent manner [35]. PRIMA-1 restored se-
quence-specific DNA-binding and transcriptional transactivation
to mutant p53 in vitro, possibly through altering mutant p53
conformation or folding stability [61] although the precise
mechanism remains to be determined. To examine the impact
of PRIMA-1, we chose a panel of p53 mutations that differ in
their relative transactivation capacity in the yeast-based assay.
Four loss-of-function mutants were tested, including the two
cancer hotspot mutants R175H and R273H that were shown to
be responsive to PRIMA in human cells [35]. We also examined
5 partial function p53 mutations since they could register negative
and positive impacts of small molecules. The transactivation
potential of the p53 mutants ranged from 50 to 80% of the WT
protein in the reporter strain containing the PUMA p53 RE
under moderate expression from the GAL1 promoter. As
described in the supplementary material, we were unable to
detect any effect of PRIMA-1 on transcription by WT or mutant
p53 in WT (not shown) or in pdr5 mutant cells (Supporting
Information S1).
Discussion
In this study we have greatly expanded the features of our
previously described yeast strains for assessing p53 and p53 RE
function in order to develop a system that is both more efficient
and miniaturized. The system provides for rapid assessment of p53
transactivation potential as well as the impact of p53 mutations,
cofactors and small molecules. In particular, it integrates variable
expression of p53 proteins under the finely tunable GAL1
promoter, single copy luminescence reporters that are chromo-
somally located with opportunities to co-express p53 alleles along
with chosen cofactor proteins coded from selectable low copy
number plasmids. Furthermore, the assay is based on a small-
volume format for p53 expression, treatment with chemicals, and
quantification of the reporter expression and is compatible with
high-throughput screening.
Figure 2. Either Firefly or Renilla luciferase can function as p53-dependent reporters. (A) The ability of Firefly and Renilla cDNAs to serve as
reporters for p53 transactivation was examined by placing them downstream from the moderate p53 RE derived from the PUMA promoter in
isogenic strains. The values indicate the fold induction measured over an empty vector. Presented are average and standard deviations of three
replicates relative to optical density of the cultures measured at different times (T in hrs) after switching cultures to galactose-containing medium. (B)
Dual luciferase reporter assay with a strain expressing WT p53 and containing the Firefly luciferase as p53 reporter gene and the Renilla luciferase as
constitutive reporter. Presented are the average and standard error of the Firefly luciferase activities normalized for Renilla and compared to empty
vector at various time points after shifting 100 ml yeast cultures to galactose-containing media in the 96-well plate format. (C) Comparison of relative
induction using measurement of protein from 2 ml cultures vs direct permeabilization of cells in a 384 well format following transfer from a 96-well
growth plate, as described in the text and the Materials and Methods section. Relative transactivation capacities of WT p53 and the R282Q mutant in
the ‘‘2 ml vial’’experimental set-ups were measured using either protein extraction or permeabilization. Experiments were conducted using 0.032%
galactose inducer, unless specified otherwise. Error bars plot the standard error of four biological replicates.
doi:10.1371/journal.pone.0020643.g002
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Figure 3. MDM2 co-expression reduces WT and mutant p53-dependent transactivation and can impact p53 protein level and
stability. (A) The functional interaction between p53 and MDM2 was examined using two different reporter strains, as indicated. Transformants were
cultured in 0.012% galactose to achieve low expression of p53 for 16 hours. MDM2 is expressed under the constitutive PGK1 promoter. Besides WT
p53, several mutants at Ser/Thr in the p53 N-ter were tested. The activity of each p53 mutant was set to one to better focus on the relative impact of
MDM2 co-expression on p53 transactivation capacity. The relative transactivation potential of the various p53 mutants is presented in Supporting
Information S1; 4D refers to a quadrupole mutant with S15D, T18E, S20D, S33D changes in p53 . 6A indicates a multiple mutant with alanine changes
at S15, T18, S20, S33, S37, S46. 6D indicates a multiple mutant with aspartic acid changes at S15, S20, S33, S37, S46 and a glutamic acid change at T18.
Presented are the average fold-inductions by p53 proteins compared to empty vector and normalized using the Renilla control luciferase. These
assays were conducted with diploid strains that were obtained by crossing the indicated yLFM- p53 reporter strains with the BY4704 strain (see
Materials and Method section) using the permeabilized format. (B) Western blot analyses of p53 and MDM2 protein levels. O/N cultures in synthetic
glucose medium (GLU) were washed and shifted to medium containing raffinose and 0.012% galactose (GAL) to achieve low expression of p53. The
p53 was expressed under the inducible GAL1 promoter while MDM2 was expressed at constitutive levels from a moderate PGK1 promoter. After
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Interactions with p53-cofactor proteins
Specifically, we have established that the new, dual-luciferase
based protocol can assess p53-dependent transactivation and the
impact of single amino acid changes in the p53 DBD. We found
that co-expression of MDM2 can lead to reduced p53 transactiva-
tion at low levels of p53 protein expression. p53 mutants at the
DBD that have partial transactivation function were also inhibited
by MDM2, whereas mutations introduced into the p53 N-ter
domain that mimic phosphorylation events could relieve p53 from
the MDM2-dependent inhibition. Those same amino acid changes
did not alter significantly the transactivation potential of the p53
protein, when expressed alone. This suggests that the assay can be
used to reveal ectopic p53:MDM2 physical interactions that are
likely to occur at the p53 N-ter region, similar to the endogenous
interaction in higher eukaryote cells. The assay also revealed a
modest impact of MDM2 on p53 protein stability in yeast.
Although MDM2 was recently found to bind p53 at the DNA
binding domain (DBD) and at the C-ter [62], the primary site of
interaction occurs at the transactivation domain (TAD) in the p53
N-ter region [63].
We also examined the impact on p53 transaction of another
important p53 cofactor, the protein 53BP1. The BRCT domains
present in the 53BP1 C-ter are required for the interaction with
p53 as well as with other important proteins such as BRCA1 [57].
The physical and functional interactions between p53 and 53BP1
in the context of DNA damage response appears to be complex.
Following DNA damage, 53BP1 can localize to nuclear foci in
mammalian cells, is rapidly phosphorylated in an ATM-dependent
manner [64], and is essential for DNA double strand break repair
[65]. Furthermore, 53BP1 appears to be an important mediator of
the induction of senescence and cell death pathways elicited by
BRCA1 deficiency in mice [66]. A crystal structure of p53 DBD
bound to the human 53BP1 BRCT domains led to the
identification of amino acids in the p53 DBD involved in such
interaction [67]. More recently, the Tudor domain of 53BP1 was
shown to interact with p53 proteins dimethylated in the p53 C-ter
region at lysine 382 [68]. The generation of p53 dimethylated at
Lys382 promotes the accumulation of p53 protein that occurs
upon DNA damage but this accumulation is dependent on 53BP1
[69]. These results suggest that the positive coactivator function of
53BP1 towards p53 in mammalian cells [58] may be related to its
positive impact on p53 protein amount. Possibly, 53BP1 reduces
the interaction between p53 and MDM2 (G. Selivanova,
unpublished results).
The co-expression of 53BP1 with p53 leads to a reduction in
p53-dependent transactivation, similar to previously reported
findings in yeast [51]. Unlike MDM2, the impact of 53BP1 was
lost or greatly reduced with specific partial function p53 mutants in
the DBD. For example the p53 R181L mutant was not sensitive to
53BP1. Structural studies showed that p53 R181 formed both a
16 hrs of growth in galactose-containing medium, cells were washed and transferred to glucose medium to repress the GAL1 promoter. Samples
were collected at the indicated time points to prepare protein extracts for western blot. 100 mg (MDM2 and actin, top panel) and 20 mg (p53 and
actin, lower panel) of extract was loaded in each lane. The DO-1, SMP14 and I-19-R antibodies (Santa Cruz) were used for the immunodetection of
p53, MDM2 and actin, respectively.Actin levels were used as a normalization factor to estimate relative MDM2 and p53 amounts. Consistent with a
previous study [55], we observed that MDM2 expression under the PGK1 promoter was affected by the culture state and was particularly reduced
when cell approached the stationary phase (O/N in glucose; T8 and T12 time points; at T12 cells were diluted for the additional 12 hr time point). The
relative changes in MDM2 and p53 protein amounts compared to the level observed in glucose cultures are indicated above the immunoblot. (C)
Quantification of p53 expression relative to the amount observed after 16 hrs in 0.012% galactose, normalized to actin levels. A 10% reduction in
steady-state p53 protein amount due to the co-expression of MDM2 was observed in the galactose-induced cultures. To better visualize the impact of
MDM2 on the estimated p53 half life (EHL) the relative amount of p53 observed after 16 hrs in galactose was set to 100%, both for extracts of cells
expressing only p53 or p53 + MDM2.
doi:10.1371/journal.pone.0020643.g003
Figure 4. Functional interactions between partial function p53 mutants and MDM2 or 53BP1. Mutant p53 expression was under the
control of the GAL1 promoter while MDM2 or 53BP1 (a clone containing a N-ter deletion of the first 970 amino acids) were expressed at constitutive
levels under the PGK1 and ADH1 promoters, respectively. p53 expression was induced for 16 hrs in medium containing 0.012% galactose. Presented
are results describing the impact of MDM2 or 53BP1 on transactivation of various p53 mutants that are capable of partial transactivation toward the
PUMA RE. To better visualize the impact of MDM2 and 53BP1, the activity of each p53 mutant alone is set to 100%. The relative light units of the
various mutants in this experiment were WT p53, 2.16105; A119V, 1.36105; R181L, 0.866105; P219L, 0.876105; R282Q, 0.796105; R283H, 0.536105.
Significant differences in activity relative to p53 alone are shown (*: p,0.01; ‘: p,0.05, Student’s t-test).
doi:10.1371/journal.pone.0020643.g004
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hydrogen bond and stacking interactions with 53BP1 residues in
the BRCT domains [67]. The reduced interaction between the
p53 mutant R282Q and 53BP1 could not be linked to the reported
physical interaction between the two proteins.
Overall, our results indicate that the dual-luciferase yeast-based
assay can be used to study the interaction between p53 and
cofactor proteins. While the functional interaction appears
dependent on conserved physical interactions, the outcomes of
the co-expression on p53-dependent transactivation in the yeast
assay does not always reflect expectations from mammalian cells,
although such discrepancies can be reasonably explained and
related to the defined nature of the assay, as proposed above for
the impact of 53BP1.
Impact of small molecules
Having established that the yeast-based assay can reveal a
functional interaction between p53 and its cofactors MDM2 or
53BP1, we explored the impact of small molecules targeting those
interactions using Nutlin and RITA. Nutlin had been isolated as a
small molecule that interacts with the p53-binding pocket in
MDM2, resulting in accumulation of p53 protein and possibly
inhibition of MDM2 activity towards other of its targets
[10,59,70]. Treatment with Nutlin led to p53 accumulation in a
variety of cancer cell lines, without significant induction of p53
post-translational modifications, and resulted mainly in cell cycle
arrest, although apoptosis was also detected. The compound
showed p53-dependent growth suppression in in vivo experiments
without much evidence for toxicity in nude mice. The small
molecule RITA (reactivation of p53 and induction of tumor cell
apoptosis) was obtained in a cell-based assay screening for
induction of WT p53-dependent apoptosis [25]. Its mechanism
of action appears to be at least in part related to a direct
interaction with the p53 protein and inhibition of the p53-MDM2
binding. Differently from Nutlin, which directly affects the binding
of MDM2 to the amino-terminal region of p53, RITA was
reported to bind the p53 N-ter region and indirectly affect the
Figure 5. Functional interactions between wild type p53 and
MDM2 or 53BP1 and the impact of Nutlin and RITA. WT p53 was
expressed at low-level achieved by culturing cells in medium containing
0.012% galactose for 16 hrs in the 96-well plate format. MDM2 was
expressed from the moderate PGK1 promoter. (A) The impact of MDM2
on p53-dependent transactivation was examined in the presence of
different concentrations of Nutlin added to the medium at the time of
the switch to galactose-containing medium using a reporter strain
containing the moderate PUMA p53 RE. The average transactivation
relative to the basal level of reporter activity measured in cells that do
not express p53 and standard deviations of three biological repeats are
presented. Significant differences in activity relative to p53 alone are
shown (*: p,0.01, Student’s t-test). (B) Firefly luciferase activities
normalized using the control luciferase Renilla are presented for empty
vector and wild type p53 in the presence of different amounts of RITA.
(C) Nutlin and RITA impact on the functional interactions between p53
and MDM2 or 53BP1. Nutlin (20 mM) or RITA (0.5 mM) were added at the
time of switching cultures to galactose-containing medium. The
luciferase activity by wild type p53 alone, normalized using the Renilla
control luciferase, is set at 100%. Both MDM2 and 53BP1 co-expression
reduced p53-dependent transactivation. Nutlin partially relieved the
functional impact of MDM2, but not that of 53BP1. RITA partially
relieved p53 from the inhibition by both MDM2 and 53BP1. Significant
differences are shown (*: p,0.01; ‘: p,0.05, Student’s t-test). (D) MDM2
and p53 immunoblot in mock-, RITA- and Nutlin-treated yeast cells.
Proteins were prepared from cells grown in medium containing 0.012%
galactose for 16 hrs and treated with DMSO solvent control 0.5 mM RITA
or 20 mM Nutlin. 25 mg were loaded to detect p53 and 100 mg of
protein extracts were loaded to probe for MDM2. Actin was used as a
loading control.
doi:10.1371/journal.pone.0020643.g005
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functional interaction with MDM2 [59,70]. RITA could induce
p53-dependent apoptosis in a variety of tumor cell lines [25].
Our results establish that treatment of yeast cells with the small
molecules Nutlin or RITA could partially relieve WT p53 from
the MDM2-dependent inhibition, similar to what is observed in
mammalian cells. Furthermore, while Nutlin treatment had no
impact on the functional interaction between p53 and 53BP1,
RITA was also able to target the p53/53BP1. Combined with the
observation that 53BP1 appeared to interact with p53 mutants in a
manner that is mutant-specific, our results suggest that the yeast-
based assay could be used to screen a large panel of tumor-
associated p53 mutations for differential impact of these chemicals
on p53 functional interaction with cofactors.
Attempts to modify WT or mutant p53 function by PRIMA-1
were unsuccessful. PRIMA-1 was reported to restore the sequence-
specific DNA-binding and transcriptional transactivation of some
p53 mutants in vitro and to suppress tumor-cell growth in mice by
inducing apoptosis (Bykov et al., Nat Med. 2002). Interestingly,
PRIMA-1 inhibited the growth of cell lines derived from various
human tumor types in a mutant p53-dependent manner [71]. The
precise mechanism of action of this compound is not clear;
moreover its selectivity for mutant p53 remains to be fully
established and may also be related to indirect effects on p53
folding and nuclear localization. For example PRIMA-1 induced
the expression of heat shock protein 90 (Hsp90) in breast cancer
cells, restored the p53-Hsp90 interaction and enhanced the
translocation of the p53-Hsp90 complex to the nucleus [72].
Recently the ability of PRIMA-1 to induce nucleolar localization
and degradation of mutant p53 protein has been demonstrated
[73], suggesting the existence of a complex mode of action, likely
cell-type specific, that can be independent from the restoration of
transactivation functions to mutant p53. Indeed, PRIMA-1 fails to
stimulate the DNA binding potential of isolated mutant p53 DBD
in vitro [59]. The apparent lack of effect of PRIMA-1 in our assay
might be due to poor uptake, even in the pdr5 mutant, or
modification of the chemical in yeast. It has been shown that
PRIMA-1 is converted to compounds that forms adducts with
thiols on mutant p53 and such p53 protein modifications can
trigger apoptosis [61]. It might well be that these activating
modifications are impaired in yeast.
Overview
Cell-based functional assays are expected to be useful tools for
identifying molecules targeting mutant p53 or impacting on the
interaction between p53 and cofactors. They can provide unbiased
screening opportunities for leads that act beyond steric hindrance
of protein:protein interactions including allosteric modifiers of
protein folding or stability. Allosteric modulators could be
combined potentially with rationally designed drugs to increase
potency or overcome single agent resistance in vivo [74]. In this
regard initial studies suggest that the combination of Nutlin and
RITA might provide additional stimulation of p53-induced
responses, consistent with the different broad transcriptional
responses induced by the two compounds when given as single
agents [75]. However, off-target effects that impact the biological
endpoints being measured, such as the induction of apoptosis, can
hamper identification of mechanisms of action of molecules
scoring positively in cell-based screening assays. This potentially
limiting feature is especially relevant in the case of proteins like
p53, whose functions are wired into many cell-signaling pathways.
Furthermore, the tremendous variability in tumor-associated p53
mutations and in expression levels of distinct p53-interacting
proteins and p53 splice and promoter variants as well as p53-
related proteins p63 and p73 could significantly affect the outcome
of small molecule treatments. The yeast-based assay described
here has the advantage of generally being free of p53 biological
consequences. Alternatively, assays have been developed that
exploit the impact of moderate/high levels of p53 expression on
the growth of yeast [76,77]. This type of assay provides the
opportunity to score the effect of cofactors or small molecules that
may also act on p53 transcriptional-independent functions.
However, the exact mechanisms of p53-mediated growth
retardation in yeast are not well-defined. The growth retardation
could be, in part, dependent on effects on transcriptional
complexes, based on our previous identification of toxic p53
alleles in yeast that at low expression levels result in enhanced
transactivation capacity and on the loss of the toxicity caused by
second-site loss-of-function missense mutations in p53 ([47,78].
The spectrum of missense p53 mutations associated with
sporadic and familial cancer comprises more than 1200 distinct
sporadic and ,110 germline mutations (www.iarc.fr/P53/) [79].
Furthermore, biochemical, and functional assays have revealed
that the degree of thermodynamic as well as folding instability
caused by the mutations and their impact on sequence-specific
transactivation function can vary greatly [30,80,81]. These
differences could impact the activity of small molecule modifiers.
Furthermore, the efficacy of allosteric modifiers could be
significantly affected by the cellular/nuclear amounts of p53
mutant proteins or by the ratio between wild type p53 and specific
negative cofactors, such as MDM2 or MDM4. Finally, the impact
of small molecules could be, in part, influenced by the nature of
the interaction between p53 and its many different cognate
response elements located in the large number (hundreds) of
human p53 target genes [82,83,84].
In summary, we propose that the miniaturized yeast dual
luciferase system we developed provides a genetically well-defined,
robust and cost-effective assay that can be used in parallel to
mammalian cell-based assays to screen molecules or further
evaluate leads that target p53 functions. A specific advantage of
the assay is the potential for high-throughput assessment of a
matrix of factors that include low and variable levels of p53
proteins, nature of the p53 response elements and specific, disease-
associated p53 mutations. All these variables could impact the
activity of small-molecule modifiers of p53 functions. Our assay
system could be particularly relevant for further characterization
of small molecules that may act as allosteric modifiers of p53
functions or p53-cofactor interactions.
Supporting Information
Supporting Information S1 1. Small-volume yeast func-
tional assay with constitutive expression of p53 pro-
teins. Presented is the comparison of the relative transactivation
capacity of wild type (WT) and the R282Q p53 towards four
different response elements (REs) obtained with the traditional
assay based on 2 ml liquid cultures in individual tubes (A,
traditional assay) and with the permeabilized assay format based
on 100 ml cultures prepared directly in 96-well plates (C,
miniaturized assay). p53 proteins were expressed under the
moderate, constitutive ADH1 promoter. Cells collected from the
two different culture protocols were used for the measurement of
luciferase activity as described in the Materials and Methods
section. Presented are the average fold-induction of luciferase by
p53 proteins relative to the activity obtained with an empty
vector; included is the standard deviations of three replicates. In
these experiments the light units per OD for WT p53 and the
p21-59 RE were 2.86106 for the 2 ml cultures and 2.56107 for
the 100 ml cultures. 2. Impact of genetic modifications at
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the ABC transporter system on cell sensitivity to
cycloheximide. Based on the experiments described by
Stepanov et. al. [39] we used cycloheximide treatment to evaluate
whether the disruption of PDR1 and replacement with the PDR1-
repressor construct, the disruption of PDR5, or the combined
modifications would result in enhanced toxicity in our reporter
strain background. Cells from the indicated strains were
resuspended in sterile water and transferred to a 96-well plate.
Serial dilutions (1:5) were prepared and cells were transferred to
plates containing synthetic medium (SD) with different concen-
trations of cycloheximide using a 48-pin replicator. A rich
(YPDA) and an SD control plates were also spotted for
comparison. Plates were incubated for two days at 30uC. 3.
Phenotypic analysis of the impact of MDM2 on WT and
mutant p53 transactivation. The ADE2-based red/white
assay was used to examine p53 dependent transactivation and the
impact of MDM2. p53 was expressed at low levels under the
GAL1 promoter in media containing only raffinose (2%), or
raffinose plus 0.002%, 0.004% or 0.016%, galactose. MDM2 was
expressed from the constitutive PGK1 promoter. p53 transactiva-
tion was examined from three REs upstream of ADE2-based p53
reporter strains as indicated. The optimized consensus (CON)
and P21-59 p53 RE yield levels of high transactivation while the
NOXA RE is weaker [38]. In the ADE2-based p53 functional
assays, cells grown on plates containing a low-amount of adenine
(5 mg/L) result in small red colonies when p53 is not present or
not transcriptionally active. p53-dependent expression of ADE2
results in the appearance of colonies with a color ranging from
light red to white, depending on the level of transactivation. To
reveal the dependency of the phenotype on p53 expression levels,
streaks are prepared on glucose plates containing high amount of
adenine (200 mg/L) and the plates are incubated for two days at
30uC, resulting in the appearance of white colonies. These plates
are then replica-plated to a stack of plates containing 2%
raffinose plus various levels galactose along with the low-level of
adenine. The replica plates are then incubated at 30uC for 2-3
days. Images of a section of the replicas are presented. For each
image the upper section corresponds to colonies expressing p53
alone, while in the lower section the colonies also express MDM2.
Various multiple mutants were tested, as indicated. 4. Relative
transactivation capacity of p53 phosphorylation-site
mutants. The activity of the p53 mutants described in
Figure 4 is presented as relative light units in two p53 reporter
strains using the Killer/DR5 or the p21-59 REs upstream of a
luciferase reporter. Results were obtained with the traditional
assay format and are normalized to amount of soluble proteins.
4D refers to a quadruple mutant with the S15D, T18E, S20D,
S33D changes in p53. 6A indicates a multiple mutant with
alanine changes at S15, T18, S20, S33, S37, S46. 6D indicates a
multiple mutant with aspartic acid changes at S15, S20, S33, S37,
S46 and a glutamic acid change at T18. 5. Impact of small
molecules Nutlin and RITA on the growth of WT yeast
reporter strains or the isogenic derivatives with
modified chemical uptake. Overnight cultures grown in
synthetic glucose medium were washed and diluted to ,0.1
OD600nm as measured by a plate reader. (A) The WT strain was
treated with 40 mM or 80 mM Nutlin (indicated as nutlin 1 and
nutlin 2 respectively) and 1 mM or 2 mM RITA (indicated as rita1
and rita2). (B) The indicated mutant ABC-transporter strains
were treated with1 mM RITA (or DMSO solvent control). OD
was measured at the following times: 2, 4, 8, 12 and 24 hrs. Error
bars correspond to the standard deviations of three biological
replicates. 6. Negative impact of RITA on the Firefly
luciferase but not the Renilla luciferase. To confirm that
the negative impact of RITA on the Firefly reporter was not
dependent on modulation of p53 transactivation, an isogenic
derivative strain was developed containing the PUMA p53 RE
upstream of the Renilla luciferase. Wild-type p53-dependent
transactivation was examined in cultures treated with DMSO
control solvent or with 1 mM RITA. Presented are relative light
units normalized to OD600nm of the cultures. The error bars
correspond to standard deviations for three biological repeats. 7.
Apparent lack of PRIMA-1 effects on yeast growth or
p53-dependent transactivation. (A) The small molecule
PRIMA-1 does not affect yeast growth. Overnight cultures grown in
synthetic glucose medium were washed, diluted to ,0.1
OD600nm, as measured by a plate reader, and treated with
200 mM PRIMA-1. Growth curves were compared for the wild
type strain or the indicated ABC-transporter mutants. OD600nm-
was measured at the 2-, 4-, 8-, 12- and 24-hr time points.
Presented are standard deviations for three biological repeats. (B)
The small molecule PRIMA-1 does not impact wild type p53 transactivation
capacity. Cells were grown in glucose-containing media to keep
p53 expression repressed and transferred to galactose-containing
media followed by the addition of PRIMA-1. Dual luciferase
assays were conducted 16 hrs after the treatment. Renilla
luciferase was used as normalization factor. There was no
significant effect of PRIMA-1 on WT p53 transactivation. The
same result was obtained with a diploid yeast strain, in which
both the p53-dependent reporter (Firefly) and the control
luciferase (Renilla) were placed at the ADE2 chromosomal locus
(i.e., heteroalleles), thus removing potential chromatin effects on
reporter expression. The diploid strain was obtained starting from
two isogenic isolates of our yLFM strain background that differ
for the mating type locus. Presented is the fold-induction of the
Firefly reporter over the Renilla reporter relative to strains that do
not express p53, as they contain an empty expression vector. (C)
The small molecule PRIMA-1 does not affect mutant p53 transactivation
capacity. Different p53 alleles were expressed at moderate levels
using medium containing 0.128% galactose. PRIMA-1 (200 mM)
was added to the cultures at the time of the switch to galactose-
containing medium. Presented are the average fold-induction by
p53 proteins compared to empty vector and normalized using the
Renilla control luciferase. Presented are standard deviations for
three biological repeats.
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Supporting Information 
1.	  Small-­‐volume	  yeast	  functional	  assay	  with	  constitutive	  expression	  of	  p53	  proteins.	  Presented	  
is	  the	  comparison	  of	  the	  relative	  transactivation	  capacity	  of	  wild	  type	  (WT)	  and	  the	  R282Q	  p53	  
towards	  four	  different	  response	  elements	  (REs)	  obtained	  with	  the	  traditional	  assay	  based	  on	  2	  ml	  
liquid	  cultures	  in	  individual	  tubes	  (A,	  traditional	  assay)	  and	  with	  the	  permeabilized	  assay	  format	  
based	  on	  100	  µl	  cultures	  prepared	  directly	  in	  96-­‐well	  plates	  (C,	  miniaturized	  assay).	  p53	  proteins	  
were	  expressed	  under	  the	  moderate,	  constitutive	  ADH1	  promoter.	  Cells	  collected	  from	  the	  two	  
different	  culture	  protocols	  were	  used	  for	  the	  measurement	  of	  luciferase	  activity	  as	  described	  in	  
the	  Materials	  and	  Methods	  section.	  Presented	  are	  the	  average	  fold-­‐induction	  of	  luciferase	  by	  p53	  
proteins	  relative	  to	  the	  activity	  obtained	  with	  an	  empty	  vector;	  included	  is	  the	  standard	  deviations	  
of	  three	  replicates.	  In	  these	  experiments	  the	  light	  units	  per	  OD	  for	  WT	  p53	  and	  the	  p21-­‐5 	  RE	  
were	  2.8×106	  for	  the	  2	  ml	  cultures	  and	  2.5×107	  for	  the	  100	  µl	  cultures.	  2.	  Impact	  of	  genetic	  
modifications	  at	  the	  ABC	  transporter	  system	  on	  cell	  sensitivity	  to	  cycloheximide.	  Based	  on	  the	  
experiments	  described	  by	  Stepanov	  et.	  al.	  [39]	  we	  used	  cycloheximide	  treatment	  to	  evaluate	  
whether	  the	  disruption	  of	  PDR1	  and	  replacement	  with	  the	  PDR1-­‐repressor	  construct,	  the	  
disruption	  of	  PDR5,	  or	  the	  combined	  modifications	  would	  result	  in	  enhanced	  toxicity	  in	  our	  
reporter	  strain	  background.	  Cells	  from	  the	  indicated	  strains	  were	  resuspended	  in	  sterile	  water	  and	  
transferred	  to	  a	  96-­‐well	  plate.	  Serial	  dilutions	  (1:5)	  were	  prepared	  and	  cells	  were	  transferred	  to	  
plates	  containing	  synthetic	  medium	  (SD)	  with	  different	  concentrations	  of	  cycloheximide	  using	  a	  
48-­‐pin	  replicator.	  A	  rich	  (YPDA)	  and	  an	  SD	  control	  plates	  were	  also	  spotted	  for	  comparison.	  Plates	  
were	  incubated	  for	  two	  days	  at	  30°C.	  3.	  Phenotypic	  analysis	  of	  the	  impact	  of	  MDM2	  on	  WT	  and	  
mutant	  p53	  transactivation.	  The	  ADE2-­‐based	  red/white	  assay	  was	  used	  to	  examine	  p53	  
dependent	  transactivation	  and	  the	  impact	  of	  MDM2.	  p53	  was	  expressed	  at	  low	  levels	  under	  the	  
GAL1	  promoter	  in	  media	  containing	  only	  raffinose	  (2%),	  or	  raffinose	  plus	  0.002%,	  0.004%	  or	  
0.016%,	  galactose.	  MDM2	  was	  expressed	  from	  the	  constitutive	  PGK1	  promoter.	  p53	  
transactivation	  was	  examined	  from	  three	  REs	  upstream	  of	  ADE2-­‐based	  p53	  reporter	  strains	  as	  
indicated.	  The	  optimized	  consensus	  (CON)	  and	  P21-­‐5 	  p53	  RE	  yield	  levels	  of	  high	  transactivation	  
while	  the	  NOXA	  RE	  is	  weaker	  [38].	  In	  the	  ADE2-­‐based	  p53	  functional	  assays,	  cells	  grown	  on	  plates	  
containing	  a	  low-­‐amount	  of	  adenine	  (5	  mg/L)	  result	  in	  small	  red	  colonies	  when	  p53	  is	  not	  present	  
or	  not	  transcriptionally	  active.	  p53-­‐dependent	  expression	  of	  ADE2	  results	  in	  the	  appearance	  of	  
colonies	  with	  a	  color	  ranging	  from	  light	  red	  to	  white,	  depending	  on	  the	  level	  of	  transactivation.	  To	  
reveal	  the	  dependency	  of	  the	  phenotype	  on	  p53	  expression	  levels,	  streaks	  are	  prepared	  on	  
glucose	  plates	  containing	  high	  amount	  of	  adenine	  (200	  mg/L)	  and	  the	  plates	  are	  incubated	  for	  two	  
days	  at	  30°C,	  resulting	  in	  the	  appearance	  of	  white	  colonies.	  These	  plates	  are	  then	  replica-­‐plated	  to	  
a	  stack	  of	  plates	  containing	  2%	  raffinose	  plus	  various	  levels	  galactose	  along	  with	  the	  low-­‐level	  of	  
adenine.	  The	  replica	  plates	  are	  then	  incubated	  at	  30°C	  for	  2-­‐3	  days.	  Images	  of	  a	  section	  of	  the	  
replicas	  are	  presented.	  For	  each	  image	  the	  upper	  section	  corresponds	  to	  colonies	  expressing	  p53	  
alone,	  while	  in	  the	  lower	  section	  the	  colonies	  also	  express	  MDM2.	  Various	  multiple	  mutants	  were	  
tested,	  as	  indicated.	  4.	  Relative	  transactivation	  capacity	  of	  p53	  phosphorylation-­‐site	  mutants.	  
The	  activity	  of	  the	  p53	  mutants	  described	  in	  Figure	  4	  is	  presented	  as	  relative	  light	  units	  in	  two	  p53	  
reporter	  strains	  using	  the	  Killer/DR5	  or	  the	  p21-­‐5 	  REs	  upstream	  of	  a	  luciferase	  reporter.	  Results	  
were	  obtained	  with	  the	  traditional	  assay	  format	  and	  are	  normalized	  to	  amount	  of	  soluble	  
proteins.	  4D	  refers	  to	  a	  quadruple	  mutant	  with	  the	  S15D,	  T18E,	  S20D,	  S33D	  changes	  in	  p53.	  6A	  
indicates	  a	  multiple	  mutant	  with	  alanine	  changes	  at	  S15,	  T18,	  S20,	  S33,	  S37,	  S46.	  6D	  indicates	  a	  
multiple	  mutant	  with	  aspartic	  acid	  changes	  at	  S15,	  S20,	  S33,	  S37,	  S46	  and	  a	  glutamic	  acid	  change	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at	  T18.	  5.	  Impact	  of	  small	  molecules	  Nutlin	  and	  RITA	  on	  the	  growth	  of	  WT	  yeast	  reporter	  strains	  
or	  the	  isogenic	  derivatives	  with	  modified	  chemical	  uptake.	  Overnight	  cultures	  grown	  in	  synthetic	  
glucose	  medium	  were	  washed	  and	  diluted	  to	  ~0.1	  OD600nm	  as	  measured	  by	  a	  plate	  reader.	  (A)	  The	  
WT	  strain	  was	  treated	  with	  40	  µM	  or	  80	  µM	  Nutlin	  (indicated	  as	  nutlin	  1	  and	  nutlin	  2	  respectively)	  
and	  1	  µM	  or	  2	  µM	  RITA	  (indicated	  as	  rita1	  and	  rita2).	  (B)	  The	  indicated	  mutant	  ABC-­‐transporter	  
strains	  were	  treated	  with1	  µM	  RITA	  (or	  DMSO	  solvent	  control).	  OD	  was	  measured	  at	  the	  following	  
times:	  2,	  4,	  8,	  12	  and	  24	  hrs.	  Error	  bars	  correspond	  to	  the	  standard	  deviations	  of	  three	  biological	  
replicates.	  6.	  Negative	  impact	  of	  RITA	  on	  the	  Firefly	  luciferase	  but	  not	  the	  Renilla	  luciferase.	  To	  
confirm	  that	  the	  negative	  impact	  of	  RITA	  on	  the	  Firefly	  reporter	  was	  not	  dependent	  on	  
modulation	  of	  p53	  transactivation,	  an	  isogenic	  derivative	  strain	  was	  developed	  containing	  the	  
PUMA	  p53	  RE	  upstream	  of	  the	  Renilla	  luciferase.	  Wild-­‐type	  p53-­‐dependent	  transactivation	  was	  
examined	  in	  cultures	  treated	  with	  DMSO	  control	  solvent	  or	  with	  1	  µM	  RITA.	  Presented	  are	  relative	  
light	  units	  normalized	  to	  OD600nm	  of	  the	  cultures.	  The	  error	  bars	  correspond	  to	  standard	  deviations	  
for	  three	  biological	  repeats.	  7.	  Apparent	  lack	  of	  PRIMA-­‐1	  effects	  on	  yeast	  growth	  or	  p53-­‐
dependent	  transactivation.	  (A)	  The	  small	  molecule	  PRIMA-­‐1	  does	  not	  affect	  yeast	  growth.	  
Overnight	  cultures	  grown	  in	  synthetic	  glucose	  medium	  were	  washed,	  diluted	  to	  ~0.1	  OD600nm,	  as	  
measured	  by	  a	  plate	  reader,	  and	  treated	  with	  200	  µM	  PRIMA-­‐1.	  Growth	  curves	  were	  compared	  
for	  the	  wild	  type	  strain	  or	  the	  indicated	  ABC-­‐transporter	  mutants.	  OD600nmwas	  measured	  at	  the	  2-­‐,	  
4-­‐,	  8-­‐,	  12-­‐	  and	  24-­‐hr	  time	  points.	  Presented	  are	  standard	  deviations	  for	  three	  biological	  repeats.	  
(B)	  The	  small	  molecule	  PRIMA-­‐1	  does	  not	  impact	  wild	  type	  p53	  transactivation	  capacity.	  Cells	  were	  
grown	  in	  glucose-­‐containing	  media	  to	  keep	  p53	  expression	  repressed	  and	  transferred	  to	  
galactose-­‐containing	  media	  followed	  by	  the	  addition	  of	  PRIMA-­‐1.	  Dual	  luciferase	  assays	  were	  
conducted	  16	  hrs	  after	  the	  treatment.	  Renilla	  luciferase	  was	  used	  as	  normalization	  factor.	  There	  
was	  no	  significant	  effect	  of	  PRIMA-­‐1	  on	  WT	  p53	  transactivation.	  The	  same	  result	  was	  obtained	  
with	  a	  diploid	  yeast	  strain,	  in	  which	  both	  the	  p53-­‐dependent	  reporter	  (Firefly)	  and	  the	  control	  
luciferase	  (Renilla)	  were	  placed	  at	  the	  ADE2	  chromosomal	  locus	  (i.e.,	  heteroalleles),	  thus	  
removing	  potential	  chromatin	  effects	  on	  reporter	  expression.	  The	  diploid	  strain	  was	  obtained	  
starting	  from	  two	  isogenic	  isolates	  of	  our	  yLFM	  strain	  background	  that	  differ	  for	  the	  mating	  type	  
locus.	  Presented	  is	  the	  fold-­‐induction	  of	  the	  Firefly	  reporter	  over	  the	  Renilla	  reporter	  relative	  to	  
strains	  that	  do	  not	  express	  p53,	  as	  they	  contain	  an	  empty	  expression	  vector.	  (C)	  The	  small	  
molecule	  PRIMA-­‐1	  does	  not	  affect	  mutant	  p53	  transactivation	  capacity.	  Different	  p53	  alleles	  were	  
expressed	  at	  moderate	  levels	  using	  medium	  containing	  0.128%	  galactose.	  PRIMA-­‐1	  (200	  µM)	  was	  
added	  to	  the	  cultures	  at	  the	  time	  of	  the	  switch	  to	  galactose-­‐containing	  medium.	  Presented	  are	  
the	  average	  fold-­‐induction	  by	  p53	  proteins	  compared	  to	  empty	  vector	  and	  normalized	  using	  the	  
Renilla	  control	  luciferase.	  Presented	  are	  standard	  deviations	  for	  three	  biological	  repeats.	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